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Abstract 
A successful cancer gene therapy requires systemic gene delivery vectors capable of efficient 
and selective gene transfer to tumour sites. Two main approaches have been undertaken for 
targeted cancer gene therapy: i) restriction of transgene expression in tumour cells by using 
tumour specific promoters and ii) selective delivery of vectors of gene therapy to tumours by 
ligand targeting. Amongst many characterised tumour specific promoters, the stress-inducible 
promoter of the Glucose-regulated protein 78 (Grp78) gene holds great potential to improve 
the practice of cancer gene therapy as its activity is highly induced under conditions often 
found in the tumour microenvironment such as acidic pH, glucose deprivation and chronic 
anoxia. However, the clinical application of the Grp78 promoter in cancer gene therapy has 
been limited by lack of delivery strategies via the systemic routes. In 2006, an efficient 
tumour targeted vector, adeno-associated virus/phage termed AAV/Phage or AAVP, was 
reported. In this AAVP vector, the M13 bacteriophage (phage) was used as a vehicle to target 
αv integrin receptors, which are selectively overexpressed in tumours, and to deliver the AAV 
transgene cassette driving transgene expression from a cytomegalovirus (CMV) promoter. 
Systemic administration of the targeted AAVP viral phage vector has been shown to 
successfully mediate therapeutic transgene expression in several preclinical tumour models. 
Thus, the AAVP particle provides a suitable vector candidate for double targeting of cancer 
after systemic administration. Herein, I combined ligand-directed targeting of AAVP vector 
with transcriptional targeting using the Grp78 promoter in one single platform. In the first 
half of the thesis I show that the double-targeted vector provides sustained and long-term 
transgene expression in transduced tumour cells in vitro. Moreover, compared to the 
conventional phage carrying the CMV promoter, the new hybrid phage provided a significant 
tumour killing both in vitro and in vivo using the HSVtk gene and ganciclovir suicide therapy. 
More importantly in chapter 5, I describe a novel mechanism of Grp78 promoter activation 
by HSVtk and ganciclovir suicide therapy. In chapter 6, in addition to the vector safety, I 
show the superior tumour transduction in vivo after systemic administration of double-
targeted AAVP vector over the original AAVP carrying the CMV promoter. In Chapter 7, I 
demonstrate strong dose dependent chemotherapeutic induction of the Grp78 promoter in the 
context of AAVP vector. Together, all data presented in this thesis validate the great potential 
of the Grp78 promoter in targeted systemic cancer gene therapy and report the efficacy of the 
double-targeted AAVP vector which proves useful for translation into clinical applications. 
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Chapter 1 
 
 
Introduction 
 
 
 
 
1.1 Treatment of cancer 
 
Cancer is a large group of diseases that develop by the rapid unregulated growth of cells. 
Cancer cells can invade neighbouring tissue and/or spread to other organs through the 
bloodstream or lymphatic system. This process, which is referred to as metastasis, results in 
the most aggressive types of cancer and therefore has the highest mortality rates. Cancer is a 
leading cause of death worldwide, with an estimated 7.9 million deaths reported in 2010; it 
has been predicted to rise to approximately 13.1 million deaths by 2030 (Jemal et al., 2011). 
In addition to surgery, conventional cytotoxic therapies, such as chemotherapy and radiation, 
are currently used for cancer treatment. However, as most cancer cells are resistant to 
apoptosis and can remove chemotherapeutic drugs from their local environment, 
conventional therapies have shown limited success, especially against solid, metastatic 
cancers (Liu, 2009). Moreover both therapies often exhibit high toxicity with a wide variety 
of severe side effects. In addition, most of the chemotherapeutic drugs circulate around the 
entire body and in fact the dose that reaches the tumour cells (normalized per gram of tissue) 
may be as little as 5–10% of the dose that accumulates in normal organs (Bosslet et al., 
1998). Thus development of targeted anticancer drugs is arguably one of the most important 
goals of current anticancer research as this drug release at the tumour tissue will reduce 
toxicity.  
In the past two decades many novel cancer treatments have been developed with the aim to 
deliver therapeutic drugs directly to tumour tissue and thus to reduce the toxicity for normal 
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tissues- an objective that conventional therapies have failed to achieve. One promising area 
with fast-expanding clinical trial data is cancer gene therapy which mostly utilizes vectors 
derived from viruses. 
1.2 Cancer gene therapy  
 
Gene therapy aims to transfer exogenous genes, called transgenes into the diseased cells in 
order to achieve a therapeutic effect. First developed in 1970s as a gene replacement tool 
(Friedmann, 1992), gene therapy has been utilised in numerous cancer research projects with 
the aim of developing efficient vectors that both can be safely administrated and tolerated by 
the human body and can discriminate between normal and tumour tissues. To date, due to 
lack of an efficient vector able to target therapeutic transgenes to the tumour tissue after 
systemic administration, most clinical trials have focused on direct intratumoural 
administrations of either viral or nonviral vector systems. A local delivery of the transgene is 
necessary as proof-of-principle, but real clinical benefit can only follow systemic 
administration in order to reach both metastases and some of the primary tumours that 
necessitate invasive procedures for local access and delivery.  
 
Indeed, a successful clinical gene therapy will depend on the development of efficient 
systemic vectors. Such vectors also need to be safe after systemic administration, so that the 
appropriate genes can be delivered to and be expressed in target cells only. It is well known 
that the main challenges of clinical gene therapy trials are vector targeting and the high cost 
of vector production. Therefore development of efficient targeted vectors that mediate 
efficient and long-term expression of the therapeutic gene in tumour tissues after systemic 
administration presents an interesting approach to cancer gene therapy.  
 
To date, two main approaches have been used for targeting: i) transcriptional targeting that 
uses promoters that are active only in the target tumour cells and ii) ligand-targeting of 
vectors. Each of these two approaches have been attempted individually and showed 
promising results for vector delivery and transgene expression in preclinical tumour models. 
Combining these two strategies in one vector system is challenging but would provide a 
major advance in cancer gene therapy. 
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1.2.1 Transcriptional targeting 
 
Selective targeting and killing of tumour cells is a major goal of current cancer gene therapy. 
One targeting approach is to use specific promoters that are active in the tumour tissue only 
(Sadeghi and Hitt, 2005). The use of such promoters in cancer gene therapy will lead to 
transcriptional targeting, which can reduce or even eliminate potential toxic side effects of the 
therapeutic gene in normal tissues. One of the common promoters used in gene therapy 
vectors is the cytomegalovirus (CMV) promoter, which can constitutively express the 
transgene at high levels. Nonetheless, its non-specific and unregulated activity may become 
problematic in the context of cancer gene therapy since the expression pattern of the 
transgene will be constitutive in normal as well as in tumour tissues.  
On the other hand, promoters which are active in tumour cells only have been used for 
targeted gene delivery to tumours in order to deliver transgene expression to the tumour 
tissue only while sparing the normal organs (Robson and Hirst, 2003).  
Transcription targeting was first established by two studies in 1997. Rodriguez et al. have 
restricted transgene expression in prostate-specific antigen (PSA) producing prostate cells by 
applying the prostate-specific antigen promoter into adenovirus type 5 DNA to drive 
transgene expression which they referred to as “attenuated replication-competent 
adenovirus”(Rodriguez et al., 1997). Morover, using the albumin promoter, Miyatake et al. 
could restrict the replication of the herpes simplex virus type 1 (HSV-1) vector to albumin-
expressing liver cells (Miyatake et al., 1997). Since then, numerous types of promoters have 
been characterised and used in targeted cancer gene therapy, each of which are discussed in 
the following sections. 
 
1.2.1.1 Tissue-specific promoters 
 
This group of promoters are active, and mediate transgene expression, in specific tissues 
only. Several tissue-specific promoters that target tumour of a single origin were 
characterized and used in cancer gene therapy (Robson and Hirst, 2003). Examples include 
the ovarian-specific promoter to target ovarian cancer (Bao et al., 2002, Selvakumaran et al., 
2001), albumin promoter to target hepatocellular carcinoma (Su et al., 1997), and the 
thyroglobulin promoter for thyroid carcinomas (Zhang et al., 2001). Moreover, the tyrosinase 
promoter has been used both in vitro and in vivo to target melanocytes and melanomas (Vile 
and Hart, 1993, Fecker et al., 2011).  
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The PSA promoter was used in targeting prostate cancer (Wu et al., 2001, Lu and Madu, 
2010, Latham et al., 2000). PSA is predominantly expressed in prostate cells due to 
transcriptional activation. The PSA promoter has been previously shown to express Herpes 
Simplex Virus thymidine kinase (HSVtk) suicide gene in PSA-positive prostate cancer cells 
and prostate tumours. However, no transgene expression was observed in cells that do not 
express PSA (Gotoh et al., 1998). 
Although these promoters proved efficient to induce transgene expression in tumour cells, 
their activity in both normal and tumour cells is a major drawback. 
 
1.2.1.2 Tumour-specific promoters 
 
Tumour-specific promoters constitute an ideal choice for targeted cancer gene therapy to 
direct the expression of therapeutic genes. They have been shown to be highly active in 
tumour cells while having little or no activity in normal cells. Based on their characteristics, 
tumour-specific promoters have been subdivided into 4 groups (Harrington et al., 2000, 
Robson and Hirst, 2003): cancer-specific promoters, tumour-type-specific promoters, 
tumour-vasculature-related promoters, and tumour-microenvironment-related promoters. 
 
1.2.1.2.1 Cancer-specific promoters 
 
Cancer-specific promoters, such as the promoter of the telomerase gene, are specifically 
active in malignant cells and have great potential in cancer gene therapy to target a wide 
variety of tumours. According to previous reports, telomerase is highly active in around 85-
90% of human cancer cells, while in normal tissues its activity is either low or undetectable 
(Kim et al., 1994, Broccoli et al., 1995). Telomerase is composed of two subunits- the human 
telomerase RNA (hTR) and a catalytic component called human telomerase reverse 
transcriptase (hTERT)- both of which are required for its activity (Shay and Wright, 2001). 
The promoters of these two subunits are highly active in cells that are positive for telomerase 
activity such as tumour and fetal cells. Thus, both of these two promoters can be used in 
many targeted cancer gene therapy studies to drive therapeutic gene expression. The 
enhanced killing of telomerase-positive cells upon utilization of either hTR or hTERT 
promoters in tumour cells was reported in several studies (Song and Kim, 2004, Plumb et al., 
2001). Although the hTR or hTERT promoters have been broadly utilized for transcriptional 
regulation of therapeutic genes, they have some limitations for clinical use. For instance, they 
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possess low activity, and some potential toxicity to certain normal cells have been reported 
(Xiong et al., 2012).  
 
1.2.1.2.2 Tumour-type-specific promoters 
 
Tumour-type-specific promoters are the promoters of oncofetal genes that are often 
overexpressed in certain types of tumours and are silent in normal tissues. Examples of the 
most well-characterised promoters of this group include the promoter of the gene encoding α-
fetoprotein, which has been found to be active in fetal liver and hepatocellular carcinomas 
(Ishikawa et al., 1999), and the promoter of the gene for the carcinoembryonic antigen 
(CEA), which is active in a proportion of breast, lung, colorectal and pancreatic cancers 
(Richards et al., 1995). The CEA promoter was extensively used in different vector systems 
to selectively deliver various therapeutic genes such as the cytosine deaminase (CD) gene or 
HSVtk in CEA- positive cells. The outcome was significant tumour growth suppression or 
regression with no toxicity to the liver and other normal organs (Brand et al., 1998, Cao et al., 
1999, Zhang et al., 2009a, Richards et al., 1995).  
Although these promoters mediate transgene expression in tumour tissues and may therefore 
be good candidates for transcriptional targeting in cancer gene therapy, their application 
remains limited because they cannot be administered to a variety of tumours. 
 
1.2.1.2.3 Tumour-vasculature-related promoters 
 
Another group of promoters used in targeted cancer gene therapy is tumour-vasculature-
related promoters as their genes are overexpressed in proliferating endothelium of the tumour 
blood vessels. Examples of such promoters that have been used in targeted gene therapy are 
E-selectin and endothelial-specific kinase insert domain receptor (KDR/flk-1), which are 
upregulated in tumour endothelium. The promoter of E-selectin and KDR/flk-1 were used to 
drive the expression of an inflammatory cytokine, tumour necrosis factor-α (TNF-α) and 
results shown 10- fold increase of transgene expression in endothelioma cells compared to 
non-endothelioma cells (Jaggar et al., 1997). In addition, the promoters of genes encoding 
vascular endothelial growth factor receptor (Flt-1), and human preproendothelin-1 have also 
been used in gene therapy vector systems and proved efficient at driving transgene expression 
in the vasculature of tumours and metastases (Varda-Bloom et al., 2001, Bauerschmitz et al., 
2002). While the usage of these promoters in targeted cancer gene therapy proved efficient to 
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drive transgene expression in tumour vasculature, their limitation still remains as some of 
these promoters were shown to be active in normal small vessels and also upregulated in 
injured vessels (Herz et al., 2012). 
 
1.2.1.2.4 Tumour-microenvironment-related promoters 
 
Tumour-microenvironment-related promoters belong to the genes that are upregulated in 
response to the tumour microenvironment and physiology. Solid tumours intend to grow 
faster than their blood vessels leading to an inadequate supply of vital nutrition to the tumour 
cells. This condition creates a unique tumour microenvironment characterized by hypoxia, 
acidosis and glucose deprivation which persist in poorly vascularized solid tumours. As part 
of the cancer cell’s adaptation to these conditions, the promoters of some genes, such as 
hypoxia response elements (HREs) and some of the heat shock family genes, become 
induced. 
Recently, the heat shock genes have been of increasing interest in targeted cancer gene 
therapy because of their activation in a wide variety of tumours, such as the genes of the 
Glucose-regulated protein 78 (Grp78), the promoter which responds to glucose starvation 
and hypoxia. This promoter’s activity and its ability to drive transgene expression within 
areas of tumour hypoxia- which are highly resistant to current forms of treatment- make it 
even more attractive for use in targeted cancer gene therapy. Indeed, therapeutic transgene 
expression driven by this promoter is induced in response to insufficient blood supply and 
tumour necrosis, and reaches high levels leading to complete tumour eradication in 
preclinical models (Dong et al., 2004, Chen et al., 2000). 
For cancer targeting gene therapy, the Grp78 promoter seems to be an ideal promoter to 
restrict expression of the therapeutic gene within the tumour tissue and was therefore selected 
for our studies. 
 
1.2.1.2.4.1 Grp78 
 
The Grp78 gene encodes a 78-kDa protein – the stress-response chaperone glucose-regulated 
protein 78 (Grp78). Grp78 gets its name from the discovery in the late 1970s, that upon rapid 
glucose removal from the culture medium of chick embryo fibroblasts a rapid increase in a 
protein with a molecular weight of 78-kDa was spotted (Lee, 2001). Grp78, also referred to 
as BiP (immunoglobulin heavy chain binding protein) (Lee, 2001), is encoded by a single 
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copy gene in both human and mouse genomes (Ting and Lee, 1988). With similar function 
and 60% amino acid homology to the 70kDa heat shock protein (HSP70), Grp78 has been 
categorized within the HSP70 family (Munro and Pelham, 1986). However in contrast to 
HSP70, Grp78 is not induced by heat stress. Moreover, whereas HSP70 mainly localises in 
the cytoplasm of cells, the endoplasmic reticulum (ER) retention signal peptide KDEL 
located in the carboxy-terminus of Grp78, primarily localises this chaperone protein into the 
ER lumen where it retains its functions as a molecular chaperone in an ATP-dependent 
manner (Dorner et al., 1990).  
Grp78 plays an important role in orchestrating the unfolded protein response (UPR) by 
binding and assembling unfolded or misfolded membrane and secretory proteins within the 
ER lumen as well as degrading irreversibly misfolded proteins (Li and Lee, 2006, Zhang and 
Zhang, 2010, Lee, 2007). Moreover by binding to Ca
2+
 ions in the ER, Grp78 maintains the 
ER calcium homeostasis and serves as an ER stress signalling regulator. Under normal 
conditions, Grp78 chaperon binds to three ER transmembrane sensor proteins, protein kinase-
like ER kinase (PERK), inositol requiring enzyme 1 (IRE1) and activating transcription 
factor 6 (ATF6), maintaining them in an inactive form. However, when mammalian cells are 
subjected to ER stress, such as ER Ca
2+
 efflux or accumulation of supra-threshold unfolded 
or misfolded protein load, Grp78 dissociates from these three sensors and binds the unfolded 
or misfolded proteins to assist their proper folding. Upon dissociation of Grp78 from PERK, 
IRE1 and ATF6, their downstream pathways are activated, resulting in activation and 
translocation of some of the transcription factors to the Grp78 promoter and thus initiation of 
the UPR (also see introduction of chapter 5) (Ni et al., 2009, Baumeister et al., 2005).  
 
The expression of stress-inducible Grp78 is regulated at the transcription level. Upon 
blockage of protein glycosylation or depletion of the ER calcium store, the transcriptional 
activity of the Grp78 promoter is induced by around 10-25 fold (Lee, 1992, Fernandez et al., 
2000, Li et al., 1993). This process, is primarily controlled by multiple stress-inducible 
elements located upstream of the TATA element of the mammalian Grp78 promoter. These 
regulatory elements are composed of: (i) highly conserved copies of the 19 bp sequence 
CCAATN9CCACG (N9 represents conserved 9 bp of the GC-rich sequence) termed ER stress 
response element (ERSE) (Hong et al., 2005) and (ii) the cAMP response element (CRE), 
which is located upstream of the ERSE.  
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The mammalian Grp78 promoter contains three such ERSEs and one CRE, which 
collectively serve as a binding site for a variety of transcription factors including YY1, TFII-I 
and ATF6 in order to activate transcription of the chaperone molecule Grp78.  
 
1.2.1.2.4.1.1 Role of Grp78 in cancer 
 
Compared to normal cells, the rapidly growing tumour cells show high growth rate and 
increased glucose metabolism. The glucose level of many cancer cells therefor can be as low 
as 0-2 mM compared with 5mM in normal cells. Moreover, neovascularization and 
angiogenesis often fail to keep pace with tumour growth leading to hypoxia, acidosis and 
nutrient deprivation. These intrinsic and extrinsic factors within tumour cells and the tumour 
microenvironment result in accumulation of unfolded or misfolded ER proteins which 
subsequently trigger the UPR. Thus, while expression of the Grp78 chaperone protein is 
maintained at low basal level in major adult organs such as brain, heart and lung, it is highly 
upregulated in transformed cells (Patierno et al., 1987) as well as in a wide variety of tumours 
(Lee, 2007, Lee, 2001, Hendershot, 2004, Yu et al., 1999, Li et al., 2006). Interestingly, in 
addition to solid tumours, Grp78 expression is highly induced in the endothelia of tumour 
vasculature (Dong et al., 2011).  
Overexpression of Grp78 has been shown to correlate with an increased tumour recurrence 
risk and decreased survival rate in cancer patients (Pfaffenbach and Lee, 2011). Moreover 
there is a positive correlation between the tumour grade and the level of Grp78 expression in 
breast, liver, prostate, colon, gastric, and brain tumours (Lee et al., 2008, Wang et al., 2010). 
Grp78 plays a major role in cancer cell survival by activating the prosurvival pathway. In 
vivo studies with heterozygous Grp78 mice (Grp78
 +/‒
) demonstrated a marked impediment in 
tumour progression compared to wild-type Grp78 mice, as tumour size was reduced and 
apoptosis was promoted (Dong et al., 2008). In addition to primary tumours, overexpression 
of Grp78 has been shown to assist tumour and lymph node metastasis. Interestingly Grp78 
gene knockout has been shown to inhibit tumour cell invasion in vitro as well as growth and 
metastasis in vivo in the Grp78
 +/‒
 xenograft models (Fu and Lee, 2006, Zhang et al., 2006, 
Dong et al., 2011). It has been demonstrated that during tumour growth and metastasis, 
Grp78 plays an important role in tumour neovascularisation. Compared to wild type Grp78 
mice, the microvessel density (MVD) of the endogenous tumours in the Grp78
 +/‒
 mice was 
decreased by 70%, while the vasculature of normal organs remained intact (Dong et al., 
2011). 
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The stress-inducible Grp78 is also required for tumour cell proliferation. The direct 
correlation between Grp78 level and proliferation rate of a range of glioblastoma cells has 
been previously demonstrated. Grp78 knockdown in glioblastoma cells leads to decreased 
tumour cell proliferation (Pyrko et al., 2007). In addition to tumour cell survival and 
proliferation, Grp78 plays an important role in blocking apoptosis in stressed cells.  
Although Grp78 primarily resides in the ER lumen, upon ER stress, a fraction of the 
overproduced Grp78 can be distributed to regions outside the ER such as mitochondria, 
cytoplasm (Ni et al., 2009), plasma membrane and can be released even into the culture 
medium. Within the cytoplasm, this molecular chaperone binds to caspase-7 and caspase-12 
and inhibits their activation, thus blocking apoptosis. Moreover, the mitochondrial Grp78 
fraction is capable of forming complexes with pro-apoptotic proteins and prevents 
cytochrome c release from the mitochondria, blocking apoptosis (Lee, 2007, Zhang and 
Zhang, 2010).  
Interestingly, Grp78 in the tumour cell surface has been used as a reliable receptor for tumour 
targeting. Indeed, systemic administration of synthetic chimeric peptides composed of Grp78 
binding motifs fused to a proapoptotic sequence could efficiently target tumours and inhibit 
their growth without affecting normal tissues (Arap et al., 2004). Moreover in a variety of 
tumours, cell surface Grp78 has been shown to promote cell proliferation, survival and 
metastasis by binding to plasma proteinase inhibitor α2-macroglobulin and activation of its 
downstream signalling pathway (Misra et al., 2006, Shu et al., 2008, Zhang and Zhang, 
2010).  
 
1.2.1.2.4.1.2 Role of Grp78 in drug resistance  
 
Previous reports showed that increased expression of Grp78 in a variety of cancers such as 
prostate, breast and lung tumours in addition to glioma is correlated with cancer progression, 
metastasis and drug resistance (Wang et al., 2009, Fu and Lee, 2006, Zhang et al., 2009c, 
Racek et al., 2008). Although development of drug resistance in tumour cells is rather 
complex and involves various mechanisms, induction of Grp78 is arguably a major 
contributing factor. 
Glioblastoma multiforme (GBM; grade IV), the most aggressive form of gliomas, is highly 
resistant to chemotherapy. Interestingly, the level of Grp78 chaperone molecule is markedly 
induced in human glioblastoma cell lines and malignant glioma specimens, while Grp78 
expression is maintained at a low level in normal adult brain. As a proof of principle, 
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knockdown of Grp78 resulted in sensitization of glioblastoma cells to chemotherapeutic 
drugs such as temozolomide (Pyrko et al., 2007). In addition to glioblastoma cells, significant 
induction of Grp78 has been reported in the vasculature derived from human glioma 
specimens both in vitro in cell culture and in situ in tissue. Interestingly, similar to 
glioblastoma cells, human brain endothelial cells derived from blood vessels of malignant 
glioma (TuBECs) show resistance to various chemotherapeutic drugs such as temozolomide, 
etoposide and CPT-11. Indeed, down regulation of Grp78 in TuBECs using small interfering 
RNA has been shown to significantly reverse resistance to chemotherapy. By suppressing the 
Grp78, previous studies could successfully sensitize human breast cancer cells to etoposide-
induced apoptosis (Reddy et al., 2003). Thus tumour drug resistance resulting from high 
levels of Grp78, might be due to the prosurvival property of this chaperone molecule.  
 
1.2.1.2.4.1.3 The Grp78 promoter and targeted gene therapy 
 
The use of the Grp78 promoter in cancer gene therapy was first reported by Dr Lee’s group 
(Little et al., 1994). The team had fully characterised the efficacy of this promoter in several 
tumour systems. They used the Grp78 promoter in the context of a retroviral system to drive 
the expression of the HSVtk gene in tumours followed by ganciclovir (GCV) administration. 
GCV, a nontoxic prodrug, phosphorylated by the HSVtk enzyme, and then converted by 
cellular kinases into triphosphate GCV, which incorporates into DNA leading to inhibition of 
DNA polymerase and resulting in cell death. Studies of HSVtk driven by the Grp78 promoter 
demonstrated complete eradication of murine tumours and human xenografts in mice with no 
recurrence of tumour growth (Dong et al., 2004, Chen et al., 2000). 
Previous work demonstrated that the Grp78 promoter is highly induced in human breast 
carcinomas and that its activity is not affected by either p53 or estrogen receptor status (Dong 
et al., 2004). Suppression and eradication of human breast xenografts such as MCF7, MDA-
MB-435 and T47D in nude mice were observed after using the Grp78 promoter to drive 
HSVtk in the context of a retroviral vector (Dong et al., 2004). Similar results were reported 
in a murine mammary adenocarcinoma cell line (TSA) in immune-competent mice (Chen et 
al., 2000). Moreover, another group assessed the efficacy of HSVtk under the control of the 
Grp78 promoter in gastroesophageal junction and gastric adenocarcinoma cells, and found 
significant cell death in vitro and tumour regression in vivo following GCV treatment 
(Azatian et al., 2009).  
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Induction of the Grp78 promoter in response to photodynamic therapy (PDT) has also been 
reported (Luna et al., 2002). PDT generates cytotoxic singlet oxygen species, which are 
potent activators of the Grp78 promoter. Inducible expression of HSVtk under the control of 
the Grp78 promoter was also observed after PDT of stably retroviral-transduced mouse 
mammary carcinoma cells.  
Interestingly, transgenic mice in which a LacZ transgene was driven by the rat Grp78 
promoter showed high transgene expression in cancer cells, while no promoter activity was 
detected in major adult organs (Dong et al., 2004). Thus, transcriptional control mediated by 
Grp78 promoter offers a novel approach for human cancer gene therapy. In addition to the 
vector safety, this can increase gene transcription because, unlike viral promoters such as 
CMV, mammalian promoters are not silenced in eukaryotic cells (Brooks et al., 2004). This 
can lead to stronger and longer-term transgene expression from the vector.  
Despite these potential advantages of the Grp78 promoter in cancer gene therapy, 
transcriptional targeting alone is not sufficient to ensure gene expression in the target cell, 
which also requires efficient introduction of the therapeutic transgene cassette in the correct 
cells. A real clinical application and benefit of the Grp78 promoter will depend on the 
generation of vectors that can specifically and efficiently deliver a Grp78-driven transgene 
expression cassette to the tumour tissue after systemic administration. Thus, further 
optimization of vectors, especially ligand targeting of vectors, may facilitate application of 
the Grp78 promoter for efficient gene therapy.  
 
1.2.2 Ligand-directed targeting  
 
Cancer gene therapy is limited by side effects that result from non-specific delivery of 
therapeutic genes. To circumvent this limitation, ligand-directed targeting of gene delivery 
vectors has been attempted. The ligand-targeting strategy using animal viruses involves 
manipulation of ligands on the outer viral coat proteins to mediate binding to
 
the cells of 
interest. This process often necessitates ablation of the virus natural tropism for mammalian 
cells and displaying specific peptide ligands on their surface to retarget them to specific cell 
type receptors within the host. A number of such ligands have been identified by phage 
display technology, an in vivo screening method in which peptides
 
homing to tissue-specific 
receptors are selected after intravenous administration
 
of a phage display random peptide 
library (Pasqualini and Ruoslahti, 1996). Through this process several tumour-specific and 
tumour-associated endothelial cell-specific receptors, which hold great potential for ligand-
29 
 
directed targeting in cancer gene therapy, have been characterised and some have been 
assessed in preclinical tumour models (Hajitou et al., 2006a) (Table 1.1). In recent years, in 
addition to primary tumours, targeting the tumour vasculature has been of great interest in 
cancer gene therapy as vascular cells are readily accessible through the systemic circulation 
of the vector and are also known to express several different surface markers that are absent 
or barely detectable in normal quiescent blood vessels. Furthermore given the estimates that 
up to 100 tumour cells are sustained by a single endothelial cell (Folkman, 1997), gene 
targeting of tumour vasculature might mediate a pronounced anti-cancer effect. However, a 
successful tumour-vasculature-targeted therapy will depend on the development of efficient 
vectors that can deliver and express therapeutic genes specifically in the tumour vasculature 
of the primary and metastatic tumours.  
 
Table 1.1. List of receptors being targeted in cancer therapy. (Hajitou et al., 2006a) 
 
 
 
 
1.2.2.1 Ligand targeting of viral gene therapy vectors 
 
In the past decade, several techniques have been developed with the aim of facilitating vector 
targeting to specific cells after systemic administration. However, for systemic targeted 
cancer gene therapy, the choice of an efficient vector system capable of mediating an 
appropriate expression level of the therapeutic gene to cancer cells is the most crucial step.  
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Nonviral vectors, such as gene gun, magnetofection, lipoplexes, inorganic nanoparticles and 
injection of naked DNA, hold some potential due to their mass production, safety and low 
host immunogenicity. Nevertheless their low level of transfection and transgene expression 
still represent a great challenge (Li and Huang, 2006).  
In contrast to nonviral vectors, viral vectors have arguably proved to be the vector of choice 
as they naturally evolved to infect mammalian cells and can mediate high level of 
transduction. Although in 2007, viral vectors were used in 70% of clinical trials involving 
gene therapy (Waehler et al., 2007), many groups are focused on improving viral vectors 
features for gene therapy purpose. Most progress in viral gene therapy has involved 
Lentiviruses, Adenoviruses (Ad) and Adeno-associated viruses (AAV) (Bouard et al., 2009). 
In particular, Ads are attractive for cancer gene therapy and are the most frequently used 
vectors in clinical trials (Kay, 2011). Ads contain a 36 kb double-stranded DNA genome 
which provides plenty of space for inserting large sequence fragments. In addition to the ease 
of vector manipulation and the capability to produce high titers, Ad vectors are known to 
mediate efficient transgene expression in both dividing and non-dividing cells. Despite all the 
advantages of Ad vectors, they can induce severe toxicity by stimulating host immune 
response after systemic delivery of the required dose of vector. Thus for selective killing of 
tumour cells, many studies have focused on modifying the adenoviral genome in such a way 
to achieve cancer specificity at different stages through the adenoviral life cycle (Green and 
Seymour, 2002). One main approach has involved a specific deletion in the Ad genome and 
generation of replication-incompetent Ad vectors which attenuate the viral amplification and 
thus inhibit the infection. These engineered vectors can be further modified to selectively 
replicate in tumour cells and mediate their lysis. The ONYX-015 vector is one such example 
of a replication-incompetent Ad vector. This vector cannot defend itself against the products 
of the p53 tumour suppressor gene and thus is destroyed in healthy cells. In contrast, as the 
p53 gene is defective in most tumour cells, ONYX-015 can proliferate within these cells and 
mediate their lysis (McCormick, 2000). Moreover, if the tumour lysis mediated by these 
vectors is inefficient, researchers can insert therapeutic genes into the Ad vector genome in 
order to enhance its antitumour efficacy (Oosterhoff et al., 2005). 
AAVs, which are members of the parvovirus family, are also promising vectors and have 
been used in a variety of gene-therapy applications as they confer low immunogenicity within 
the host. Moreover, AAVs have been shown to mediate stable and long-term gene expression 
in vivo (Duan et al., 1998). Additionally, AAV vectors are purified to high titers and, like 
Ads, can transduce both dividing and non-dividing cells. However, one of the severe 
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limitations of AAV vectors for gene therapy is their limited capacity for gene cloning which 
is due to their small genome (Kay, 2011). 
AAVs contain a 4.7 kb single-stranded DNA genome encoding for two genes: rep which is 
responsible for viral DNA replication and cap, which directs packaging of the viral genome. 
Rep and cap open reading frames (ORFs) are flanked by two inverted terminal repeats (ITRs) 
(Buning et al., 2008). Upon entry into the host cell, the AAV single-stranded DNA is 
converted to transcriptionally active double-stranded DNA and remains episomal (Duan et 
al., 1998). To generate recombinant AAV, rep and cap are replaced by transgene cassettes, 
leaving the ITR cis elements which serve as an origin of replication (Buning et al., 2008, 
Samulski et al., 1987).  
Despite the fact that animal viruses such as Ad and AAVs hold potential for targeted cancer 
gene therapy, their native tropism for mammalian cells must be eliminated prior to re-
targeting them to specific receptors. This process often makes the vectors quite unstable and 
also leads to reduced cells transduction resulting from entry via non-natural receptors (Kay, 
2011). Moreover, addition of targeting peptides derived from phage display screenings to 
eukaryotic viruses has not been successful, as this process seems to alter the structure of the 
viral capsid and diminish the targeting properties of the peptide ligands themselves
 
(Hatefi 
and Canine, 2009). Indeed, peptides isolated from
 
phage libraries are selected in the protein 
structural context
 
of the pIII capsid protein of the filamentous M13 bacteriophage (phage) and 
are then translated into different
 
protein structures of a viral capsid protein. Due to these 
limitations, bacteriophage itself has been proposed as a safe vector for targeted gene therapy 
(Piersanti et al., 2004, Ghaemi et al., 2010, Di Giovine et al., 2001). 
 
1.2.2.2 Bacteriophage gene therapy 
 
Another approach in ligand-directed gene therapy uses targeted bacteriophage directly for 
gene delivery to mammalian cells without the need to transfer peptides from phage display to 
a eukaryotic vector. Bacteriophage, which is a prokaryotic virus, has no tropism for 
mammalian cells, but can be engineered to deliver genes to such cells. They are safe and can 
be targeted by a ligand displayed on their capsid, to a specific mammalian receptor after 
systemic administration. This can be achieved by DNA sequence insertion into the phage 
Gene III which encodes the pIII minor coat protein. Moreover, phage-based vectors have 
some potential advantages over animal viruses for targeted delivery of transgenes into 
mammalian cells. First, there are no known natural receptors for phage on mammalian cells. 
32 
 
Additionally, bacteriophage have been used for antibiotic therapy before the discovery of 
antibiotics and are safe even in children after systemic administration (Barrow and Soothill, 
1997). In 2006, the US Food and Drug Administration (FDA) announced that it had approved 
the use of some bacteriophage preparations on ready-to-eat (RTE) meat and poultry products 
as antibacterial food additives (Lang, 2006). Moreover, bacteriophage are cheap to produce in 
bacteria and have very high titers (Hajitou et al., 2007). Most importantly, unlike eukaryotic 
viruses, bacteriophage do not require further context modification of their capsid; the 
targeting peptides are actually selected and isolated directly to target specific cell-surface 
receptors after screening of a phage display peptide library. Despite all these advantages, 
however, phage-based vectors are not ideal as bacteriophage only infect bacteria and cannot 
efficiently express transgenes upon entry into eukaryotic cells.  
To circumvent this limitation, Hajitou et al. created a new generation of targeted hybrid 
prokaryotic-eukaryotic vectors. These vectors are chimeras between two single-stranded 
DNA viruses: (i) an adeno-associated virus (AAV2) and (ii) a targeted filamentous M13 
bacteriophage termed AAV/phage (AAVP) (Hajitou et al., 2006b).  
 
1.2.2.3 Adeno-Associated Virus/Phage (AAVP) 
 
In the AAVP vector, devoid of any sequence encoding the AAV capsid, the AAV transgene 
cassette containing a CMV promoter flanked by inverted terminal repeats (ITRs) from AAV 
serotype 2 (Fig. 1.1a) was inserted into an intergenomic region of the phage genome and 
packaged with the phage DNA into the bacteriophage capsid (Fig. 1.1b). This AAVP vector 
was genetically modified to display a double-cyclic Arginine-Glycine-Aspartate 
(CDCRGDCFC, RGD4C) motif, on the minor pIII coat protein of the bacteriophage (Hajitou 
et al., 2006b). The RGD4C motif has been shown to specifically target αv integrin receptors 
which are overexpressed in tumour blood vessels and tumour cells but are absent or are 
barely expressed in normal vascular endothelial cells (Pasqualini et al., 1997, Ruoslahti, 
1996). The use of AAV ITRs in the RGD4C AAVP results in improved transduction 
efficiency which is associated with an improved fate of the delivered transgene, through 
maintenance of the entire mammalian transgene cassette, better persistence of episomal DNA 
and formation of concatamers of the transgene cassette
 
(Hajitou et al., 2006b).
 
AAVP-mediated reporter transgene expression was observed in mammalian cells treated with 
targeted RGD4C AAVP only, while control non-targeted RGD4C AAVP or AAVP bearing 
mutated/ scrambled ligand RGD4C motifs were unable to bind or transduce mammalian cells 
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in vitro and in vivo (Hajitou et al., 2006b). This ligand-directed AAVP was systemically 
delivered to tumour-bearing mice and proved efficient in expressing both imaging and 
therapeutic genes into tumours specifically. Indeed, the in vivo biodistribution of the RGD4C 
AAVP vector after systemic administration to mice bearing human prostate xenografts or rats 
bearing human soft tissue sarcoma was evaluated using in vivo Positron Emission 
Tomography (PET) imaging of HSVtk and [
18
F]-FEAU or bioluminescence imaging of the 
luciferase reporter gene. Interestingly, the results demonstrated specific tumour mediated 
transgene expression (Hajitou et al., 2008, Hajitou et al., 2006b).  
More interestingly, despite the nonspecific hepatic clearance of phage particles (Geier et al., 
1973), systemic administration of targeted RGD4C AAVP  resulted in no gene transduction 
of the liver or other control organs (Tandle et al., 2009, Paoloni et al., 2009, Hajitou et al., 
2006b, Hajitou et al., 2008). These findings make phage a more advantageous vector for 
systemic delivery than eukaryotic viral vectors which widely transduce the normal organs 
after systemic administration (Donsante et al., 2007).  
 
Therapeutic efficiency of the targeted RGD4C AAVP vector was evaluated using vector 
carrying the HSV1-tk gene in combination with the prodrug GCV. Interestingly, a single 
intravenous administration of the RGD4C AAVP-HSVtk vector in immunodeficient nude 
mice bearing Kaposi’s sarcoma KS1767 tumours, resulted in marked tumour suppression 
compared with mice treated with vehicle or with non-targeted AAVP (Hajitou et al., 2006b). 
Similar tumour growth suppressive effects were reported in DU145-derived prostate 
carcinomas and UC3-derived bladder carcinomas in nude mice (Hajitou et al., 2006b). The 
RGD4C AAVP-HSVtk vector was also systemically administered to athymic rats bearing an 
orthotopic model of SKLMS human soft tissue sarcoma and the results at day seven post 
GCV treatment demonstrated an extensive tumour destruction and tumour blood vessel 
apoptosis which resulted in tumour growth suppression (Hajitou et al., 2008).   
Further to these experiments, targeted RGD4C AAVP carrying Tumour Necrosis Factor α 
(TNFα) was systemically administered to mice bearing human melanoma (Tandle et al., 
2009). This systemic administration of targeted RGD4C AAVP/TNFα resulted in both 
tumour growth inhibition, and induction of apoptosis in tumour blood vessels. In a study 
carried out under the direction of the National Cancer Institute (NCI)- USA, targeted RGD4C 
AAVP was used to deliver TNFα to naturally occurring cancers diagnosed in pet dogs 
(Paoloni et al., 2009). In this study, single and repeated dosing using targeted AAVP-TNFα 
vector proved safe in treated animals. Remarkably, repeated therapy resulted in complete 
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tumour eradication in a few dogs with aggressive cancers such as fibrosarcoma (Paoloni et 
al., 2009). 
 
 
      a) 
 
 
      b) 
 
   
  
Figure 1.1. Schematic diagram of targeted AAVP vector. a) A mammalian transgene 
cassette flanked by ITRs from AAV2. b) AAVP particle bearing the targeting double-cyclic 
RGD4C ligand on the pIII minor coat protein. The virus structure consists of 2,700 - 3,000 
copies of the major coat protein pVIII with approximately 5 copies of the four minor capsid 
proteins pIII, pVI, pVII and pIX which are located at the ends of the filamentous particle. A 
mammalian transgene cassette flanked by ITRs from AAV is inserted into the intergenomic 
region of an RGD4C-FUSE5 bacteriophage. (ITR: inverted terminal repeat, pA: 
polyadenylation site). 
 
 
To date, the reports continue to show that AAVP can be used to target gene therapy to distant 
tumours after systemic administration, a route that is applicable for localized and metastatic 
disease. The ligand-directed RGD4C AAVP particle provides a suitable vector system 
candidate to target a Grp78-driven transgene expression cassette to the tumour tissue after 
systemic administration. Combining ligand and transcriptional targeting in one single vector 
5’ ITR 3’ ITRCMV GFP pA
PvuII PvuII
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would lead to a safer system with high specificity and strong transgene expression at the 
transcription level. Such a system would provide a novel double-targeted vector that would 
enhance the clinical applicability of the Grp78 promoter in cancer gene therapy. 
 
1.3 Therapeutic genes for cancer gene therapy 
 
In addition to generation of an efficient tumour-targeted vector for cancer gene therapy, the 
choice of the right therapeutic gene to eliminate tumour cells is important. Many different 
therapeutic genes with numerous different functions have been characterised and used in 
cancer gene therapy including antiangiogenesis genes, cellular stasis genes and suicide genes, 
which mediate cell death when expressed.  
As tumour growth and invasion are highly dependent on tumour vasculature, anti-
angiogenesis genes are emerging as promising therapeutic genes for many cancers. However 
for successful tumour treatment, continuous expression of anti-angiogenesis genes such as 
human Angiostatin (hANG), human Troponin I (hTnI) or soluble receptor (sFlt) for vascular 
endothelial growth factor (VEGF) is needed (Ohlfest et al., 2005).  
Other groups of therapeutic genes such as Rexin-G (which is known to interfere with the 
cyclin G1 gene) and p53 (an important cell-cycle regulator which is defective in cancerous 
cells) have also been used in cancer gene therapy in clinical trials and showed promising 
results against several different tumours such as pancreatic cancer, colon cancer (Gordon et 
al., 2004), head and neck squamous cancers, prostate cancer, glioma and bladder cancer 
(Merritt et al., 2001, Swisher et al., 2003, Cross and Burmester, 2006) respectively.  
 
In addition to the above, TNFα has been shown to have antivascular and antitumour activity 
(ten Hagen and Eggermont, 2003) and has been utilised in cancer gene therapy against 
several different tumours such as soft tissue sarcoma, pancreatic and rectal cancers and 
melanoma. However due to severe systemic toxicity of TNFα at therapeutic doses, there has 
been limited clinical utility of this gene (Burton and Libutti, 2009). Thus many studies 
attempted intratumoural injection of this gene and/or used inducible promoters to restrict its 
expression within the tumour cells (Rasmussen et al., 2002, Senzer et al., 2004).  
 
Suicide genes which necessitate the presence of the prodrug for their function as a therapeutic 
gene, have been proposed by Moolten (Moolten, 1986). HSVtk from the virus Herpes 
Simplex, the most widely used suicide gene in cancer gene therapy (Miller, 1992), has been 
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considered as an ideal therapeutic gene for cancer therapy. GCV, the prodrug of the HSVtk, 
is not toxic and can easily penetrate into tumour tissues and can be further taken up by 
individual cells after systemic injection. Moreover upon reaching the tumour cells, the protein 
product of HSVtk suicide gene which has 1000 times more affinity for the GCV than the 
mammalian tk , phosphorylates the GCV (Elion et al., 1977). Upon generation of 
monophosphate GCV, host cell kinases will further phosphorylate the GCV monophosphate 
and generate the highly toxic GCV triphosphate. As a guanosine analogue, the triphosphate 
form of GCV can incorporate into replicating DNA and inhibit DNA polymerase and further 
initiate the apoptotic pathway. Interestingly, GCV monophosphate, is also believed to induce 
cell death by being incorporated into the entire genome (Mesnil and Yamasaki, 2000). 
Although the exact mechanism of cell death with HSVtk/GCV is not fully understood, it has 
been clearly shown that cell apoptosis is due to GCV-induced cell-cycle arrest but not due to 
a direct chemical effect (Wei et al., 1998).  
The converted toxic GCV, of about 500 Da molecular weight, can be transported from 
transduced cells to neighbouring non-transduced cells through the Gap junctions and induce 
apoptosis of cells which do not contain HSVtk (Mesnil and Yamasaki, 2000). This recent 
unique phenomenon refered to as the bystander effect can augment the effect of toxic drugs 
by several fold and reduce the need for transduction of a high number of cells in order to 
mediate an efficient therapeutic effect.  
Despite the fact that HSVtk/GCV holds a great potential for cancer gene therapy, its toxicity 
for the dividing healthy tissue has limited its clinical usefulness. Thus, to circumvent the 
above problem, either direct intratumoural injection or using tumour-type-specific promoters 
such as α-fetoprotein to drive HSVtk expression have been attempted (Su et al., 1997). 
However, intratumoural perfusion of the vector is not a practical option for treatment of many 
tumour types and metastases. Thus development of a tumour targeted HSVtk delivery system 
should overcome the above limitations. Indeed as discussed earlier, targeted RGD4C AAVP 
vector was previously used to systemically deliver HSVtk under the control of CMV promoter 
to tumour-bearing mice and the results demonstrated significant tumour size reduction or 
marked tumour growth suppression compared to controls, with no evidence of systemic 
toxicity (Hajitou et al., 2006b). 
Moreover by transducing the tumour endothelial cells, recently targeted RGD4C 
AAVP/CMV-HSVtk has been shown to induce cell death in tumour vasculature and more 
importantly in non-transduced tumour cells both in vitro and in vivo (Trepel et al., 2009). 
These data suggest the presence of a bystander effect between the endothelial cells and 
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tumour cells, implying that the therapeutic efficacy of RGD4C AAVP/HSVtk will not be 
completely limited by transduction efficiency. Thus with its ability to specifically target and 
infect tumour vasculature, avoid normal tissues and mediate substantial tumour cell death via 
the HSVtk/GCV treatment, AAVP holds considerable promise to achieve HSVtk clinical 
applicability.  
On the other hand previous reports demonstrated strong expression of the HSVtk under the 
control of the Grp78 promoter in a variety of human tumours and its ablility to eradicate 
murine tumours and human xenografts in mice. Thus, as a potential therapeutic gene I aimed 
to utilise the HSVtk suicide gene in the context of a double-targeted RGD4C AAVP/Grp78 
vector for systemic cancer gene therapy. 
 
Work presented in this thesis 
  
This work centres around construction and further evaluation of a double-targeted RGD4C 
AAVP/Grp78 vector with the aim of combining ligand-directed chimera and transcriptional 
targeting to safely deliver transgene expression to tumour cells after systemic administration 
of the vector. 
 Chapter 3: constructing a double-targeted vector carrying 
either GFP or Luc reporter genes, or the HSVtk therapeutic gene. The generated 
double-targeted vector was further fully characterised in vitro using breast 
cancer and glioblastoma models. 
 
 Chapter 4: Focusing on the effect of CMV promoter silencing in the context of 
AAVP while showing long-term transgene expression mediated by the 
AAVP/Grp78 vector in vitro using human and rat glioblastoma models. 
 
 Chapter 5:  Showing a novel mechanism of Grp78 promoter induction 
by HSVtk and GCV suicide gene therapy. 
 
 Chapter 6: Presenting in vivo biodistribution of transgene expression as well as 
therapeutic effects of the final ligand-directed and transcriptionally targeted 
AAVP vector in subcutaneous models of glioblastomas in mice. 
 
 Chapter 7: Describing the effects of chemotherapeutic drugs on Grp78 promoter 
induction. 
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Chapter 2 
 
 
 
Materials and Methods 
 
 
 
2.1 General material sources 
 
Unless otherwise stated, all chemicals were purchased from Sigma Aldrich. All restriction 
enzymes were purchased from New England Biolabs. 
 
2.2 Plasmid 
 
Plasmid                          Source                 Description 
pDrive-rGRP78              InvivoGen            pDRIVE bearing the rat GRP78 promoter. 
 
pBluescript II SK(+/-)    Stratagene             Phagemid vector contains Amp
R
  sequence   
                                                                      for bacterial maintenance. T7 and T3      
                                                                      promoters flank the multiple cloning site                
                                                                      (MCS), which is situated in the lacZ gene. 
 
pGL4.20                          Promega               Containing the luciferase reporter gene   
                                                                      Luc2 (Photinus pyralis) and mammalian  
                                                                      selectable marker puro
R
 gene under the  
                                                                      control of SV40 early  enhancer promoter.  
                                                                      multiple cloning site (MCS) located       
                                                                      upstream of Luc2 for the cloning of a                                                               
                                                                      promoter of choice. 
  
pPUR                              Clontech                Selection vector that has the puro
R
 gene  
                                                                      under the control of SV40 early promoter  
                                                                      for mammalian selection and Amp
R
 gene   
                                                                      for bacterial maintenance.  
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2.3 Oligos 
 
Oligo                     Sequence (5’-3’) 
Rat-XBP-F            TTACGAGAGAAAACTCATGGGC 
Rat-XBP-R           GGGTCCAACTTGTCCAGAATGC 
Hu-XBP-F            TTACGAGAGAAAACTCATGGCC 
Hu-XBP-R            GGGTCCAAGTTGTCCAGAATGC 
GAPDH-F             CCTGTACGCCAACACAGTGC 
GAPDH-R            ATACTCCTGCTTGCTGATCC 
Grp78-R               TCACAGAGTCCAGCAACAGG 
PIII-F                     TAATACGACTCACTATAGGGCAAG CTGATAAACCGATACAATT 
PIII-R                     CCCTCATAGTTAGCGTAACGATCT 
 
 
All oligos were made by Invitrogen. The stock of 100 pmol/µl was stored at -20ºC and 8 
pmol/µl stock was kept at 4ºC. Forward primers (5’-3’) are named ending in (F) and reverse 
ending in (R).  
 
2.4 DNA cloning  
 
2.4.1 Agarose gel electrophoresis 
 
Electrophoresis of DNA was carried out as previously described (Sambrook, 1989). Agarose 
gels (between 0.5% to 2.5%) were prepared in 1x TAE (40mM Tris-acetate, 1mM EDTA) 
containing 0.5 µg/ml ethidium bromide (EtBr) for DNA visualisation. Samples were mixed 
with loading buffer, then loaded onto the gel alongside a DNA ladder and run at 80 Volts 
until the dyes had reached the desired position on gel. The bands were visualised under 
ultraviolet light using the UVP Bio Doc-It imaging system. The concentration of DNA was 
evaluated by visual comparisons of samples with known standards on agarose gels under UV 
transillumination. If DNA fragments were to be purified, a slice of agarose gel containing the 
DNA band of interest was cut out and isolated using the Qiaquick Gel Extraction kit 
(Qiagen), eluted in EB buffer.  
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2.4.2 Standard Polymerase Chain Reaction (PCR) 
 
Standard PCR was set up as follows: 1x GoTaq reaction buffer, 250µM dNTPs, 1.25 units 
GoTaq
TM
 DNA Polymerase (Promega), 20 pmol of each primer, 10% v/v of DMSO, 1mM 
MgCl2 in a final volume of 50µl. PCR reactions were carried out in the Biorad PCR machine. 
PCR conditions for GoTaq
TM
 DNA Polymerase were as follows: denaturing at 94ºC for 5 
minutes (1 cycle) followed by further denaturing at 94ºC for 30 seconds, annealing at 55 ºC-
60ºC for 1 minute and elongation at 72ºC (35 cycles; elongation time was determined on the 
basis of the processivity of the polymerase being 1 minute per kb of DNA). A final 
elongation step at 72ºC for 5 minutes (1 cycle) was carried out. PCR products were analysed 
by agarose gel electrophoresis 
 
2.4.3 Endonuclease restriction digestion 
 
Restriction digests were performed using 3 units of restriction enzyme per 1µg of DNA in 1x 
reaction buffer, 1% Bovine Serum Albumin (BSA) and appropriate amount of H2O. The 
mixture was incubated for 2-3 hours at the supplier recommended temperature. When 
necessary, restriction enzymes were heat-inactivated for 20 minutes at 65°C. Digested DNA 
was analysed by agarose gel electrophoresis.  
 
2.4.4 Dephosphorylation of DNA fragments 
 
For DNA dephosphorylation, 1pmol of digested DNA from the digestion reaction was added 
to 1 unit of Alkaline Phosphatase (AP) (Roche) and 1× AP reaction buffer. The reaction 
mixture was incubated at 37
°
C for 1 hour, and AP was irreversibly inactivated by heating at 
65
°
C for 30 minutes. The dephosphorylation process was necessary to prevent the self-
ligation of cloning vectors. 
 
2.4.5 DNA ligation 
 
Each ligation reaction was performed in a final volume of 20-30µl, containing vector/insert at 
the ratio of 1:6, 1x ligase buffer and 30 units of T4 DNA ligase (Fermentas). A tube of vector 
without insert was also included in order to estimate the background generated by vector 
alone. The mixture was incubated at 22
°
C for 4 hours, followed by overnight incubation at 
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18°C. The mixture was next transformed into E.coli Competent Cells. The next day, colonies 
were picked and grown in 5ml of Luria-Bertani (LB) broth containing appropriate antibiotics. 
After overnight incubation at 37°C in a shaker incubator, shaking at 250 revolutions per 
minute (rpm), plasmids were extracted and analysed by restriction digestion.  
 
2.4.6 Ethanol precipitation of DNA 
 
Final concentration of 10% v/v 3M Sodium acetate (NaAc) plus 200-250 v/v of ice-cold 
absolute ethanol were added to the DNA then mixed and incubated at -20°C overnight. After 
centrifugation, the DNA pellet was washed with 1 ml of 70% Ethanol and centrifuged again 
for 15 minutes. Next, the ethanol was discarded and the pellet of DNA was air-dried before 
re-suspension in 10-20 l of EB buffer. 
 
2.4.7 Generation of DNA blunt ends 
 
To make DNA blunt ends, DNA polymerase I large fragment (Klenow) (1unit/ µg DNA) and 
dNTP mix (33µM) (Invitrogen) were added to DNA. After 15 minutes incubation at 25°C, 
the reaction was stopped using 10mM EDTA, followed by further incubation at 75°C for 20 
minutes. 
Blunt ended DNA was further purified by ethanol precipitation and pellet was re-suspension 
EB buffer. 
 
2.4.8 DNA sequence analysis 
 
DNA sequence analysis of the Grp78 promoter was carried out by the DNA Core Laboratory 
in the Automated sequencing facility of Imperial College London using the Grp78-R primer 
(see section 2.3). 
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2.5 Protein analysis methods 
 
2.5.1 Protein extraction from tissue cultured cells 
 
To extract whole cell protein from cultured cells, first the medium was removed and cells 
were washed twice with cold 1x PBS, then RIPA lysis buffer (Thermo Scientific) 
supplemented with a protease-inhibitor cocktail (Roche) and phosphatase inhibitor sodium 
orthovanadate (2 mM) were added directly to the cells. A total of 150 µl of lysis buffer was 
used per well for cells grown on a 24-well plate. Using a pipette tip, the bottom of the wells 
was scraped to remove all cell residues. The entire lysate was collected and instantly placed 
on ice prior to centrifugation at 13,000 rpm for 10 minutes at 4 ºC. The supernatant was 
harvested and stored at -80ºC.  
 
2.5.2 Quantification of protein 
 
Protein concentration was quantified by using the Bradford method (Bradford, 1976). 315μl 
of Bradford reagent was mixed with 34μl dH2O and added to 1μl of lysate. Then, 100 μl of 
samples were added to a clear 96-well plate in triplicate and the absorbance measured at 
595nm using a Versamax microplate reader. The protein concentration of the samples was 
derived from a standard BSA curve. 
 
2.5.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Polyacrylamide gels were prepared as follows for the BioRad mini-protean gel apparatus. 
The 8% resolving gel consisted of 2.4 ml lower buffer (1.5 M Tris-HCl, 0.4% SDS pH 8.8) 
and 2.6 ml of 30% acrylamide, 4.9 ml water, 32 μl of 15% ammonium persulphate (APS) and 
5 μl of TEMED. The mixture was well mixed and poured immediately between the glass 
plates. The resolving gel was poured to about ¾ the height of the gel and overlaid with 300 μl 
of water. Once polymerised, the water was removed and the stacking gel (0.75 ml of 30% 
acrylamide, 1.87 ml of upper buffer (0.5 M Tris-HCl, 0.4% SDS pH 6.8), 4.87 ml water and 
7.5 μl TEMED, 75 μl 15% APS) was poured on top of the stacking gel. The comb was 
immediately inserted and the stacking gel was allowed to polymerise. A total of 50- 70 μg of 
sample proteins were mixed with sample buffer (60 mM Tris-HCl pH 6.8, 2% SDS, 20% 
Glycerol, 0.01% bromophenol blue and 100 mM DTT) and heated at 100ºC for 5 minutes 
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before loaded onto the gel. For all gels 8 μl of full-range rainbow molecular weight marker 
(GE Healthcare) was also loaded. Gels were run in 1x running buffer (192 mM glycine, 25 
mM Tris-base, 1% SDS) at 80 volts until the bromophenol blue present in the samples 
reached the resolving gel, then the voltage was increased to 140 volts until the dye reached 
the bottom of the resolving gel. 
 
2.5.4 Western Blot analysis 
 
Following separation by SDS-PAGE electrophoresis, proteins were transferred in 1x transfer 
buffer (25 mM Tris, 192 mM glycine, 0.02% SDS, 20% (v/v) methanol) onto immobullin-P 
PVDF transfer membrane using the BioRad Protean II mini trans-blot electrophoresis 
apparatus. PVDF membranes were first pre-soaked in 100% pure methanol for 1 minute, then 
placed in transfer buffer for a few minutes prior to transferring at 400mA for 1 hour. Once 
transferred, non-specific protein binding sites on the membrane were blocked by incubation 
with blocking buffer (1x TBS-T and 5% (w/v) milk [Marvel]) for 1 hour at room temperature. 
Subsequently the membrane was incubated with primary antibody for 2-3 hours at room 
temperature or overnight at 4ºC according to the manufacturer’s instructions. Primary 
antibodies were goat anti-Grp78 (C-20, 1:400), mouse anti-GAPDH (6C5, 1:1000) (Santa 
Cruz Biotechnology), rabbit anti-HSVtk (1:100) (Dr. William Summers, Yale university, 
USA), mouse anti-ATF6 (IMG-273, 5 µg/ml), (Imgenex, USA) and rabbit-anti phosphor-
eIF2α (1:1000), (Cell Signaling). Apart from the anti phosphor-eIF2α which was diluted in 
1x TBS-T and 5% (w/v) BSA, the rest of primary antibodies were diluted in 1x TBS-T and 
5% (w/v) milk. After incubation with primary antibody, membranes were washed for 3x 5 
minutes in blocking buffer. Next, membranes were incubated with a horse radish peroxidase 
(HRP)-conjugated secondary antibody for 1 hour. Membranes were washed 3x 10 minutes in 
1x TBS-T and secondary antibodies were detected with Super Signal West Pico 
chemiluminescence (ECL) (Thermo Scientific) according to the manufacturer’s instructions 
and exposed to X-ray films ((Biomax MS, Kodak). The density of each band was further 
quantified using ImageJ software and results were normalized against the density of the 
corresponding GAPDH band for each condition. 
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 2.6 Bacterial work 
 
2.6.1 Bacterial strains 
 
Competent E.Coli DH5α cells (ATCC) were used for routine cloning. 
Kanamycin-resistant Escherichia coli (K91 Kan
R
) was kindly provided by Professor 
Pasqualini & Arap, USA. This host bacterial strain was used for propagating filamentous 
phage (Smith and Scott, 1993).  
 
2.6.2 Media 
 
Autoclaved LB media or LB-agar plates (LB with 15g/l agar) were used for general bacterial 
growth. To select for a plasmid or AAVP vector, either one or a combination of antibiotics as 
shown below, were added to the medium. 
 
Antibiotics                           Final concentration 
Kanamycin (Kan)                100 µg/ml 
Tetracycline (Tet)                40 µg/ml 
Ampicillin (Amp)                 50 µg/ml 
 
2.6.3 Transformation 
 
2.6.3.1 Preparation of competent cells 
 
A single colony of E.coli DH5α cells was used to inoculate 5 ml of LB broth and grown 
overnight at 37ºC, in a shaker incubator shaking at 250 rpm. This culture was used to 
inoculate a 300ml to 1 litre LB medium and grown at 37ºC until the OD600 = 0.4-0.6. The 
cells were harvested by centrifugation (15 minutes, 4000 rpm) and the cell pellet was 
resuspended in ¼ of the initial volume of solution A (10 mM MnCl2, 50 mM CaCl2, 10 mM 
MES (from MES stock of 50 mM pH 6.3)) and incubated on ice for 30 minutes. The cells 
were harvested by centrifugation (15 minutes, 4000 rpm) using pre-chilled centrifuge bottles 
and rotors. The supernatant was discarded and the pellet was resuspended in 1/40
th
 the 
volume of solution A containing 15% glycerol. 100- 200 µl aliquots in pre chilled eppendorf 
tubes were quick frozen on a dry ice/ ethanol bath and then stored at -80ºC until required. 
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2.6.3.2 Heat shock 
 
DH5α competent cells, were thawed on ice and mixed with 10 to 100 ng of plasmid DNA. 
The cells were then incubated on ice for 20 minutes. The cells were heat-shocked at 42

C for 
40-45 seconds and immediately returned back on ice for 2 minutes. A volume of 250 l of 
super optimal broth (SOC) medium (Invitrogen) was added to each reaction and incubated for 
30-60 minutes at 37

C with 250 rpm of shaking. Dilutions of the transformation culture were 
plated on LB-agar plates containing the appropriate selective antibiotic and incubated 
overnight at 37

C. 
 
2.6.4 Recovery of plasmid DNA- Qiagen miniprep 
 
A single transformed bacterial colony was used to inoculate 5ml of LB medium containing 
the appropriate selective antibiotic. The culture was incubated overnight, shaking at 37
°
C. 
Plasmid DNA was extracted using a Miniprep kit (Qiagen) according to the manufacturer’s 
instructions. The culture of bacteria was centrifuged at 10,000×g for 10 minutes, then the 
bacterial pellet was thoroughly resuspended in 250µl P1 Resuspension Solution (50mM 
Tris.HCl, 10mM EDTA, and 100µg/ml RNase A) and lysed in 250µl P2 Cell Lysis Solution 
(0.2M NaOH and 1% SDS). The mixture was neutralized by adding 350µl of N3 
Neutralization Solution (4.2M guanidine hydrochloride, 0.9M potassium acetate, pH 4.8) and 
centrifuged at 17,900×g for 10 minutes at room temperature. The clear lysate was applied to a 
QIAprep spin column in collection tubes, centrifuged for 1 minute and the flow-through was 
discarded. The column was washed with PB buffer (5M guanidine hydrochloride 30% 
ethanol) and spun for 1 minute. The QIAprep spin column was washed with PE buffer (10 
mM Tris-HCL60%, 80% ethanol) by centrifugation at 17,000×g for 1 minute. The plasmid 
DNA was eluted with 30μl EB buffer by centrifugation for 1 minute at 17,000×g. DNA was 
stored at –20°C.  
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2.7 Phage work 
 
2.7.1 Phage production 
 
production and purification of AAVP protocol has been carried out as reported by Hajitou et 
al. (Hajitou et al., 2007). 
Kanamycin-resistant E.coli (K91) was grown in 7ml Terrific Broth (TB) at 37°C, in a 
shaking incubator (250rpm) until the cells reached log-phase growth. This was achieved by 
growing cells to the optical density (OD) of between 1.6 and 2.0 (OD600). Next, AAVP was 
incubated with 1ml of K91 for 1hour at room temperature, then transferred to 450 ml LB 
broth containing tetracycline and kanamycin and incubated for 14-16 hours at 37°C, with 
shaking (250rpm).  
The culture was then centrifuged at 6000×g for 30 minutes at 4°C, the supernatant was 
collected and the procedure was repeated again under the same conditions in order to remove 
bacterial debris. To precipitate the phage particles, the supernatant was incubated with 
Polyethylene-glycol/Sodium chloride (PEG/NaCl) (15% supernatant volume), for 2-3 hours 
on ice and then centrifuged at 10,000×g for 30 minutes at 4°C. The resulting viral pellet was 
resuspended in 10ml PBS with agitation for 30 minutes at 37°C. The precipitation with 
PEG/NaCl was repeated for a second time for 30 minutes on ice, followed by centrifugation 
at 14,000×g for 30minutes, at 4°C. The pellet was resuspended in sterile PBS, then filtered 
through a 0.45μm filter before titration.  
 
2.7.2 Titration 
 
Serial dilutions of the AAVP were prepared in PBS in order to achieve final dilutions of 10
8
 
and 10
9
. Then 5μl of the above dilutions were used to infect 1ml K91 cells (OD600 =1.6-2) for 
20 minutes at room temperature. Volumes of 20 and 200μl of infected cells were plated onto 
LB-Agar plates containing 40ug/ml Tetracycline and 100μg/ml Kanamycin. After overnight 
incubation at 37°C, the colonies were counted and titers were expressed as bacterial 
Transducing Units per μl (TU/μl).  
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2.7.3 PCR to verify the correct display of RGD4C 
 
The purity of the phage was checked by PCR. 5µl of the 1:1000 diluted phage in molecular 
biology grade water was mixed with standard PCR mixture (2.4.2). In order to amplify and 
sequence the targeting ligand inserted into the pIII phage DNA, the PIII-F and PIII-R primers 
were used (2-3). The PCR products from both targeted RGD4C AAVP and control insertless 
non-targeted vectors were run on an agarose gel and visualized using a transilluminator. 
RGD4C AAVP which display a targeting peptide within the site of the gene of the pIII coat 
protein display a shift on the gel compared to parental insertless non-targeted AAVP. 
 
2.7.4 Transduction of eukaryotic cells by AAVP 
 
Cells were seeded into 48–well culture plates. The cells were transduced when they reached 
approximately 80% confluency. Prior to transduction, cells were counted in order to calculate 
the number of vector TU/cell to add to each well. The medium was removed and replaced 
with 100µl serum-free medium containing either targeted RGD4C or non-targeted insertless 
AAVP phage encoding luciferase (Luc) or Green Fluorescent Protein (GFP) reporter genes 
or the HSVtk therapeutic gene at varying TU/ cell. Incubation of cells with vectors was 
carried out for 4 hours by manually mixing every 30 minutes in order to maintain 
homogeneous distribution of phage before adding 400µl of complete medium to the cells. 
GFP expression was monitored using a Nikon Eclipse TE2000-S fluorescence microscope 
fitted with a Nikon digital camera (DXM1200F); luciferase expression was quantified using a 
Turner Biosystems microplate luminometer and therapy was induced by addition of the GCV 
prodrug. Each variable experiment was set up in triplicate. 
 
2.8 Cell Culture 
 
2.8.1 Cell lines  
 
The Human Embryonic Kidney (HEK-293) cell line was obtained from the American Type 
Culture Collection (ATCC), Human breast cancer cells from Michigan Cancer Foundation-7 
(MCF-7) and human glioblastoma U87 cells (gift from Cancer Research UK) were also used. 
The rat glioblastoma 9L cell line was kindly provided by Dr Hrvoje Miletic, Norway. All the 
above cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 
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4.5 mg/ml glucose sodium pyrovate, and supplemented with 10% foetal bovine serum (FBS), 
100 units/mL penicillin, 100µg/ml streptomycin, and 2mM L-Glutamine (Sigma-Aldrich) at
 
37
°
C, in a humidified CO2 (5%) incubator.  
When cells reached 80-90% confluence, the medium was discarded and cells were washed 
once with PBS in order to remove residual serum. The cells were incubated at 37
 º
C with pre-
warmed trypsin- ethylenediaminetetraacetic acid (Trypsin-EDTA) for about 1-2 minute(s) 
until they were detached from the flask. Pre-warmed complete medium was added to the cells 
in order to inactivate the trypsin. HEK293 and 9L cells were regularly split 1:6, while MCF-7 
and U87 were split 1:4.  
Cells were tested for Mycoplasma contamination regularly by using the MycoAlert
 
Mycoplasma detection kit (Lonza). 
 
2.8.2 Freezing and thawing of the cells 
 
Cells were harvested where they were 70- 90% confluence and frozen. After trypsinization 
and centrifugation at 170×g for 5 minutes, the cell pellet was re-suspended in fresh cooled 
freezing medium (5% DMSO and 95% FBS). The cells were aliquoted into cryogenic vials, 
then placed into an isopropanol containing freezing container and frozen overnight at –70°C. 
Frozen cells were transferred to a liquid nitrogen container the following day. 
To thaw cells, complete medium was added to the frozen cells. Then, thawed cells were 
transferred to 9ml complete medium and centrifuged at 170×g for 5 minutes. The supernatant 
containing DMSO was discarded and the cell pellet was re-suspended in 5ml of complete 
medium and incubated in a 25cm
2 
tissue culture flask. 
 
2.8.3 Stress treatment 
 
Thapsigargin (TG) was purchased from Sigma-Aldrich. TG was prepared as a 1.92 mM stock 
solution in DMSO and added to cell cultures at 300 nM final concentration for 16 hours. 
A23187 was dissolved in DMSO and added to cell culture at 0.5µM and 2µM final 
concentrations for 5 hours.  
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2.8.4 Cell proliferation assay 
 
For the proliferation assay, the parental 9L, U87 and MCF-7 cell lines were seeded at a 
density of 10
4
 cells/ well of a 24-well plate in triplicate. Cells grown in 10% FBS-containing, 
medium as well as 0.5% FBS-containing medium, were tripsynized on days 2, 3, 4, 5 and 6 
and counted using trypan blue. Viable cells were counted by two observers and the 
experiment was performed twice (Correa et al., 2006).  
 
2.8.5 Transfection of Cells 
 
All plasmid transfections were carried out by using FuGene 6 transfection reagent (Roche) 
according to manufacturer's instructions. FuGene 6 transfection reagent was mixed with 
serum free medium and incubated at room temperature for 5 minutes. Then the DNA plasmid 
was added to diluted FuGene 6 reagent (1:3 w/v ratio of DNA to FuGENE 6) and incubated 
for 45 minutes at room temperature. The transfection mixture was added dropwise to 70-80% 
confluent cells, which were then placed at 37
°
C for a further incubation of 48 hours. In order 
to assess transfection efficacy, vectors carrying the reporter genes GFP or Luc were used.  
 
2.8.6 Generation of cells stably expressing the Luc reporter gene 
 
A pGL4-20 plasmid (Promega) containing a Luc reporter gene as well as a puromycin 
resistance gene was used for this purpose. This plasmid was transfected into 70-80% 
confluent cells in a 6-well plate. After 48 hours, cells of each were split and stably selected 
using appropriate puromycin concentration for approximately 2 weeks. Resistant cell clones 
were pooled, cultured in a 24 cm
2
 plate, then screened for luciferase activity by using the 
Luc-Screen® System (Applied Biosystems). The cells were expanded and continuously 
grown under selection. 
Prior to the start of the above experiment, the minimal concentration of puromycin required 
to kill cells that do not have the resistance gene was determined. Briefly, 5x10
4 
cells were 
plated per well of a 48-well plate, and when 70-80% confluent, cells were treated with 
different concentration of puromycin (0-10 µg/ml). Each concentration was applied in 
triplicate. Antibiotic containing medium was replaced every 2 days and cell killing was daily 
monitored under the microscope. The minimal puromycin concentration for 9L cells was 
7µg/ml and for U87 cells was 1µg/ml. 
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2.9 Luciferase enzymatic assay (in vitro) 
 
The Luc-Screen® System (Applied Biosystems) was used to determine luciferase reporter 
expression in cells transduced with AAVP carrying the Luc reporter transgene. Luc-Screen® 
reagents include two buffers which are added to culture medium in a 2:1:1 (culture medium: 
Buffer 1: Buffer 2) ratio. 
At indicated time-points, the old culture medium was replaced with 200μl of serum free 
DMEM. Lysis buffer (buffer 1, 100μl) was added to the cells and incubated at room 
temperature for 15minutes. Before addition of buffer 2 (100μl), 1μl of lysate was removed 
and used for Bradford assay.  
After 10 minutes incubation at room temperature, luciferase expression was quantified. 
Luciferase assays were performed in triplicate and normalised to 1µg cell protein. 
 
2.10 Fluorescence Activated Cell Sorting (FACS) 
 
The percentage of cells expressing GFP following stable cell transduction with either RGD4C 
AAVP/Grp78-GFP-puro
R 
or RGD4C AAVP/CMV-GFP-puro
R
 was determined using 
Fluorescence Activated Cell Sorting (FACS). U87 and 9L cells were seeded in 6-well plates 
at a density of 3 × 10
5
 cells/well in 6-well plates using complete DMEM. After 48 hours, 
cells were washed with PBS and trypsinised. Trypsin was neutralised with complete DMEM 
and cells centrifuged at 2000 rpm for 5minutes. The medium was removed and the cell pellet 
was resuspended in PBS containing 0.5% FBS and kept on ice until individual cells were 
analyzed by FACS. FACS analysis was performed using a FACScalibur instrument. GFP 
fluorescence signals were detected using a blue argon laser and standard FITC detector 
settings. To eliminate debris and dead cells, cells were manually gated on forward- and side-
scatter characteristics. A total of 20,000 individual cells were amounted within a manual gate 
in each condition.  
To validate reactivation of the CMV promoter activity, stably transduced U87 and 9L cells for 
GFP reporter gene as well as U87 and 9L parental cells, were seeded in 6-well plates. 24 
hours later, cells were treated with DNA methyltransferase inhibitor and HDACs inhibitor 
drugs for different time intervals, ranging from 1 to 3 days. Cells were monitored by 
fluorescent microscope during the time intervals. Afterwards, cells were washed, trypsinized 
and resuspended in PBS containing 0.5% FBS and analyzed by FACS. 
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The median fluorescence intensity (MFI) was used to define the fluorescence intensity of 
each cell population analyzed and % of GFP positive cells were calculated by normalizing to 
the control (parental cells grown in the similar condition). Data were analyzed using FlowJo 
software. 
 
2.11 In vitro cell killing using vectors carrying the HSVtk  
 
Each cell line, 9L and U87, was plated in triplicate at 3 x 10
4
 cells/well of a 48-well plate. 
After 24 hours, cells were transduced with either RGD4C targeted or insertless AAVP vector 
containing either Grp78 or CMV promoter driving the HSVtk suicide gene at the dose of 2
10
6
 TU vector particles/cell. Three days post-vector transduction, 9L and U87 cells were 
treated with 300 nM TG for 16 hours. Then, cells were incubated with medium containing 
20µmol/L GCV. Fresh GCV was added daily to the cells which were monitored under a 
microscope on a daily basis. Surviving cells were counted using the trypan blue dye 
exclusion method. 
 
2.12 Generation of stably transduced cells 
 
70% confluent 9L or U87 cells were transduced with either targeted RGD4C AAVP/Grp78-
puro
R
 or targeted RGD4C AAVP/CMV- puro
R
 AAVP phage encoding Luc or GFP reporter 
genes, or the HSVtk therapeutic gene at 2 x 10
6
 TU/ cell. At day 3 post-vector transduction, 
cells were trypsinized and suspended in medium containing an appropriate dose of puromycin 
(7 µg/ml for 9L cells and 1 µg/ml for U87 cells) in which only few cells could be seen per 
field of view of the microscope. Parental non-transduced cells were used as a control. 
The medium was removed and replaced with fresh medium containing puromycin every 2-3 
days. After around 2 weeks, all the control cells were killed by and puromycin- resistant 
single cell clones, which were derived from single cells, were monitored under the 
microscope. When the puromycin- resistant single cell clones were visible, either a 
population of clones or single cell clones were collected and expanded. Single cell clones 
were isolated and picked by autoclaved filter paper (Whatman). 4-5 mm
2
 paper was at first 
soaked with trypsin, then by using sterile forceps the paper was brought in contact with the 
cell clone and then transferred into a well of a 24-well plate and grown until 60-70% 
confluent. Subsequently the paper was removed and the cells were trypsinized and expanded. 
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At this point, stable selected clones were frozen and stored at -80ºC until needed. Note that 
all the stable selected cells were always maintained in medium containing puromycin. 
Stable selected GFP clones or population were imaged and monitored under a fluorescent 
microscope every 2-3 days and further analysed by FACS. 
Luciferase assay was performed to determine luciferase reporter expression in stable selected 
Luc clones or cell population. 
 
2.13 In vitro chemotherapy 
 
9L parental cells as well as 9L cells stably transduced with either RGD4C AAVP/CMV-
HSVtk- puro
R
 or RGD4C AAVP/Grp78-HSVtk- puro
R
 were plated at 7 x 10
4 
cells/ well of a 
24-well plates. After 24 hours, cells were incubated with increasing concentrations of 
cisplatin (0-100 µM) (kind gift from Dr. Paul Mintz, Imperial College London) or 
temozolomide (0-250 µM) for 12 hours. Chemotherapeutic drug concentrations were 
obtained from relevant literature (Mandic et al., 2003, Gaddameedhi and Chatterjee, 2009, 
Jiang et al., 2009, Pyrko et al., 2007).  
 
2.14 RNA Methods 
 
2.14.1 RNA extraction 
 
Using an RNeasy Mini Kit (Qiagen), total RNA was extracted from untreated or 9L and U87 
cells treated with GCV for various times or with Thapsigargin for 16 hours. Briefly, cells 
(around 106) were washed with cold 1x PBS and then 600μl of buffer containing 10 µl/ mL β-
mercaptoethanol was added to each well of 6-well plate. Cells were scraped using a rubber 
policeman and then an equal volume of 70% ethanol was added to the lysates and mixed by 
pipetting. Samples were applied to RNeasy spin columns in collection tubes, centrifuged for 
15 seconds at 15,000 rpm, and the flow-through was discarded. The RNeasy column was 
washed once with 700μl buffer RW1 (15 seconds at 15,000 rpm centrifugation), and twice 
with 500μl buffer RPE (15 seconds and 2 minutes respectively at 15,000 rpm centrifugation). 
The column was placed in a new 1.5ml collection tube and total RNA, bound to the 
membrane, was eluted with 30μl RNase-free water by centrifugation for 1 minute at 15,000 
rpm. RNA was stored at –80°C until used. Total RNA concentration and purity were 
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determined by measuring the absorption at 260nm using the Nanodrop ND-1000 
spectrophotometer (Agilent Technologies, DE, USA) and analysed on a 2% agarose gel. 
 
2.14.2 Reverse transcription 
 
1µg of total RNA, extracted from either U87 or 9L cells, was reverse-transcribed for cDNA 
synthesis using a “Super Script III First-Strand Synthesis SuperMix” (Invitrogen). According 
to the manufacturer’s instructions, 1µg of total RNA was mixed with 1μl Annealing Buffer 
and 50 ng random hexamers in a total volume of 8μl (made up with RNase-free water) and 
incubated for 5 minutes at 65
ºC. The reaction was placed back on ice and added to 10μl of 
First-Strand Reaction Mix and 2μl of SuperScript III Enzyme Mix. The reverse-transcription 
reaction was incubated for 7 minutes at 25
º
C, followed by 50 minutes at 50
º
C and terminated 
at 85
º
C for 5 minutes. cDNA was stored at –20°C until used.  
 
2.14.3 Semiquantitative RT-PCR 
 
Semiquantitative RT-PCR was carried out by following the standard PCR condition (2.4.2) 
and using 1μl of synthesised cDNA (around 500 ng) to determine both unspliced and spliced 
isoforms of XBP1. The 5’ to 3’ sequences of primers used to detect unspliced and spliced 
XBP1 mRNA are indicated in 2.3 (Samali et al., 2010). 
The size of PCR products for both human and rat species are as follows; unspliced XBP1= 
289 bp, spliced XBP1= 263 bp. The PCR products were checked on a 3.5% agarose gel. 
As an internal standard control, a PCR using both primers for GAPDH (2.3) was performed 
on each cDNA sample and the products were checked on a 2% agarose gel (Wang et al., 
2005). 
 
2.15 In vivo work 
  
Cells (80-90% confluent) were trypsinized, counted, washed twice with PBS by 
centrifugation and resuspeneded in serum-free DMEM medium. To establish tumours in 
mice, a total of 10
6
 cells from 9L rat glioblastoma
 
or 10
7
cells from U87 human glioblastoma 
were subcutaneously implanted into the right flank of 5-7 weeks old female immunodeficient 
nude mice (20-25gram). Tumour growth was monitored and once tumours reached the 
desired volume, tumour-bearing mice were anesthetized by 2% isoflurane and 98% oxygen 
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inhalation and received a single intravenous dose of targeted or insertless non-targeted AAVP 
(5x 10
10
 TU /mouse resuspended in 200µl PBS) through the tail vein. To compare the growth 
of tumours in mice between the different groups and to establish tumour growth curves, 
tumour size was monitored
 
by caliper measurement and tumour volume was calculated from 
the below formula and expressed
 
as the mean tumoural volume ± standard error of the mean 
(s.e.m), (Hajitou et al., 2006b, Hajitou et al., 2008, Arap et al., 2004): 
Tumour volume (mm
3
) = (width) 
2
 x (length) x 0.4
   
 
2.15.1 Bioluminescence imaging 
  
Vectors carrying the reporter gene Luc encoding the firefly luciferase were used to evaluate 
gene delivery to tumours as well as vector biodistribution. Luciferase expression was 
monitored over a time course in order to determine initiation and maximal expression after 
administration of vector. To monitor the luciferase expression, mice were anesthetized and 
administered with 100 mg/kg of D-luciferin (Gold Biotechnology) by subcutaneous injection 
into the loose skin over the neck. Five minutes post D-luciferin injection, photonic emission 
was imaged using the In Vivo Imaging System (IVIS 100) (Caliper life Sciences). To avoid 
image saturation various imaging times (from 1 second to 5 minutes) were applied depending 
on signal strength. A region of interest (ROI) was defined manually either over the tumours 
or whole body to measure signal intensities. Within experiments the area of the ROI was kept 
constant and the intensity was recorded as total photon counts per second per cm
2
 per 
steradian (photons/sec/cm
2
/sr) within a ROI. Negative control, insertless AAVP vectors were 
used in these experiments to validate specificity. For all the representative images the same 
colour scale bar was applied. 
 
2.15.2 In vivo gene therapy using vectors carrying the HSVtk 
 
To assess the therapeutic efficacy of the HSVtk suicide gene in vivo, tumour-bearing mice 
were randomly sorted and RGD4C targeted or insertless AAVP vector carrying the 
therapeutic gene HSVtk was delivered intravenously through the tail vein. At day 3 post 
vector injection, mice received intraperitoneal injections of the GCV prodrug at a dosage of 
75 mg/kg/day until the experiment had ended or mice were sacrificed. 
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Growth of tumours in mice between the different groups was measured by caliper and tumour 
viability was monitored by Bioluminescnce imaging of tumour cells stably expressing the 
Luc reporter gene.  
 
2.16 Histology 
 
Mice were culled and tumours surgically removed. Harvested tumours were embedded in 
OCT and snap frozen in liquid nitrogen, then stored at -80º C. Tumour sections were made at 
7µm thickness with a Cryostat microtome and placed on glass slides. The sections were air 
dried for 30-60 minutes and either stained immediately or stored at -80º C. 
 
2.16.1 Haematoxylin and Eosin (H&E) staining 
 
Sections of snap-frozen tumours were air dried for a few minutes to remove moisture, then 
immersed in filtered 0.1% haematoxylin for 10 minutes. Next, the sections were washed in 
running tap water for 5 minutes. This was followed by immersing the sections in 1% eosin 
for 2 minutes and then they were briefly dipped in water until the eosin stop streaking. 
Stained tumour sections were next dehydrated in 70%, 95% and 100% ethanol for 10 
minutes, 30 and 60 seconds, respectively. The slides were cleared by immersing them in 
xylene for several times and mounted in DPX mounting media before adding the coverslips. 
 
2.17 Statistics 
 
Statistical analyses were performed by using GraphPad Prism software (version 5.0). Error 
bars represent standard error of the mean (s.e.m). P values were generated by ANOVA and 
denoted as follows: *p < 0.05, **p < 0.01 and ***p < 0.001. 
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Chapter 3 
 
 
Generation and functional characterization of the dual tumour-
targeting phage 
 
 
 
 
 
3.1 Introduction 
 
One of the major challenges in cancer gene therapy is generating a systemic gene delivery 
vector that can selectively target malignant tissues and mediate efficient level of transgene 
expression solely within tumour cells. In order to strictly ensure transgene expression in 
target cells, one main strategy is to introduce one or multiple checkpoints which act as 
barriers to cell entry and gene expression within the host.  
Transcriptional targeting has been widely introduced in gene therapy vectors and has been 
considered an important checkpoint barrier. In cancer gene therapy, many tumour specific 
promoters have been identified and characterized; however, the promoter encoding Grp78 
has gained an increasing interest because of its high activity in a variety of primary tumours 
and metastases. 
Indeed, previous reports have shown induced therapeutic gene expression, driven by the 
Grp78 promoter in various tumours leading to complete tumour eradication while no 
therapeutic gene expression was detected in normal tissues (Dong et al., 2004, Chen et al., 
2000, Azatian et al., 2009).  
In addition to transcription targeting, ligand-directed targeting of vectors has been considered 
as another major checkpoint in systemic targeted gene therapy. In 2006, Hajitou et al. have 
reported an efficient systemic vector able to specifically target αv-integrins overexpressed on 
tumour vasculature and tumour cells (Hajitou et al., 2006c). 
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This targeted vector, which is a chimera between two single stranded DNA, AAV and a 
targeted filamentous M13 bacteriophage (AAVP), was genetically modified to express the 
RGD4C motif on the minor pIII coat protein of the filamentous phage thereby specifically 
targeting AAVP to the αv-integrins. The RGD4C AAVP vector proved efficient in targeting 
tumour vasculatures and tumour cells, and drive transgene expression within those cells after 
systemic administration.  
Moreover the targeted RGD4C AAVP vector carrying the HSVtk gene under the control of 
the CMV promoter demonstrated significant tumour growth suppression following GCV 
administration (Hajitou et al., 2006b, Hajitou et al., 2008).  
Although the CMV promoter has been shown to drive high level of transgene expression 
within cells, its non-specific activity and its susceptibility to silencing is problematic in the 
context of cancer gene therapy. Grp78 is therefore an attractive candidate as an inducible 
promoter to tightly control and mediate high levels of transgene expression within primary 
tumour, metastasis and tumour vasculature.  
Thus, for the first time we aimed to combine transcription targeting and ligand-directed 
targeting in one vector system in order to generate a double-targeted vector. 
The results of this chapter mainly describe the generation of a double-targeted AAVP vector 
displaying the RGD4C ligand and carrying the Grp78 inducible promoter. The next aim was 
to compare gene expression levels by the double-targeted vector to those obtained by using 
the original AAVP vector carrying the standard CMV promoter in cancer cells in vitro. 
Moreover, the therapeutic efficacy of the double-targeted AAVP vector carrying therapeutic 
genes was assessed in vitro against glioblastoma cells. 
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3.2 Results 
 
3.2.1 Generation of double-targeted phage vector 
 
3.2.1.1 Construction of RGD4C AAVP/Grp78-GFP and RGD4C AAVP/Grp78-HSVtk 
vector 
 
To generate the double-targeted vector displaying the RGD4C ligand and carrying the Grp78 
promoter, the CMV promoter was removed from the RGD4C AAVP vector and replaced by 
the Grp78 promoter. I used the Grp78 promoter of rat as a proof of principle because the 
promoter sequences of Grp78 are highly conserved among rodents and human, with 86% 
sequence identity between humans and rats (Ting and Lee, 1988). Moreover, it has been 
shown that this promoter is active in a wide range of species including human, rat and murine 
cells (Dong et al., 2004, Chen et al., 2000). Thus, a pDrive-rGRP78 plasmid containing the 
rat rGrp78 promoter was purchased from Invivogen. In the original RGD4C AAVP vector, 
the CMV promoter is flanked by NheI and NotI restriction sites. Thus, the 768-bp region 
containing the CMV promoter was removed from AAVP by NheI and NotI double restriction 
digestion. The strategy of cloning aimed at first flanking the rat Grp78 promoter by NheI and 
NotI restriction sites followed by ligation into the AAVP plasmid vector. This cloning 
procedure was carried out in two steps: 
 
Step-1. Subcloning of the Grp78 fragment into the XbaI site of the MCS of pBluescript II in 
order to flank the Grp78 fragment by SpeI and NotI (SpeI can ligate to NheI). 
Step-2. The plasmid generated in step-1 was used to release the Grp78 promoter flanked by 
SpeI and NotI followed by ligation into the AAVP plasmid. 
 
Step-1. To release the 689bp fragment containing the rat Grp78 promoter, the pDrive-
rGRP78 was double digested with PstI and NcoI. The purified Grp78 fragment from the 
agarose gel was blunted with DNA polymerase then ligated to XbaI linkers. After restriction 
digestion with XbaI, the Grp78 was ligated into the XbaI site of the pBluescript II plasmid 
(Fig. 3.1a). The unique XbaI site in the pBluescript is located between the NotI and SpeI 
restriction sites. The positive recombinants were identified by XbaI digestion and agarose 
electrophoresis. In order to determine the correct orientation of Grp78 among the positive 
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clones, pBluescript-Grp78 was digested with SmaI, a unique restriction site located in the 
Grp78 promoter as well as in pBluescript adjacent to the SpeI site (Fig. 3.1a).  
The recombinant plasmid showing the right direction for the Grp78 promoter was digested 
with the restriction enzymes NotI and SpeI in order to release the Grp78 promoter. The 
Grp78 promoter fragment was then ready to replace the CMV promoter in the AAVP 
plasmid. 
Step-2. The SpeI/NotI fragment containing the Grp78 promoter was ligated into the AAVP 
plasmid digested with NheI and NotI (Fig. 3.1b). Double digestion with NotI and EcoRI were 
performed to release the Grp78 promoter and to detect the positive colonies (Fig. 3.1b).  
Targeted RGD4C AAVP/Grp78-GFP and RGD4C AAVP/Grp78-HSVtk as well as control 
insertless vectors driving GFP and the HSVtk transgenes under the control of the Grp78 
promoter were generated following the above cloning procedure.  
 
3.2.1.2 Construction of the RGD4C AAVP/Grp78-Luc vector 
 
A different cloning strategy was followed in order to construct vectors carrying the firefly 
luciferase (Luc) reporter gene as the NheI restriction site is also located within the Luc region 
of the AAVP/CMV-Luc (Fig. 3.2). Briefly, AAVP/Grp78-GFP plasmids were digested with 
NotI and SphI in order to remove a fragment containing GFP and replaced by a NotI-SphI 
Luc-containing fragment from the AAVP/CMV-Luc (Fig. 3.2). 
Targeted and control vectors were amplified, isolated and purified from the culture 
supernatant of host bacteria (E. coli K91) as described in material and methods. 
 
Finally, the Grp78-R primer (Section 2.3) was designed to confirm the Grp78 promoter 
sequence in all the vectors generated above. 
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Figure 3.1. Schematic chart describing the construction of the double-targeted RGD4C 
AAVP/Grp78 vector. a) Plasmid maps of the pDrive-rGRP78 and pBluescript II SK (+/-). 
Restriction sites used for the subcloning of Grp78 promoter into pBluescript plasmid are 
shown. The Grp78 promoter was released by PstI and NcoI, ligated to XbaI linkers, then 
inserted into the XbaI site of the pBluescript. b) the Grp78 promoter flanked by SpeI and NotI 
was released from pBluescript and ligated into the AAVP plasmid digested with NheI and 
NotI. (Shble: zeocin-resistance gene, LacZ: β-galactosidase gene, amp: ampicillin resistance 
gene, TetR: tetracycline resistance gene, ITR: inverted terminal repeat, pA: polyadenylation 
site). 
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Figure 3.2. Schematic chart describing the construction of the RGD4C AAVP/Grp78-
Luc. The Luc gene flanked by SphI and NotI was released from the AAVP/CMV-Luc plasmid 
and ligated to the RGD4C AAVP/Grp78-GFP plasmid digested with SphI and NotI to replace 
GFP. (Luc: luiferase gene, TetR: tetracycline resistance gene, ITR: inverted terminal repeat, 
pA: polyadenylation site). 
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3.2.2 Characterization of a double-targeted vector using the HEK293 standard cellular 
model 
 
3.2.2.1 Transfection and induction of Grp78 in the context of the AAVP plasmid 
 
Before starting production of the phage viruses we aimed to test whether the Grp78 promoter 
retains its inducible function in the AAVP plasmid constructs generated above. Thus, 
HEK293 cells were transfected with the AAVP/Grp78-GFP naked plasmid. After 4 days, 
detectable GFP expression could be seen in a few cells transfected with this plasmid. Then, 
the HEK293 cells were treated with thapsigargin (TG), a standard inducer of the Grp78 
promoter. TG acts through blockage of the endoplasmic reticulum calcium adenosine 
triphosphatase (ATPase) pump and depletes the endoplasmic reticulum Ca
2+
 store (Denmeade 
and Isaacs, 2005, Li et al., 1993) which is required for normal protein folding, glycosylation 
and subunit association. At day 4 post plasmid transfection, cells were treated with 300nM 
TG for 16, 24 and 48 hours (Fig. 3.3). The TG concentration was chosen based on previously 
published data (Li et al., 1993, Harding et al., 2000). GFP expressing cells were monitored 
under a fluorescent microscope and at day 8 post-TG treatment, higher levels of GFP 
expression was observed from the AAVP/Grp78 plasmid construct treated with TG compared 
to untreated cells.  
 
These results confirm the inducible function of the Grp78 promoter in the plasmid constructs 
generated. Therefore, these plasmids were used to produce the AAVP phage viral particles. 
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Figure 3.3. ER stress induces GFP transgene expression driven by the Grp78 promoter 
in HEK293 cells. Cells were plated in 48-well plates to reach 70-80% confluence, then 
transfected with the AAVP/Grp78-GFP plasmid. At day 4 post-transfection, cells were 
incubated with 300nM TG for 16, 24 and 48 hours. As control, untreated cells were also 
included for comparison. GFP expression was observed under fluorescence microscope using 
a 20x objective and photographed at the indicated days. Scale bar = 45μm. 
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3.2.2.2 Transduction and induction in the context of RGD4C AAVP/Grp78 phage viral 
particle 
 
Next, it was determined whether the stress-inducible Grp78 promoter is functional in vitro in 
the context of the AAVP phage viral particle. As an initial in vitro model, the normal 
immortalised HEK293 cell line was used. These cells had previously been used as a standard 
in vitro model for transduction by RGD4C AAVP as they express high levels of the αvβ3 and 
αvβ5 integrin receptors of the RGD4C ligand (Hajitou et al., 2007, Hajitou et al., 2006b).  
To date, in most published reports, cells transduced with Grp78 expression cassettes have 
been selected and the promoter activity was thus analysed in vector-transduced and selected 
cells. Herein, no selection during transduction was applied. Hence, HEK293 cells were 
incubated with RGD4C AAVP/Grp78-GFP or control insertless AAVP/Grp78-GFP at 2x10
6
 
TU/cell. After 5 days, no GFP expression was observed in cells transduced with RGD4C 
AAVP/Grp78-GFP. However, when HEK293 cells transduced with targeted RGD4C 
AAVP/Grp78-GFP were treated with 300 nM or 400nM TG for 16hours at day 5 post-vector 
transduction, GFP expression was induced compared to untreated cells (Fig. 3.4). Since the 
GFP expression level was similar with both TG concentrations used above, it was decided to 
use the low 300 nM TG in future experiments. Moreover, induction of the Grp78 promoter 
was confirmed by using the calcium ionophore A23187 that also depletes calcium in the 
endoplasmic reticulum (Fig. 3.4). Transduced HEK293 cells with targeted RGD4C 
AAVP/Grp78-GFP were treated with either 0.5 or 2 µM of A23187 for 4 hours (Resendez et 
al., 1988). The data showed that induction of the Grp78 promoter was achieved in both 
conditions (Fig. 3.4).  
Also no GFP expression was detected in cells that received control insertless AAVP/Grp78-
GFP vector lacking the RGD4C and either TG or A23187. 
 
These results show that the Grp78 promoter is inducible and functional in the context of the 
AAVP phage viral particle. Importantly, the RGD4C AAVP/Grp78 can function as a double-
targeted vector at the transcriptional level with the Grp78 promoter as well as at the capsid 
level with the RGD4C ligand to target αv integrin receptors on HEK293 cells.  
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Figure 3.4. Double-targeted RGD4C AAVP/Grp78 phage viral particles mediate GFP 
transgene expression in HEK293 cells upon TG treatment. Human HEK293 cells (70-
80% confluent in a 48 -well plate) were incubated with targeted RGD4C AAVP/Grp78-GFP 
or control insertless AAVP/Grp78-GFP (2x10
6
 TU/cell). Five days later, cells were 
incubated with either TG (300 or 400 nM) for 48 hours or A23178 (0.5 or 2µM) for 5 hours. 
A control condition of untreated cells was also included for comparison. GFP expression was 
observed under fluorescence microscope using a 20x objective and photographed at the 
indicated days. Scale bar = 45μm. 
 
 
3.2.3 In vitro characterization of the double-targeted vector in tumour cell models 
 
3.2.3.1 Targeted RGD4C AAVP/CMV vector- mediated transgene expression in tumour 
cells in vitro  
 
Next I aimed to evaluate the efficacy of the double-targeted RGD4C AAVP-Grp78 vector to 
transduce cancer cells in vitro by using the 9L rat and U87 human glioblastoma, as well as 
the MCF-7 human breast cancer cell lines. Prior to evaluation of the double-targeted vector, it 
was first sought to confirm and assess the ability of the conventional RGD4C AAVP/CMV 
vector to transduce these cells. Tumour cells 9L, U87 and MCF-7 were incubated with the 
targeted RGD4C AAVP/CMV-GFP vector. Insertless AAVP/CMV-GFP was used as a 
negative control. GFP expression was detected in all these cell lines incubated with the 
targeted RGD4C AAVP/CMV vector while no transgene expression was observed in cells 
treated with the control vector (Fig. 3.5). These results indicate that the RGD4C AAVP 
vector can successfully transduce 9L, U87 and MCF-7 tumour cells in a ligand-dependent 
manner.  
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Figure 3.5. Targeted RGD4C AAVP/CMV particles mediate GFP transgene expression 
in tumour cells. 9L, U87 and MCF-7 tumour cells (70-80% confluent in a 48 well-plate) 
were incubated with targeted RGD4C AAVP/CMV-GFP along with control insertless 
AAVP/CMV-GFP (1x10
6
 TU/cell). GFP expression was analysed under a Nikon Eclipse 
fluorescence microscope using a 20x objective and photographed. Scale bar = 45μm. 
 
 
3.2.3.1.1 Optimal dose of AAVP vector for tumour cell transduction 
 
Previous reports have demonstrated that between 8-11% of HEK293 cells transduced with 
1x10
6
 TU/cell of RGD4C AAVP/CMV-GFP show transgene expressions (Hajitou et al., 
2007). Thus, prior to assessing the stress-inducible function of the Grp78 promoter in the 
context of the AAVP vector in tumour cells, I first aimed to determine the optimal AAVP 
dose for transduction of tumour cells. For this purpose, 9L, U87 and MCF-7 cells were 
transduced with increased doses of targeted RGD4C and the insertless control; AAVP/CMV-
Luc, at 0.25x10
6
, 0.5x10
6
, 1x10
6
, 1.5x10
6
 and 2x10
6
 TU/cell. Previous studies have shown 
that transduction with RGD4C AAVP/CMV results in transgene expression within 48-72 
hours post-vector transduction and reaches a maximum level by one week (Hajitou et al., 
2007, Hajitou et al., 2006b). At day 7 post-vector transduction, cells treated with either 
targeted or control AAVP-Luc were lysed, and Luc transgene expression was analysed by 
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luciferase assay. The results were then normalised to protein level (Fig. 3.6). The results 
confirmed successful transduction of both tumour cell lines with targeted RGD4C 
AAVP/CMV and also showed that transgene expression was dose-dependent with the highest 
expression obtained at 2x10
6
 TU/cell. Most importantly, a very negligible transgene 
expression was observed in MCF-7 cells incubated with a high dose of control insertless 
AAVP (Fig. 3.6a) while no luciferase transgene expression was detected in 9L cells 
transduced with control AAVP (Fig. 3.6b). These results demonstrate that the specificity of 
ligand-targeted AAVP vector is intact even with high phage particle/cell doses. Therefore, it 
was decided to transduce all tumour cells at 2x10
6
 TU/cell to achieve the highest transgene 
expression. 
 
3.2.3.2 Characterisation of AAVP vector-mediated transgene expression  
 
Subsequently, I assessed the efficacy of the double-targeted vector to transduce 9L, U87 and 
MCF-7 tumour cells by using the RGD4C AAVP/Grp78-Luc vector. Transduction efficiency 
was determined and compared to that of the targeted RGD4C AAVP/CMV-Luc. Insertless 
AAVP/Grp78-Luc and AAVP/CMV-Luc vectors were used as negative controls. Luciferase 
quantification was performed on transduced cells at the indicated days (Fig. 3.7). Luciferase 
quantification by RGD4C AAVP/Grp78-Luc and RGD4C AAVP/CMV-Luc vectors was 
normalised to control insertless AAVP/Grp78-Luc and AAVP/CMV-Luc vectors, 
respectively (Fig. 3.7). 
 
At day 5 post-vector transduction, the basal CMV promoter activity in 9L glioblastoma cells 
was approximately two fold higher than that of the Grp78 promoter (Fig. 3.7a). However, at 
day 7 post-vector transduction the CMV promoter activity decreased while the Grp78 
promoter activity increased by 2- fold to become 1.5- fold stronger than the CMV activity 
(Fig. 3.7a). Treatment with TG resulted in a 1.2- fold increase of Grp78 promoter activity, 
while transgene expression from the CMV promoter remained unchanged (Fig.3.7a). 
 
In U87 cells, the basal CMV promoter activity was 11- fold higher than that of the Grp78 
promoter at day 3 post-vector transduction (Fig. 3.7b). Interestingly, at day 7 the Grp78 
promoter activity increased by ~3- fold while the CMV promoter activity dramatically 
decreased to levels similar to those of the Grp78 promoter. TG treatment of cells resulted in a 
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1.7- fold increase of the Grp78 promoter activity at day 7 post-vector transduction, while 
only a slight increase of the CMV promoter activity was detected (Fig. 3.7b).  
 
For MCF-7 cells, the basal CMV promoter activity was 15- fold higher than that of the Grp78 
promoter at day 5 post-vector transduction. A dramatic decrease of the CMV promoter 
activity was observed overtime at day 10 post-vector transduction, but was still stronger (6.3- 
fold) than that of the Grp78 promoter. In contrast, the basal Grp78 promoter activity 
increased by 1.2- fold at day 10 post-vector transduction. TG treatment of cells resulted in a 
2.2- fold increase of the Grp78 promoter activity while a slight increase in the CMV promoter 
activity (1.2) was detected (Fig. 3.7c). 
 
In summary, these results show that: (i) the basic activity of the Grp78 promoter in the 
context of the RGD4C AAVP vector varied from one tumour cell line to another with the 
highest level in the 9L glioblastoma cells, and (ii) depletion of ER calcium, caused by TG, 
stimulated the Grp78 promoter activity in all three cell lines, indicating that the Grp78 
promoter is active in a stress inducible manner in the context of AAVP viral phage particles. 
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Figure 3.6. RGD4C AAVP mediated dose-dependent transgene expression in MCF-7 
and 9L cells. Cells were seeded in 48-well plates and grown until 70-80% confluent before 
transduction for 4 hours with control AAVP/CMV or targeted RGD4C AAVP/CMV carrying 
the Luc reporter transgene. Each experiment was performed twice with results of one 
representative experiment shown here. Luciferase expression in a) MCF-7 cells and b) 9L 
cells, following transduction with different AAVP TU/cell. The luciferase assay was 
performed at day7 post-transduction and normalised to protein concentration. Results 
represent the average Relative Luminescence Units/100 µg (RLU/100µg) protein of triplicate 
wells +/- the standard error of the mean (s.e.m).  
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Figure 3.7. Double-targeted RGD4C AAVP/Grp78 mediated transgene expression in 
tumour cells. Breast adenocarcinoma and glioblastoma cells (70-80% confluent in a 48-well 
plate) were incubated with either double-targeted RGD4C AAVP/Grp78-Luc or RGD4C 
AAVP/CMV-Luc. Control AAVP containing either Grp78 or CMV promoter were used as 
negative controls. Luciferase assay was performed at the indicated days and normalised to 
protein concentration using the Bradford assay. Results represent the average Relative 
Luminescence Units/ µg protein (RLU/µg) of triplicate wells. Luciferase quantification of 
targeted RGD4C AAVP/Grp78-Luc and RGD4C AAVP/CMV-Luc have been normalised to 
control insertless AAVP/Grp78-Luc and AAVP/CMV-Luc respectively. Error bars represent 
standard error of the mean (s.e.m). a) 9L cells were treated with TG (300nM-16hr) at day 5 
post- vector transduction. b) U87cells were treated with TG at day 3 post-vector transduction. 
c) MCF-7 cells were treated with TG at day 5 post-vector transduction. *p < 0.05, **p < 0.01, 
***p < 0.001and ns: non-significant. 
 
 
3.2.3.2.1 Evaluation of endogenous Grp78 level in different tumour cell lines 
 
Luciferase transgene expression mediated by the double-targeted RGD4C AAVP/Grp78 
vector demonstrated different levels of Grp78 promoter activity in 9L, U87 and MCF-7 cells. 
To further evaluate the Grp78 activity within our selected tumour cell lines, I examined the 
level of endogenous Grp78 by western blot analysis (Fig. 3.8a). Interestingly, similar to the 
results above, the Western blot results normalized to loading control GAPDH demonstrated 
different levels of Grp78; with 9L cells expressing the highest level, U87 exhibiting 
intermediate level, while MCF-7 had the lowest level of Grp78 expression (Fig. 3.8b).  
Over-activity of the endogenous Grp78 promoter has been previously reported in malignant 
tissues, including tumour-associated vasculature and tumour cells themselves (Pfaffenbach 
and Lee, 2011, Virrey et al., 2008, Dong et al., 2011, Lee, 2007). Moreover, up-regulation of 
Grp78 level in the majority of malignant glioma cells with varying levels from one cell line to 
another had previously been shown (Pyrko et al., 2007). It has been reported that Grp78 
protein level is required for glioma cell growth; thus, cells with the fastest proliferation rate 
exhibit the highest level of Grp78 and down regulation of Grp78 level will markedly slow 
down cell growth (Pyrko et al., 2007).  
To address the correlation between Grp78 activity and cell proliferation rate, the growth 
curves of all three cell lines were examined. 9L, U87 and MCF-7 cells grown in complete 
DMEM medium were plated in 6- well plates, then the cells were trypsinized, counted daily 
and numbers displayed graphically to depict proliferation rates over 5 days (Fig. 3.8c). 
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Interestingly, 9L cells with the highest Grp78 protein level showed the highest proliferation 
rate relative to the other two cell lines. U87 and MCF-7 cells showed intermediate and low 
proliferation rates, respectively. These results are in agreement with previous studies showing 
the positive correlation between Grp78 protein level and cell proliferation rate. 
 
 
 
 
Figure 3.8. Characterisation of the endogenous Grp78 level in tumour cells. a) 9L, U87 
and MCF7 cells were grown under standard conditions until 70-80% confluent , then lysed 
and their endogenous Grp78 protein levels determined by western blot. b) The intensity of 
Grp78 protein bands obtained by three independent Western blots (3.8b) were measured and 
normalised to GAPDH intensity. c) Proliferation rates of 9L, U87 glioblastoma and MCF7 
breast adenocarcinoma were quantified by counting cells over time. For growth curves 9L, 
U87 and MCF-7 cells (1x10
4
)
 
were plated in 24-wells plates and grown under standard 
conditions. Triplicates were collected on days 1, 2, 3, 4 and 5 with trypsin- EDTA, and 
counted using trypan blue. This experiment was performed twice. Results represent the 
average of 3 independent western blot analyses. Error bars represent standard error of the 
mean (s.e.m).  ***p < 0.001. 
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3.2.3.2.2 Induction of Grp78 level by TG in tumour cells 
 
To verify the effect of TG on the endogenous Grp78 protein level, the tumour cells 9L, U87 
and MCF-7 were incubated with 300nM TG for 16 hours. Then equal amount of sample 
proteins extracted from treated or untreated cells with TG were subjected to western blot 
analysis. Endogenous Grp78 level was normalized to GAPDH and the results confirmed 
induction of Grp78 level by 1.4-, 3.4- and 2.2 -fold upon TG treatment in 9L, U87 and MCF-
7 cells, respectively (Fig. 3.9). 
 
 
 
 
Figure 3.9. Thapsigargin induces endogenous Grp78 in tumour cells. 9L, U87 
glioblastoma and MCF7 breast adenocarcinoma cells were grown in the presence or absence 
of 300nM TG for 16 hours, then lysed, harvested and analysed by Western blot with 
antibodies against Grp78 and also GAPDH as a control. 
 
 
3.2.3.3 Tumour cell killing efficacy of a double-targeted vector carrying the HSVtk suicide 
gene  
 
3.2.3.3.1 The double-targeted RGD4C AAVP/Grp78-HSVtk vector mediated strong cell 
death in combination with GCV in 9L glioblastoma cells in vitro 
 
Next, I determined the therapeutic efficacy of the double-targeted RGD4C AAVP/Grp78 in 
9L cancer cells. This was achieved by two different experiments. First, 9L cells were 
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transduced with either double-targeted RGD4C AAVP/Grp78 or targeted RGD4C 
AAVP/CMV carrying the HSVtk suicide gene at 2x10
6
 TU/cell. Insertless AAVP vectors 
were used as negative controls. At day 3 post-vector transduction, cells were stressed using 
TG in order to induce the Grp78 promoter prior to GCV treatment. After 5 days of GCV 
treatment, live cells were counted using trypan blue method. The results are shown as the 
number of surviving cells at day 5 post GCV treatment normalized to the number of cells 
grown in the absence of GCV (Fig. 3.10a and 3.10b). Addition of GCV resulted in cell death 
by > 90% of the 9L tumour cells transduced with the double-targeted RGD4C AAVP/Grp78-
HSVtk (Fig. 3.10b). The Grp78 promoter driving HSVtk expression proved to be 10 times 
more efficient than the CMV promoter after GCV treatment in vitro in TG-stressed 9L cells 
(Figs. 3.10a and 3.10b). Representative phase contrast images also depict relatively more cell 
death in cells transduced with RGD4C AAVP/Grp78-HSVtk particles (Fig. 3.12a). 
 
To further confirm the above results I applied another strategy in which I could quantify the 
percentage of live cells by luciferase assay. For this purpose, stably luciferase-labelled 9L 
cells were transduced with either double-targeted RGD4C AAVP/Grp78 or targeted RGD4C 
AAVP/CMV carrying the HSVtk gene at 2x10
6
 TU/cell. As negative controls, insertless 
AAVP vectors were used. Cells were incubated with TG prior to GCV treatment as described 
above. After 5 days of GCV treatment, surviving cells were calculated by luciferase assay. 
The results were further normalised to protein concentration. Consistent with previous 
experiments, the data were calculated by dividing the percent conversion under GCV by 
those under non-GCV conditions. The results indicated > 74% cell death upon GCV 
treatment in 9L tumour cells transduced with the double-targeted RGD4C AAVP/Grp78-
HSVtk (Fig. 3.10d). However, interestingly, upon TG stress treatment, cell death was 
increased to 90% which was 3.2 times more efficient than the CMV promoter (Fig. 3.10c and 
3.10d). 
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 Figure 3.10. Therapeutic efficacy in vitro of the double-targeted RGD4CAAVP/Grp78 
driving HSVtk expression in 9L rat glioblastoma cells. 9L cells (70-80% confluent in a 48-
well plate) were incubated with either double-targeted RGD4C AAVP/Grp78-HSVtk or 
targeted RGD4C AAVP/CMV-HSVtk. Insertless AAVP containing either the Grp78 or CMV 
promoters were used as negative controls. At day 3 post- vector transduction, cells were 
treated with TG (300nM for 16hr), followed by GCV treatment for 5 days. Viable cells were 
counted using the trypan blue method. HSVtk/GCV mediated a) by double-targeted RGD4C 
AAVP/Grp78 and b) by targeted RGD4C AAVP/CMV in 9L cells. c, d) the same as above; 
however, instead of 9L parental cells, 9L-luciferase stably selected cells were incubated with 
either targeted RGD4C AAVP/CMV-HSVtk or double-targeted RGD4C AAVP/Grp78-
HSVtk, respectively. After 5 days of GCV treatment, cells were lysed and the luciferase assay 
was performed. The results were normalised to protein concentration using the Bradford 
assay. Data were calculated by dividing the percent conversion under GCV by that under 
non-GCV conditions. Data represent the mean s.e.m obtained from triplicate wells and are 
representative of two independent experiments. *p < 0.05, **p < 0.01 and ns: non-significant. 
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 3.2.3.3.2 The double-targeted RGD4C AAVP/Grp78-HSVtk vector mediated strong cell 
death in combination with GCV in U87 glioblastoma cells in vitro 
 
Therapeutic efficacy of the double-targeted vector was assessed in 9L cells through two 
different methods: i) counting live cells using trypan blue and ii) quantifying the percentage 
of live cells by luciferase assay of stably luciferase-labelled cells. Since similar data were 
obtained with both methods, I decided to validate therapeutic efficacy of the double-targeted 
AAVP/Grp78-HSVtk in U87 cells by simply counting the live cells. All the steps followed 
were similar to the experiment in 9L cells. Transduction of the U87 human glioblastoma cells 
with the double-targeted RGD4C AAVP/Grp78-HSVtk vector followed by GCV treatment 
resulted in ~75% cell death (Fig. 3.11b). However, upon TG stress treatment the cell death 
increased to 87% (Fig. 3.11b). Interestingly, the Grp78 promoter driving HSVtk expression 
was approximately 3 times more efficient compared to the CMV promoter after GCV 
treatment in vitro in TG-stressed U87 cells (Fig. 3.11a, 3.11b and 3.12b).  
 
Taken together, these results demonstrate that HSVtk/GCV suicide gene therapy by the 
double-targeted vector RGD4C AAVP/Grp78-HSVtk was more efficient than the RGD4C 
AAVP/CMV-HSVtk in both the 9L and U87 cell lines (Fig.3.10, 3.11 and 3.12).  
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Figure 3.11. Therapeutic efficacy in vitro of the double-targeted RGD4CAAVP/Grp78 
driven HSVtk expression in U87 human glioblastoma cells. U87 cells (70-80% confluent 
in 48-well plate) were incubated with either double-targeted RGD4C AAVP/Grp78-HSVtk or 
targeted RGD4C AAVP/CMV-HSVtk. Insertless AAVP containing either Grp78 or CMV 
promoter were used as negative controls. At day 3 post- vector transduction, cells were 
treated with TG (300nM for 16hr), followed by GCV treatment for 5 days. Viable cells were 
counted using trypan blue method. Data were calculated by dividing the percent conversion 
under GCV condition by that under non-GCV condition. Data represent the mean s.e.m 
obtained from triplicate wells. HSVtk/GCV mediated a) by the double-targeted RGD4C 
AAVP/Grp78 and b) by the targeted RGD4C AAVP/CMV. These data are representative of 
two independent experiments. *p < 0.05 and ns: non-significant. 
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a) 
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b)  
 
Figure 3.12. Phase contrast images showing tumour cell killing efficacy of the double-
targeted RGD4C AAVP/Grp78-HSVtk in glioblastoma cells in vitro. a) The rat 9L and b) 
U87 human tumour cells (70-80% confluent in 48-well plate) were incubated with either 
double-targeted RGD4C AAVP/Grp78-HSVtk or targeted RGD4C AAVP/CMV-HSVtk. 
Insertless AAVP containing either Grp78 or CMV promoter were used as negative controls. 
Cells were treated with TG (300nM for 16hr) at day 3 post- vector transduction, followed by 
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GCV treatment for 5 days. Cells were photographed using a 20x objective at day 5 post GCV 
treatment. Scale bar = 45μm. 
 
 
3.3 Discussion 
 
Transcriptional and ligand-targeting of vectors have been attempted to yield targeted 
systemic vectors for selective cancer gene therapy. Each of these two approaches have been 
used individually and showed promising results in preclinical tumour models.  
Recently a novel prokaryotic-eukaryotic hybrid viral vector termed as AAV/Phage or AAVP 
was reported in which the AAV transgene cassette containing a CMV promoter was inserted 
into an intergenomic region of a targeted M13 filamentous bacteriophage genome (Hajitou et 
al., 2006b). Tumour targeting of imaging and therapeutic transgenes after systemic delivery 
of targeted AAVP has been established. Herein, I aimed at further increasing the tumour 
targeting and efficacy of gene delivery by AAVP by driving transgene expression with a 
mammalian tumour specific promoter, the stress-inducible promoter of the glucose regulated 
protein Grp78 gene. The Grp78 gene is overexpressed under conditions often found in 
tumour microenvironment such as acidic pH, glucose deprivation and chronic anoxia. 
Previous studies reported the selective activation of the Grp78 promoter in tumour cells, but 
not in normal organs (Li and Lee, 2006, Lee, 2007). More interestingly high therapeutic 
transgene expression driven by this promoter in a variety of tumours in vivo resulted in 
complete eradication of tumours with no recurrence of tumour growth (Dong et al., 2004, 
Chen et al., 2000). To date, targeted gene therapy has been attempted by either using ligand-
directed vectors or by transcriptional targeting. Herein, I used the targeted AAVP vector in 
order to combine these two targeting approaches into one vector system, and generated a 
novel double-targeted particle for systemic gene delivery to cancer cells or tumours.  
First I showed that the rat Grp78 promoter, in the context of the double-targeted AAVP 
vector, retains its ability to respond to ER stress by TG leading to up-regulation of transgene 
expression of GFP and Luc by AAVP. These results were obtained in vitro by using the 
normal immortalized human embryonic kidney HEK293 cells as well as tumour cells such as 
9L rat glioblastoma, U87 human glioblastoma and MCF-7 human breast cancer. These data 
are in agreement with previous studies showing that the Grp78 promoter activity is 
independent of the p53 or phosphatase and tensin homolog (PTEN) status in glioma and 
breast cancer cells. Indeed, the p53 and PTEN status is variable in 9L cells (Lilge, 2002) 
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(mutated p53 gene- wild type PTEN), U87 (wild type p53- mutated PTEN) (Lu et al., 2004) 
(Senatus et al., 2006) and MCF-7 cells (wild type p53 protein)(Lim et al., 2009). 
Interestingly, transgene expression driven by the double-targeted RGD4C AAVP/Grp78-Luc 
showed better persistence overtime than the targeted RGD4C AAVP/CMV-Luc in all tested 
cell lines. Initially the basal CMV promoter activity proved higher than that of the Grp78 in 
all cell lines; however, luciferase transgene expression from the CMV promoter decreased 
dramatically overtime, while a steady increase in Grp78 promoter activity was observed. 
Although, viral promoters express high levels of the transgene upon entry into mammalian 
cells, it is well known that their long-term activity becomes silenced in cells. Our results are 
in agreement with other studies reporting transgene silencing with CMV promoters. Although 
the CMV promoter is active in mammalian cells, it is susceptible to transcriptional 
inactivation by DNA methylation and histone deacetylation (Mehta et al., 2009). In contrast 
eukaryotic promoters such as Grp78 can sustain long-term transgene expression in 
mammalian cells. 
 
Luciferase quantification showed stronger basal activity of the Grp78 promoter compared to 
CMV at day 7 post-vector transduction of 9L and U87 cells, and increased further after TG 
treatment. These data are consistent with previous studies reporting elevated Grp78 protein 
level in malignant glioma specimens, human malignant glioma cells as well as in vasculature 
derived from human glioma specimens, both in situ in tissue and in vitro in primary cell 
cultures (Pyrko et al., 2007, Virrey et al., 2008). The Grp78 overexpression in glioma cells 
correlated with the rate of cell proliferation (Pyrko et al., 2007). Interestingly, transgene 
expression by the double-targeted AAVP/Grp78 reached the highest level in the 9L cells that 
exhibit the highest rate of proliferation compared to U87. The hormone-dependent MCF-7 
breast cancer cells with the least proliferation rate showed the lowest luciferase expression 
driven by the Grp78 promoter. Consistently, analysis of Grp78 gene expression in human 
breast tumours from patients showed overexpression of the Grp78 in 100% of the aggressive 
hormone-independent breast tumours compared to hormone-dependent tumours (Fernandez 
et al., 2000). 
 
Treatment with TG resulted in 2.2- fold increase of Grp78 activity in MCF-7 cells. Induction 
of the Grp78 promoter activity in MCF-7 by TG treatment was previously reported in the 
context of retroviral vectors (Dong et al., 2004). The authors reported an 8- fold increase of 
transgene expression driven by Grp78 in a retroviral vector upon TG treatment of MCF-7. 
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These differences can be explained by the fact that the measurements of transgene expression 
in other studies were carried out on vector-selected cells stably expressing the transgene 
under the control of the Grp78 promoter. In our work, I did not apply any selection force to 
select for vector-transduced cells, as compared to previous reports in which the cells were 
selected after transduction with vectors carrying a Grp78 transgene expression cassette. 
Indeed, AAVP has been designed for systemic gene therapy; thus, this part of our work 
aimed at mimicking more accurately the in vivo situation where no selection can be applied to 
select for vector-transduced cells after systemic administration.  
 
After confirming the efficacy of the double-targeted vector to deliver reporter transgene 
expression in tumour cells, I subsequently evaluated the therapeutic effect of HSVtk as a 
therapeutic gene combined with the GCV prodrug. The advantage of HSVtk/GCV therapeutic 
approach is that the converted cytotoxic triphosphate GCV can spread from transduced cells 
to non-transduced cells via gap junction intercellular communication. This “bystander effect” 
may overcome the low transduction of tumours and the need for all cells to be transduced in 
order to achieve a therapeutic effect. Expression of HSVtk in 10 to 20% of the tumour cells 
can result in complete tumour cell death in vitro and tumour eradication in vivo upon cell 
implantation in mice (Freeman et al., 1993).The HSVtk/GCV bystander effect has already 
been reported in 9L and U87cells (Trepel et al., 2009, Zhang et al., 2009b). 
Herein I showed that the Grp78 promoter driving HSVtk gene expression in the context of 
double-targeted RGD4C AAVP led to dramatic 9L and U87 cell death in vitro. More 
interestingly this in vitro therapeutic effect of the RGD4C AAVP/Grp78-HSVtk proved more 
efficient than that of the targeted AAVP/CMV-HSVtk as measured at day 9 post- vector 
transduction. This finding is consistent with our luciferase quantification experiments that 
showed better persistence of Grp78 promoter activity overtime in these cells. Our results are 
also in agreement with previous reports that demonstrated the superiority of retroviral vectors 
driving HSVtk expression under Grp78 promoter control over retroviral vectors carrying the 
HSVtk gene under the control of the murine leukemia virus (MuLV) long-terminal repeat 
(LTR) promoter (Huang et al., 2000, Azatian et al., 2009).  
 
In conclusion, I have shown that the Grp78 promoter is functional and retains its inducible 
characteristic in the context of the AAVP phage viral vector. Thus, I have generated a novel 
double-targeted vector that proved efficient to target the αv integrin receptors on the cell 
surface as well as target transgene expression at the transcriptional level in vitro. I found that 
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the double-targeted AAVP/Grp78 vector provides better long-term transgene expression in 
tumour cells in vitro than the original targeted AAVP/CMV vector. Finally, the therapeutic 
efficacy of the double-targeted RGD4C AAVP/Grp78-HSVtk proved more efficient on 
tumour cells in vitro.  
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Chapter 4 
 
 
 
 
Long-term Grp78 and CMV promoter activity in the context of the 
AAVP vector in vitro 
 
 
 
 
4.1 Introduction 
 
The CMV promoter has been largely utilized in many gene therapy vectors, because of its 
ability to drive strong and constitutive expression of transgenes both in vitro and in vivo. 
However, one problematic feature of this promoter is its nonspecific nature; the promoter 
itself does not significantly discriminate between different cell types or conditions as its 
activity is high in a range of mammalian tissues (Cheng et al., 1993). In addition to the above 
issue, the CMV promoter has been reported to undergo silencing by mammalian host cells 
(Brooks et al., 2004, Grassi et al., 2003, Prosch et al., 1996) . Although the exact mechanisms 
of silencing of viral DNAs have remained mainly unknown, several studies have 
demonstrated the association of DNA methylation and histone deacetylation with inactivation 
of the CMV promoter (Swindle and Klug, 2002, Murphy et al., 2002). Generally DNA 
methylation/demethylation and histone acetylation/deacetylation play major roles in 
epigenetic gene regulation through providing accessibility of transcription factors to gene 
promoters. 
 
DNA methylation is mediated by the DNA methyltransferase enzymes DNMT1, DNMT3A 
and DNMT3B. Using S-adenosyl-methionine as the methyl donor, DNMTs can covalently 
methylate a cytosine residue adjacent to guanosine in the 5’ direction of DNA (CpG islands) 
(Singal and Ginder, 1999). Following DNA methylation, particular proteins containing a 
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methylcytosine-binding domain (MBD) will be recruited to the methylated DNA and 
consequently repress the gene transcription by obstructing the access of transcription factors 
to the gene promoter (Jin et al., 2011). 55% of all human gene promoters contain CpG islands 
while the presence of CpG islands in human genome is quite infrequent. This proportion 
demonstrates the significant role of DNA methylation in the regulation of gene expression.  
 
Drugs such as 5-Azacytidine (5-Aza) which can incorporate into the DNA of dividing cells 
instead of deoxycytosine and covalently binds and inhibits the DNMT activity, was shown to 
promote the expression of previously silenced genes. By inhibition of DNMT activity, the 
MBD proteins cannot bind to DNA and as a result there is access for transcription factors to 
bind to gene promoters. 5-Aza has successfully been used to reactivate silenced gene 
expression from several gene therapy vectors such as retroviral and adeno-associated viral 
vectors (Jaenisch et al., 1985, Gram et al., 1998). 
 
Previous studies demonstrated complete repression of CMV promoter activity by Spiroplasma 
methyltransferase SssI, a prokaryotic DNA methyltransferase, which mediates DNA 
methylation through 5’ CpG islands (Prosch et al., 1996). In the same study, they partially 
reversed CMV repression by simultaneously transfecting cells with highly methylated DNA 
which suggests a repressive control via a trans-acting factor that binds to 5’CpG methylated 
DNA (Prosch et al., 1996). Moreover, other reports also confirmed the inactivation of the 
CMV promoter in transfected cells in vitro by methylation. In addition, CMV-driven human 
transgenes delivered to rat muscle via first-generation adenovirus underwent a 53- fold 
decrease in expression over 24 hours (Brooks et al., 2004). In the same study, bisulfite 
sequencing revealed extensive methylation of both 5’CpG and non-CpG sites in the promoter 
region, with 5’CpA methylation predominating among the non-CpG sites. Notably, 
hypermethylation of tumour suppressor genes is an attribute of many cancers, with 95% of 
acute leukemias displaying hypermethylated calcitonin, and more than 40 genes are being 
hypermethylated in breast cancer (Das and Singal, 2004). This raises the question of whether 
cancer cells, with their tendency toward extensive methylation, are predisposed to CMV 
methylation in particular (Robertson and Jones, 2000, Herman and Baylin, 2003). 
Another mechanism which has been implicated in modifying gene expression epigenetically 
is histone acetylation/ deacetylation. The histone acetylation status and consequently 
regulation of gene transcription are maintained by a balance between acetylation by histone 
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acetyltransferase (HATs) and deacetylation by histone deacetylase enzymes (HDACs) (de 
Ruijter et al., 2003). HATs mediate histone hyperacetylation which assist the relaxed form of 
chromatin and activate gene transcription, while HDACs function in opposition to HATs. 
HDACs can catalyse removal of acetyl groups from specific lysine residues located in N-
terminal parts of the histone tail, resulting in chromatin condensation, and therefore 
prevention of recruitment of transcription factors on gene promoters leading to silencing of 
gene expression.  
The link between transcriptional repression and HDAC activity was first demonstrated by the 
identification of the first HDAC (HDAC1) which shares significant homology to budding 
yeast Rpd3p that has previously been implicated in transcriptional repression (Taunton et al., 
1996). 
In mammalian cells, eighteen HDACs have been identified so far and based on their 
homology to budding yeast’s HDACs, they are classified into four groups (de Ruijter et al., 
2003, Blander and Guarente, 2004, Kim and Bae, 2011). Members of class I (HDAC1, 2, 3 
and 8) have homology to yeast reduced potassium dependency 3 (Rpd3) which are located 
within the nucleus. Class II members (HDAC4, 5, 6, 7, 9 and 10) share homology to yeast 
histone deacetylase 1 (Hda1) and are located in both nucleus and cytoplasm.  
Based on the sequence homology and domain organization, Class II is further subdivided into 
class IIa (HDACs 4, 5, 7, and 9) and class IIb (HDACs 6 and 10). Class IIa is composed of a 
highly conserved C-terminal deacetylase catalytic domain, while Class IIb is characterized by 
having two deacetylase domains (Verdin et al., 2003).  
HDAC11 is the sole member of class IV which shares sequence similarity with catalytic core 
regions of class I and class II members, however since it does not show enough similarity it 
has been placed in class IV. Classes I, II, and IV require a zinc molecule as a cofactor in their 
active site for their deacetylase activity; hence, their activities are inhibited by Zn
2+ 
binding 
HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA). 
The classification of the eleven Zn
2+
 dependent HDACs is shown in Table 4.1. 
Class III HDACs (SIRT1, 2, 3, 4, 5, 6 and 7) were first found with the discovery of yeast 
silent information regulator 2 (Sir2) which exhibits NAD-dependent histone deacetylase 
activity (Imai et al., 2000). Since this class of HDACs requires NAD
+ 
as a cofactor, their 
activity cannot be inhibited by Zn
2+ 
binding HDAC inhibitors. 
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The involvement of histone deacetylation in gene silencing might occur in conjugation with 
DNA methylation. It has been reported that DNMT and MBD proteins can recruit HDACs 
following DNA methylation. Several studies demonstrated the key function of gene 
hypermethylation and histone deacetylation in human malignancies as well as silencing and 
protection against viral DNA sequences such as the CMV promoter (Baylin, 2005, Cedar and 
Bergman, 2009).  
The first characterized organic HDAC inhibitor drug, TSA (Yoshida et al., 1990) has been 
wildly utilized to study the reactivation of silenced viral constructs. Also SAHA, structurally 
similar to TSA, has been categorized as a histone deacetylase inhibitor. Both chemicals can 
mediate inhibition of HDACs of class I and II by binding and blocking the catalytic site of 
the HDACs (Bi and Jiang, 2006). 
 
Previous studies demonstrated that removal of trichostatin-A (TSA), a histone deacetylase 
inhibitor, from the medium of HeLa cells transduced with a recombinant AAV/CMV-LacZ 
construct resulted in chromatin remodelling and transcriptional repression of the LacZ gene. 
This change in chromatin structure was rapid, with 90% of silencing occurring within 4hrs of 
TSA removal (Chen and Townes, 2000). Although the CMV promoter silencing has involved 
considerable controversy, these data and others suggest that, regardless of the mechanism, 
silencing of the CMV promoter region over time will lead to reduced transgene expression. 
Consequently, consideration of alternate promoters will be necessary for a number of gene 
therapy pursuits requiring long-term transgene expression.  
In chapter 3, our data demonstrated a marked decrease in CMV promoter activity in 9L, U87 
and MCF-7 cells over 7-10 days post RGD4C AAVP/CMV-Luc vector transduction. In 
contrast Grp78- regulated Luc expression increased over 7-10 days post RGD4C 
AAVP/Grp78-Luc vector transduction. Unfortunately due to a dilution effect of proliferating 
transduced cells within a larger population of proliferating nontransduced cells (Hajitou et al., 
2008) I could not further monitor the promoter’s activity beyond that time point. Therefore, 
much of the effort in this chapter was devoted to characterizing both CMV and Grp78 
promoter activitiy over a long time course. For this purpose I first cloned a puromycine 
resistance cassette into the AAVP vector to enable generation of stably transduced cells. The 
results of this chapter address the CMV promoter silencing in the context of AAVP whose 
activity I consequently tried to further restore by treatment with the DNA methylation 
inhibitor 5-Aza, as well as histone deacetylation inhibitors such as TSA and SAHA which are 
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known to inhibit class I and II HDACs, and valporic acid (VPA) which inhibits class I and 
nicotinamide which inhibits Class III HDAC enzyme activity (Johnstone, 2002) (Table 4.1). 
It is noteworthy to mention that the work presented in sections 4.2.4 and 4.2.5 was 
undertaken with the assistance of Miss Nastasia Nianiaris, MSc student in Molecular 
Medicine at Imperial College. 
 
 
Table 4.1. Schematic representation of the Zn
2+
 dependent histone deacetylase family. 
(VPA: valporic acid, TSA: trichostatin A and SAHA: suberoylanilide hydroxamic acid. 
Adapted from Kim, H.J. & Bae, S.C., 2011. 
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4.2 Results 
 
4.2.1 Generation of an AAVP vector containing a puromycin resistance cassette 
 
4.2.1.1 RGD4C AAVP/Grp78-GFP-puro
R
 and RGD4C AAVP/CMV-GFP-puro
R 
 
To generate the double-targeted RGD4C AAVP/ Grp78-GFP-puro
R
 and targeted RGD4C 
AAVP/CMV-GFP-puro
R
 vector, a puromycin resistance cassette was cloned into the SacI site 
of AAVP located next to the AAV transgene cassette (Fig. 4.1). First, the 1168bp fragment 
containing the puromycin resistance gene under the control of SV40 early enhancer/ promoter 
was released from the pGL4.20 plasmid (promega) by BamHI and SalI double restriction 
digestion. The purified puromycine resistance cassette fragment from the agarose gel was 
blunted with DNA polymerase and further ligated to SacI linkers. After restriction digestion 
with SacI, the puromycine resistance cassette was ligated into the SacI site of the RGD4C 
AAVP/CMV-GFP and RGD4C AAVP/Grp78-GFP plasmids (Fig. 4.1a and 4.1b). The 
unique SacI site in the RGD4C AAVP/GFP is located next to the AAV transgene cassette. 
The positive recombinants were identified by SacI digestion and agarose gel electrophoresis.  
 
4.2.1.2 RGD4C AAVP/Grp78-Luc-puro
R
 and RGD4C AAVP/CMV-Luc-puro
R 
 
To insert the puromycin resistance cassette into AAVP carrying Luc as a reporter gene, a 
different strategy was performed as the SacI restriction site is located within the Luc region. 
Briefly, AAVP/Grp78-GFP-puro
R
 plasmid was digested with NotI and SphI in order to 
remove a fragment containing GFP and replaced by a NotI- SphI Luc-containing fragment 
from the AAVP/Grp78-Luc (Fig. 4.2). The same strategy was applied for the RGD4C 
AAVP/CMV-Luc-puro
R
 construct. 
The positive recombinants were identified by NotI- SphI digestion and agarose gel 
electrophoresis.  
 
4.2.1.3 RGD4C AAVP/Grp78-HSVtk-puro
R
 and RGD4C AAVP/CMV-HSVtk-puro
R
 
 
To generate RGD4C AAVP/Grp78-HSVtk-puro
R
, a different strategy from the previous 
constructs was adapted since both SacI and SphI restriction sites are located within the HSVtk 
gene. Briefly, the AAVP/Grp78-GFP-puro
R
 plasmid was digested with SacII in order to 
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remove the Grp78-GFP fragment. This fragment was subsequently replaced by a SacII 
HSVtk-containing fragment from the AAVP/Grp78-HSVtk (Fig. 4.3). The correct orientation 
of the Grp78-HSVtk fragment within AAVP was evaluated by BamHI digestion. The same 
procedure was performed to generate the RGD4C AAVP/CMV-HSVtk-puro
R
 vector.  
All the generated vectors were amplified, isolated and purified from the culture supernatant 
of host bacteria (E.coli K91) as described in materials and methods. 
 
 
 
 
 
 
 
Figure 4.1. Schematic chart of the a) RGD4C AAVP/CMV-GFP-puro
R
 and b) RGD4C 
AAVP/Grp78-GFP-puro
R
 vectors. The puromycin resistance gene under the control of the 
SV40 promoter was released from the pGL4.20 by BamHI and SalI digestion and then ligated 
to SacI linkers. This fragment was subsequently inserted into the unique SacI site of the 
RGD4C AAVP/CMV-GFP and RGD4C AAVP/Grp78-GFP plasmids. (Puro: puromycin-
resistance gene, TetR: tetracycline resistance gene, ITR: inverted terminal repeat, pA: 
polyadenylation site). 
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Figure 4.2. Schematic chart describing construction of the RGD4C AAVP/Grp78-Luc-
puro
R
. The Luc gene flanked by SphI and NotI was released from the AAVP/Grp78-Luc 
plasmid and ligated to the RGD4C AAVP/Grp78-GFP-puro
R
 plasmid digested with SphI and 
NotI to replace GFP. (Puro: puromycin-resistance gene, TetR: tetracycline resistance gene, 
ITR: inverted terminal repeat, pA: polyadenylation site).
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Figure 4.3. Schematic chart describing construction of the RGD4C AAVP/Grp78-
HSVtk-puro
R
.
 
The Grp78-HSVtk fragment flanked by SacII was released from the RGD4C 
AAVP/Grp78-HSVtk plasmid and ligated to the RGD4C AAVP/Grp78-GFP-puro
R
 plasmid 
digested with SacII to replace the Grp78- GFP fragment. (Puro: puromycin-resistance gene, 
TetR: tetracycline resistance gene, ITR: inverted terminal repeat, pA: polyadenylation site). 
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4.2.2 TG treatment of glioblastoma cells induces Grp78 promoter activity at both the 
endogenous and AAVP vector level 
 
In the previous chapter, I showed an induction of endogenous Grp78 following TG treatment 
in 9L and U87 cells. Herein, I aimed at assessing the Grp78 promoter activity in the context 
of double-targeted AAVP vector after TG treatment, an inducer of ER stress, in vitro. Thus, 
Western blot analysis of stably transduced 9L as well as U87 cells with RGD4C 
AAVP/Grp78-HSVtk-puro
R
 or RGD4C AAVP/CMV-HSVtk-puro
R
 following treatment with 
300nM TG for 16 hours was performed to evaluate both endogenous Grp78 and transgene 
HSVtk expression. Non-transduced parental cells were also used as controls. As shown in 
figure 4.4, following TG treatment, endogenous Grp78 expression increased in parental as 
well as stably transduced 9L and U87 cells. 
At the AAVP vector level, as expected, no effect of TG was observed on HSVtk expression 
in both 9L and U87 cells stably transduced with RGD4C AAVP/CMV-HSVtk-puro
R
. In 
contrast, TG treatment for 16 hours, resulted in increased expression of HSVtk from the 
Grp78 promoter in both cells transduced with the RGD4C AAVP/Grp78-HSVtk-puro
R 
vector. 
No HSVtk expression was detected in parental 9L and U87 cells containing no vector (Fig. 
4.4). 
These results show the induction of the rat Grp78 promoter in the context of the AAVP 
vector following TG treatment in both rat 9L and human U87 glioblastoma cells.  
Moreover, Western blot analysis of HSVtk expression driven by Grp78 in 9L cells stably 
transduced with the RGD4C AAVP/Grp78-HSVtk-puro
R
 vector showed higher activity of the 
Grp78 promoter over CMV. In contrast, CMV promoter activity was much higher than that of 
the Grp78 promoter in stably transduced U87 cells (Fig. 4.4). These data are in agreement 
with our previous results demonstrating higher activity of the Grp78 promoter in rapidly 
growing 9L cells compared to moderately fast growing U87 cells. 
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Figure 4.4. Thapsigargin induces Grp78 promoter activity in the context of the AAVP 
vector in stably transduced 9L and U87 glioblastoma cells. Stably transduced 9L and U87 
cells with RGD4C AAVP/Grp78-HSVtk-puro
R
 or RGD4C AAVP/CMV-HSVtk-puro
R
 as well 
as parental cells, were grown in the presence or absence of 300 TG for 16 hours. Then, equal 
amounts of treated and untreated cell lysates were analysed by Western blot with antibodies 
to Grp78, HSVtk and GAPDH (n=3). 
 
 
4.2.3 RGD4C AAVP/Grp78 provides long-term GFP transgene expression in glioblatoma 
cells  
 
Data obtained in chapter 3 showed that Grp78- regulated Luc expression increased in 9L, 
U87 and MCF-7 cells over 7-10 days post RGD4C AAVP/Grp78-Luc vector transduction; in 
contrast, Luc expression driven by the CMV promoter decreased over the same period post 
RGD4C AAVP/CMV-Luc vector transduction. Unfortunately, due to the dilution effect of 
proliferating transduced cells within a larger population of proliferating non-transduced cells 
(Hajitou et al., 2008) I could not further monitor the promoter activity beyond that time point. 
To overcome the above limitation and enable further characterization of both CMV and 
Grp78 promoter activities over a long time course, 9L and U87 glioblastoma cell lines were 
stably transduced with targeted RGD4C AAVP/CMV-GFP-puro
R
 or double-targeted RGD4C 
AAVP/Grp78-GFP-puro
R
 AAVP vectors, and selected in the presence of puromycin. As 
negative controls, parental cells were grown in the presence of puromycin alongside the 
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transduced cells. Next, puromycin- resistant clones were monitored over time using a 
fluorescent microscope. 
As an initial analysis of transgene expression efficiency, we counted and monitored GFP 
positive as well as GFP negative puromycin-resistance cell clones over time. Counting of 9L 
stably transduced clones started at 2 weeks post-vector transduction when they were visible 
under microscope, while U87 clones were visible at 17 days post-vector transduction. Two 
representative images of GFP positive and GFP negative cell clones under the microscope are 
shown in figure 4.5.  
At two weeks post-vector transduction, 92% of the 9L clones transduced by the RGD4C 
AAVP/Grp78-GFP-puro
R
 construct (n= 846 of 959 clones) were GFP positive, compared to 
83% of clones transduced by the RGD4C AAVP/CMV-GFP-puro
R
 (n= 845 of 1258 clones). 
At four weeks post-vector transduction, we detected the presence of GFP expression in 83% 
of the RGD4C AAVP/Grp78-GFP-puro
R
 clones, while only 59% of the clones transduced by 
the RGD4C AAVP/CMV-GFP-puro
R
 vector were GFP positive (Fig. 4.6a). Figure 4.7 
represents an example of complete silencing of the CMV promoter over two weeks in one of 
the 9L cell clones stably transduced with RGD4C AAVP/CMV-GFP-puro
R
. Also, more 
representative images depicting the initiation stage of the CMV promoter silencing in 9L 
clones stably transduced with the RGD4C AAVP/CMV-GFP-puro
R
 vector are presented in 
figure 4.8. 
 
As for U87 cells, at 17 days post-vector transduction, out of a total of 276 clones transduced 
with RGD4C AAVP/Grp78-GFP-puro
R
 67.4 % were GFP positive compared to only 47.3% 
out of a total of 300 clones transduced with RGD4C AAVP/CMV-GFP-puro
R
 (Fig. 4.6b). No 
significant change in GFP expression was observed in U87 cell clones at four weeks post-
vector transduction with either RGD4C AAVP/Grp78-GFP-puro
R
 or RGD4C AAVP/CMV-
GFP-puro
R
 (Fig. 4.6b).  
 
To further evaluate promoter activity in the course of time, all cell clones were pooled after 4 
weeks post-vector transduction and GFP expression was analysed by flow cytometry. The 
examples of histograms shown in figure 4.9a, represent the silencing of stably transduced 
cells over a time-course study. At day 39 post-vector transduction, 57% of 9L cells 
transduced by the RGD4C AAVP/Grp78-GFP- puro
R
 vector were positive for GFP 
expression and this number increased drastically to 85% towards day 97 (Fig. 4.9b). In 
contrast, only 37% of cells transduced by RGD4C AAVP/CMV-GFP expressed GFP at day 
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39 post-vector transduction, followed by a marked drop to 11% at day 97 (Fig. 4.9b). 
Moreover, this decrease in GFP positive cells was associated with ~10- fold drop of the mean 
fluorescent intensity (MFI) of RGD4C AAVP/CMV-GFP- puro
R
 cells from day 39 towards 
day 97 post-vector transduction, while MFI remained stable in cells transduced with RGD4C 
AAVP/Grp78-GFP (Fig. 4.9c). Also, representative fluorescence pictures depict a drastic 
decrease in GFP positive cells stably transduced by the RGD4C AAVP/CMV-GFP-puro
R
 
from day 39 towards day 97 post-vector transduction (Fig. 4.9d). 
Similarly, FACS analyses showed that GFP expression in U87 cells transduced with RGD4C 
AAVP/Grp78-GFP- puro
R
 increased from 40% at day 39 to 66.3% at day 75 post-vector 
transduction (Fig. 4.10a and 4.10b). In contrast, 59% of cells transduced with RGD4C 
AAVP/CMV-GFP- puro
R
 were positive for GFP expression at day 39, and this number 
decreased remarkably to 5.6% towards day 75 post-vector transduction (Fig. 4.10a and 
4.10b). Although, U87 cells transduced with RGD4C AAVP/CMV-GFP-puro
R
 presented 
significantly higher MFI than that of RGD4C AAVP/Grp78-GFP-puro
R
 cells at day 39, their 
MFI decreased by 17.6- fold towards day 75 post-vector transduction. Interestingly MFI 
remained constant in RGD4C AAVP/Grp78-GFP-puro
R
 cells over the indicated times (Fig 
4.10c). In figure 4.10d, fluorescence pictures show a marked decrease in GFP positive cells 
stably transduced by the RGD4C AAVP/CMV-GFP-puro
R
 from day 39 to day 75 post-vector 
transduction, whereas, GFP positive cells stably transduced by the RGD4C AAVP/Grp78-
GFP-puro
R
 remained constant over the indicated times. 
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Figure 4.5. Representative images of GFP positive and GFP negative clones. 9L cells 
(70-80% confluent in a 6-well plate) were transduced with targeted RGD4C AAVP/CMV-
GFP-puro
R
. At day 3 post-vector transduction cells were diluted 1:10 and grown in 
puromycin- containing medium. Representative phase contrast and fluorescence microscopy 
images captured at day 14 post-vector transduction depict GFP positive and GFP negative 
clones (n=5). Magnification= x4. Scale bar = 200μm. 
 
 
 
 
 
 
Figure 4.6. Evaluation of Grp78 and CMV promoter activity in the context of AAVP in 
glioblastoma cells. a) 9L and b) U87 cells (70-80% confluent in a 6-well plate) were 
transduced with either targeted RGD4C AAVP/CMV-GFP-puro
R
 or double-targeted RGD4C 
AAVP/Grp78-GFP-puro
R
. At day 3 post-vector transduction, cells were diluted 1:10 and 
grown in puromycin- containing medium. The total GFP positive and negative clones were 
counted under the microscope over the indicated times. The statistic analysis was performed 
using a 2-way ANOVA between two variants at each time point. ***p < 0.001. 
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Figure 4.7. CMV promoter activity silences over time during the puromycin selection 
process in 9L cell clones transduced with RGD4C AAVP/CMV-GFP-puro
R
. 9L cells (70-
80% confluent in a 6-well plate) were transduced with the targeted RGD4C AAVP/CMV-
GFP-puro
R
 vector. At day 3 post-vector transduction cells were diluted 1:10 and grown in 
puromycin- containing medium. The GFP positive clones were monitored under the 
microscope over time. Representative images were captured at days 14 and 28 post-vector 
transduction from the same clone (n=5). Scale bar = 200μm. 
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Figure 4.8. Initiation of CMV promoter silencing within puromycin resistant 9L clones. 
9L cells (70-80% confluent in a 6-well plate) were transduced with targeted RGD4C 
AAVP/CMV-GFP-puro
R
. The GFP positive clones were monitored over time under the 
microscope. Representative images captured at day 21 post-vector transduction depict 
initiation of CMV promoter silencing within stably transduced clones. Magnification= x4. 
Scale bar = 200μm. 
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Figure 4.9. Persistence of Grp78 promoter activity in 9L rat glioblastoma cells upon 
transduction with RGD4C AAVP/Grp78-GFP- puro
R
. a) Time course FACS analysis was 
performed to quantify GFP expression in the 9L cell population of pooled cell clones 
obtained with either RGD4C AAVP/Grp78-GFP or RGD4C AAVP/CMV-GFP. b) 
Percentage of GFP positive cells and c) Mean fluorescence intensity (MFI) derived by either 
Grp78 or CMV promoter over the indicated times. d) The pictures are representative of GFP 
positive cell change overtime. These data are representative of two independent experiments. 
Scale bar = 45μm. 
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Figure 4.10. Persistence of Grp78 promoter activity in U87 human glioblastoma cells 
upon transduction with RGD4C AAVP/Grp78-GFP-puro
R
. a) Time course FACS analysis 
was performed to quantify GFP expression in the U87 cell population of pooled cell clones 
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obtained with either RGD4C AAVP/Grp78-GFP or RGD4C AAVP/CMV-GFP. b) 
Percentage of GFP positive cells and c) Mean fluorescence intensity (MFI) derived by either 
Grp78 or CMV promoter activity over the indicated times. d) The pictures are representative 
of GFP positive cell change overtime. These data are representative of two independent 
experiments. Scale bar = 45μm. 
 
4.2.4 RGD4C AAVP/Grp78 mediates long-term HSVtk suicide gene expression in 
glioblastoma cells  
 
In order to confirm the long-term activity of the Grp78 promoter, we examined suicide gene 
HSVtk expression over time, controlled by either CMV or Grp78 promoters. Tumour cells 
were transduced with RGD4C AAVP/Grp78-HSVtk-puro
R
 or RGD4C AAVP/CMV-HSVtk-
puro
R
 vectors and stably transduced cells were generated under puromycin selection. 9L and 
U87 stably transduced cells were lysed and harvested at one month intervals beginning at 
days 47 and 66 post-vector transduction, respectively. Then, HSVtk expression was evaluated 
by Western blot analysis.  
Consistent with FACS analysis experiments, western blot analysis showed higher level of 
HSVtk expression in 9L cells transduced by RGD4C AAVP/Grp78-HSVtk- puro
R
 compared 
to cells transduced with RGD4C AAVP/CMV-HSVtk- puro
R
 and increased gradually over 
time (Fig. 4.11a). In contrast, a dramatic decrease of HSVtk levels was observed in cells 
transduced with RGD4C AAVP/CMV-HSVtk- puro
R
 from day 47 towards day 78 post-vector 
transduction, at day 109 post-vector transduction the HSVtk level was barely detectable (Fig. 
4.11a). Quantification of the HSVtk band intensities and normalization to loading control 
GAPDH showed ~ 6.5- fold decrease in HSVtk expression driven by the CMV promoter (Fig. 
4.10a). 
In U87 cells, consistent with FACS data, specifically MFI analysis, although HSVtk 
expression was initially stronger in cells stably transduced with RGD4C AAVP/CMV-HSVtk-
puro
R
, the levels of HSVtk decreased gradually from day 66 towards day 137 post-vector 
transduction. In contrast, HSVtk expression stayed constant over time in cells stably 
transduced with RGD4C AAVP/Grp78-HSVtk- puro
R
 (Fig. 4.11b). After normalizing HSVtk 
level to GAPDH ~ 3.3- fold decrease in HSVtk expression driven by the CMV promoter was 
detected.  
As a control, parental cell lines containing no vector were also subjected to similar analysis 
and no HSVtk expression was detected (Fig. 4.11c).  
 
105 
 
 
 
Figure 4.11. Long-term HSVtk expression driven by either Grp78 or CMV promoter in 
the context of AAVP. Whole cell lysates of a) 9L and b) U87 cells stably transduced with 
either targeted RGD4C AAVP/CMV-HSVtk-puro
R
 or double-targeted RGD4C AAVP/Grp78-
HSVtk-puro
R
 were collected at one month intervals for three months beginning at 44 and 66 
days post-vector transduction for 9L and U87 cells, respectively. c) Parental 9L and U87 cells 
were collected alongside the stably transduced cells as a control. HSVtk protein levels were 
determined by western blot analysis. The intensity of Grp78 protein bands were measured 
and normalised to GAPDH intensity. These data are representative of two independent 
experiments.  
 
 
106 
 
4.2.5 RGD4C AAVP/Grp78-HSVtk plus GCV treatment mediates strong and constant 
tumour cell killing 
 
4.2.5.1 Stably transduced 9L cells with RGD4C AAVP/Grp78-HSVtk-puro
R
 vector showed 
strong cell death in combination with GCV  
 
Next, stably transduced 9L cells with RGD4C AAVP/Grp78-HSVtk-puro
R
 or RGD4C 
AAVP/CMV-HSVtk-puro
R
 were used to assess tumour cell killing efficacy by vectors 
overtime once at day 47 (t1) and then at day 109 (t2) post-vector transduction. HSVtk suicide 
gene therapy was induced at each time point by treatment with GCV for 24hr, 48hr, 72hr or 
96 hr. Live cells were counted using the trypan blue method. The results are shown as the 
number of surviving cells post GCV treatment normalized to the number of cells grown in the 
absence of GCV at each time point. Addition of GCV at t1 resulted in significantly higher 
death of 9L cells transduced with RGD4C AAVP/Grp78-HSVtk-puro
R
 relative to those 
transduced with RGD4C AAVP/CMV-HSVtk-puro
R
 vector at each of the four time points 
(Fig. 4.12). More interestingly, consistent with Western blot experiments of HSVtk 
expression over time (Fig. 4.11a), at a later time point (t2), we observed a significant 
decrease in the efficacy of tumour cell killing by RGD4C AAVP/CMV-HSVtk- puro
R
 
compared to t1 (Fig. 4.12), in which between t1 and t2 the CMV promoter activity decreased 
by 3.3, 4.2 and 12.7 times at 24, 48 and 96 hours post GCV treatment, respectively. In 
contrast to CMV promoter efficacy, Grp78 promoter activity remained stable at both t1 and t2 
(Fig 4.12). 
Representative phase contrast images were also taken at each 24 hour interval up to 96 hours 
following GCV treatment for each of the time points (Fig. 4.13). The images also depict 
substantial cell death difference between t1 and t2 time points from 9L cells stably transduced 
with RGD4C AAVP/CMV-HSVtk-puro
R
 (Fig. 4.13a and 4.13b). In contrast, dramatic cell 
death at both t1 and t2 time points were observed in the 9L cells stably transduced with 
RGD4C AAVP/Grp78-HSVtk-puro
R 
(Fig. 4.13a and 4.13b). 
 
4.2.5.2 Stably U87 transduced cells by the RGD4C AAVP/Grp78-HSVtk-puro
R
 vector 
mediated strong cell death overtime in combination with GCV  
 
To assess long-term promoter activity in the context of AAVP in U87 cells, stably transduced 
U87 cells with RGD4C AAVP/Grp78-HSVtk-puro
R
 or RGD4C AAVP/CMV-HSVtk-puro
R
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were subjected to GCV in vitro. Cells were counted comparably to 9L cells described in 
section 4.3.2.1. The U87 stably transduced cells were first assessed at 66 days post-vector 
transduction (t1) then passaged and reassessed at day 137 (t2). 
Results demonstrated less survival in U87 cells transduced with RGD4C AAVP/Grp78-
HSVtk-puro
R
 relative to RGD4C AAVP/CMV-HSVtk-puro
R
 transduced cells at each of the 
four 24 hour intervals of GCV treatment (Fig. 4.14). This experiment was done twice and 
each time results indicated more death in cells stably transduced with RGD4C AAVP/Grp78-
HSVtk-puro
R
 than in RGD4C AAVP/CMV-HSVtk-puro
R
 transduced cells; however, in both 
experiments the differences between the two populations were not statistically significant at 
all time points.  
Interestingly, consistent with the Western blot experiment of HSVtk expression over time 
(Fig. 4.11b), at the later time point, t2, tumour cell death was significantly decreased in U87 
cells stably transduced with RGD4C AAVP/CMV-HSVtk-puro
R
 compared to t1 (Fig. 4.14a). 
While in contrast there was no significant difference in tumour cell killing efficiency in U87 
cells stably transduced with RGD4C AAVP/Grp78-HSVtk-puro
R
 at both t1 and t2 time point 
(Fig. 4.14b). 
Also, representative phase contrast images depict more cell death with RGD4C 
AAVP/Grp78-HSVtk at both time points relative to RGD4C AAVP/CMV-HSVtk in stably 
transduced U87 cells (Fig. 4.14c).  
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Figure 4.12. Long-term cell killing efficiency of RGD4C AAVP/CMV-HSVtk and 
RGD4C AAVP/Grp78-HSVtk in transduced 9L cells. 9L cells stably transduced with 
RGD4C AAVP/CMV-HSVtk and RGD4C AAVP/Grp78-HSVtk at t1= 47 days and t2=109 
days post-vector transduction, were plated at 70,000 cells/well in 24-well plates. Treatment 
with GCV commenced 48 hours after plating. Cells were counted in triplicates for each 
condition in 24 hour intervals over 96 hours post GCV treatment. The results are shown as 
the number of surviving cells post GCV treatment normalized to the number of cells grown in 
the absence of GCV at each time point. Data represent the standard error of the mean 
obtained from triplicate wells and are representative of two independent experiments. **p < 
0.01 and ns: non-significant. 
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Figure 4.13. The double-targeted RGD4C AAVP/Grp78-HSVtk mediated long-term cell 
death in 9L tumour cells in vitro. Stably transduced 9L tumour cells (70-80% confluent in a 
24-well plate) were plated at a) 47 days (t1) and b) at 109 days (t2) post-vector transduction. 
GCV treatment commenced 48 hours after plating. Cells were photographed using a 20x 
objective at 24 hour intervals over 96 hours post GCV treatment. Scale bar = 45μm. 
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Figure 4.14. Long-term cell killing efficiency of RGD4C AAVP/CMV-HSVtk and 
RGD4C AAVP/Grp78-HSVtk in transduced U87 cells. 9L cells stably transduced with 
RGD4C AAVP/CMV-HSVtk and RGD4C AAVP/Grp78-HSVtk at t1= 66 days and t2=137 
days post-vector transduction, were plated at 70,000 cells/well in 24-well plates. Treatment 
with GCV commenced 48 hours after plating. a) Cells were counted in triplicate for each 
condition in 24 hour intervals over 96 hours post GCV treatment. Data were calculated by 
dividing the percent conversion under GCV by that under non-GCV conditions. Data 
represent the standard error of the mean obtained from triplicate wells and are representative 
of two independent experiments. *p < 0.05, **p < 0.01 and ns: non-significant. 
Representative phase contrast images of stably transduced U87 cells at b) t1 and c) t2. Cells 
were photographed using a 20x objective at 24 and 96 hours post GCV treatment. Scale bar = 
45μm. 
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4.2.6 The effect of in vitro cell growth and confluence on Grp78 promoter activity 
 
We showed that the Grp78 promoter activity increases over time in 9L and U87 cells in vitro. 
Then, we raised the question whether cell growth and confluence in vitro could mediate 
Grp78 induction. To verify this effect, 9L and U87cells were stably transduced with RGD4C 
AAVP/Grp78-GFP-puro
R
 or RGD4C AAVP/CMV-GFP-puro
R
 vectors. Populations of 
pooled clones as well as two randomly isolated clones were grown in the presence of 
puromycin and plated in 6 well plates until 70% confluent. GFP expression was analysed by 
flow cytometry every other day, initiated at day 1 post cells plating. At days 7 and 10 post 
cell plating, 9L and U87 cells, respectively, reached confluent state and the experiment was 
terminated.  
As expected, the percentage of GFP positive cells in 9L cells stably transduced with RGD4C 
AAVP/Grp78-GFP-puro
R
 remained constant over time. In addition to GFP expression, the 
MFI level either remained stable or slightly decreased (Fig. 4.15). Similar results were also 
observed in 9L cells stably transduced with RGD4C AAVP/CMV-GFP-puro
R 
(Fig. 4.15). 
In U87 cells stably transduced with RGD4C AAVP/Grp78-GFP-puro
R
 , the percentage of 
GFP positive cells showed almost the same pattern as 9L cells stably transduced with 
RGD4C AAVP/Grp78-GFP-puro
R
; however, the MFI level was fluctuating slightly over 
time (Fig. 4.16). Again the same effect was detected in U87 cells stably transduced with 
RGD4C AAVP/CMV-GFP-puro
R 
(Fig. 4.16). 
These data prove that cell confluence status in vitro does not affect the Grp78 activity.  
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Figure 4.15. Assessment of the effect of cell confluence on Grp78 activity in stably 
transduced 9L cells. 9L isolated clones as well as a population of pooled clones stably 
transduced with RGD4C AAVP/CMV-GFP-puro
R
 or RGD4C AAVP/Grp78-GFP- puro
R
, 
were plated at 300,000 cells/well in 6-well plates and FACS analysis was performed to 
quantify GFP expression over the indicated times. Shown are percentage of GFP positive 
cells and MFI derived from either the Grp78 or CMV promoter over the indicated days post 
cell plating.  
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Figure 4.16. Effect of cell confluency on Grp78 activity in stably transduced U87 cells. 
U87 isolated clones or a population of pooled clones stably transduced with RGD4C 
AAVP/CMV-GFP- puro
R
 and RGD4C AAVP/Grp78-GFP- puro
R
, were plated at 300,000 
cells/well in 6-well plates and FACS analysis was performed to quantify GFP expression. 
Shown are percentage of GFP positive cells and MFI derived from either the Grp78 or CMV 
promoter over the indicated days post cell plating. 
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4.2.7 Investigation of the molecular mechanism of the CMV promoter silencing 
 
Transcriptional silencing of many virally transduced genes has been reported by several 
studies; however, the exact mechanism of silencing still remains unclear. Earlier in this 
chapter, we showed that in the rat 9L and human U87 cell lines stably transduced with 
RGD4C AAVP, expression of the GFP or HSVtk transgene under the control of the CMV 
promoter was suppressed after a few weeks. As DNA methylation and histone deacetylation 
are known to play an important role in epigenetic gene silencing; herein, we aimed at 
inhibiting DNA methylation and histone deacetylation in order to evaluate their effect on 
reactivation of the CMV promoter.  
 
4.2.7.1 DNA methylation effect on CMV and Grp78 promoter activity 
 
To investigate the mechanism regulating the CMV promoter silencing and determine if the 
silencing of the CMV promoter can be rescued in the context of AAVP, the promoter 
methylation status was first charachterised. Thus, 9L and U87 cells stably transduced with 
RGD4C AAVP/CMV-GFP-puro
R
 were passaged and grown until the CMV promoter 
silencing was detected by fluorescent microscope analysis. Next, cells were incubated with 
different concentrations of the DNA methylation inhibitor 5-Azacytidine (5-Aza) for three 
days. As 5-Aza has been shown to have a short half-life, growth medium containing 5-Aza 
was replaced on a daily basis. To quantify the effect of 5-Aza on the CMV promoter activity, 
flow cytometry was performed on treated and untreated cells. As previously explained in 
material and methods (2-10) both the percentage of GFP positive cells and the MFI were 
calculated by normalizing the results to parental non-transduced cells.  
5-Aza treatment of 9L cells stably transduced with RGD4C AAVP/CMV-GFP-puro
R
 resulted 
in a dose dependent increase in both percentage of GFP positive cells and MFI (Fig. 4.17a).  
As shown in figure 4.17a, only 3.5% of control untreated cells were positive for GFP 
expression; however, this number increased to 17.5% after 3 days of treatment with 20µM of 
5-Aza. More interestingly, this increase in GFP positive cells following treatment with 5-Aza, 
was associated with an 8.9- fold increase of the MFI compared to untreated cells. 
In contrast to the CMV promoter, 5-Aza treatment of 9L cells stably transduced with RGD4C 
AAVP/Grp78-GFP- puro
R
, resulted in no change in GFP expression. However, a slight 
increase in MFI was spotted; starting at 1µM of 5-Aza and this effect was not enhanced 
further by increasing 5-Aza concentrations (Fig. 4.17b). 
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While the above results clearly depict the efficacy of 5-Aza to rescue the CMV promoter in 
9L cells, no specific effect was observed in U87 cells stably transduced by RGD4C 
AAVP/CMV-GFP-puro
R 
following 5-Aza treatment. As shown in figure 4.17c, while the 
percentage of GFP positive U87 cells stably transduced by RGD4C AAVP/CMV-GFP- puro
R
 
remained the same following 5-Aza treatment, only 1.4- fold increase in MFI was detected 
upon treatment with 1 µM 5-Aza. Similar to 9L cells, 5-Aza treatment of RGD4C 
AAVP/Grp78-GFP-puro
R
 stably transduced U87 cells, resulted in no effect on Grp78 
promoter activity (Fig. 4.17d). 
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Figure 4.17. Effect of 5-Aza on CMV and Grp78 promoter activity. 9L cells stably 
transduced with a) RGD4C AAVP/CMV-GFP -puro
R
 or b) RGD4C AAVP/Grp78-GFP -
puro
R
 as well as U87 cells stably transduced with c) RGD4C AAVP/CMV-GFP -puro
R
 or d) 
RGD4C AAVP/Grp78-GFP -puro
R
 were plated in 6 well plates and 24 hours later, 5-Aza 
was added to cells at 4 different concentrations as indicated. At day 3 post 5-Aza treatment, 
cells were collected and GFP positive cells as well as the MFI were analysed by flow 
cytometry. These data are representative of three independent experiments. 
 
 
4.2.7.2 Effect of the HDAC inhibitors on the CMV and Grp78 promoter activity 
  
4.2.7.2.1 Assessment of the effect of HDAC inhibitors on the CMV and Grp78 promoter 
activity in stably transduced 9L cells 
 
After demonstrating the effect of DNA methylation on CMV promoter silencing, I next aimed 
to study the effect of histone deacetylation on long-term CMV promoter activity. Thus, 9L 
cells stably transduced with RGD4C AAVP/CMV-GFP-puro
R
 were passaged and grown until 
the CMV promoter silencing was detected by fluorescent microscope analysis. Next, cells 
were treated with different concentrations of the HDAC inhibitor TSA for 3 days and GFP 
expression was analysed by flow cytometry. The data showed no change in CMV promoter 
activity in 9L cells upon TSA treatment when compared to control untreated cells (Fig. 
4.18a). In contrast to the CMV promoter, treatment of 9L cells stably transduced with 
RGD4C AAVP/Grp78-GFP-puro
R
 with 0.2 µM TSA resulted in a 1.5- fold increase of the 
MFI while the percentage of GFP positive cells remained stable (Fig. 4.18b). 
As no specific effect from TSA treatment was observed on CMV reactivation, I further aimed 
to evaluate the effect of other HDAC inhibitor drugs; SAHA, VPA and Nicotinamide. Both 
SAHA and TSA mediate inhibition of class I and II HDAC family members while VPA can 
only inhibit HDAC class I. The fourth HDAC inhibitor candidate nicotinamide, can inhibit 
class III HDAC family members. Interestingly, treatment of 9L cells stably transduced with 
RGD4C AAVP/CMV-GFP-puro
R
 with SAHA, VPA and nicotinamide for three days resulted 
in no change in CMV promoter activity (Fig. 4.19a). 
In contrast, 3 days of treatment of 9L cells stably transduced by RGD4C AAVP/Grp78-GFP-
puro
R
 with SAHA, resulted in a 3.1- fold increase of the MFI compared to untreated cells 
(Fig. 4.19b). While the increase in MFI was demonstrated, the percentage of GFP positive 
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cells remained stable upon treatment. VPA and nicotinamide treatment resulted in no specific 
change in Grp78 promoter activity (Fig. 4.19b). 
 
 
 
 
 
Figure 4.18. The effect of the HDAC inhibitor TSA on CMV and Grp78 promoter 
activity in stably transduced 9L cells. 9L cells stably transduced with a) RGD4C 
AAVP/CMV-GFP-puro
R
 and b) RGD4C AAVP/Grp78-GFP-puro
R
 were plated in 6 well 
plates and 24 hours later, TSA was added to cells at 3 different concentrations as indicated. 
At day 3 post TSA treatment, cells were collected and GFP positive cells as well as the 
relative MFI were analysed by flow cytometry. These data are representative of two 
independent experiments. 
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Figure 4.19. Effect of HDAC inhibitor drugs on CMV and Grp78 promoter activity in 
stably transduced 9L cells. Stably transduced 9L cells with a) RGD4C AAVP/CMV-GFP-
puro
R
 and b) RGD4C AAVP/Grp78-GFP-puro
R
 were plated in 6 well plates and 24 hours 
later, cells were treated with either the HDAC inhibitor drug SAHA, Nicotinamide or VPA. 
Three different concentration of each compound were applied as indicated. At day 3 post 
drug treatment, cells were collected and GFP positive cells as well as relative MFI were 
analysed by flow cytometry. These data are representative of two independent experiments. 
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4.2.7.2.2 Effect of HDACs inhibitors on CMV and Grp78 promoter activity in stably 
transduced U87 cells 
 
After evaluation of the effect of HDAC inhibitors on CMV and Grp78 promoter activity in 
stably transduced 9L cells, I further aimed to find out whether this effect is also detectable in 
other U87 cells. Thus, U87 cells stably transduced with RGD4C AAVP/CMV-GFP-puro
R 
or 
RGD4C AAVP/Grp78-GFP-puro
R
 were treated with different concentrations of HDAC 
inhibitor drugs for 3 days. As shown in figure 4.20a, in contrast to 9L cells, TSA and SAHA 
treatment of U87 cells stably transduced with RGD4C AAVP/CMV-GFP-puro
R
 resulted in a 
dose dependent reactivation of the silenced CMV promoter. Treatment with 1 µM TSA 
resulted in 1.8- and 3- fold increases in the percentage of GFP positive cells and MFI 
respectively. Moreover, following SAHA treatment, the percentage of GFP positive cells and 
MFI were elevated 2.2- and 2.8- fold, respectively (Fig. 4.20a). VPA treatment did not show 
any change in CMV promoter activity. Also, treatment with nicotinamide resulted in a minor 
increase in the percentage of GFP positive cells but not MFI (Fig. 4.20a). 
In previous experiments, an induction in Grp78 promoter activity upon TSA and SAHA 
treatment in 9L cells stably transduced by RGD4C AAVP/Grp78-GFP-puro
R
 was observed. 
Interestingly in agreement with the previous study, Grp78 activity was shown to increase in 
U87 cells stably transduced by RGD4C AAVP/Grp78-GFP-puro
R
 upon TSA and SAHA 
treatment (Fig. 4.20b). Consistent with the 9L study, only the MFI was increased upon 
treatment and the percentage of GFP positive cells remained stable over treatment. No effect 
from either VPA or Nicotinamide on Grp78 promoter activity was observed (Fig. 4.20b). 
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Figure 4.20. Effect of HDAC inhibitor drugs on CMV and Grp78 promoter activity in 
stably transduced U87 cells. U87 cells stably transduced with a) RGD4C AAVP/CMV-
GFP-puro
R
 or b) RGD4C AAVP/Grp78-GFP-puro
R
 were plated in 6 well plates and 24 
hours later, different concentrations of either HDAC inhibitors TSA, SAHA, Nicotinamide or 
VPA were added to cells as indicated. At day 3 post drug treatment, cells were collected and 
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GFP positive cells as well as relative MFI were analysed by flow cytometry. These data are 
representative of two independent experiments. 
 
 
4.3 Discussion 
 
In this chapter I characterised the long-term activity of both promoters in the context of 
AAVP in vitro. Thus, initially stably U87 and 9L transduced cells with RGD4C 
AAVP/Grp78-puro
R
 and RGD4C AAVP/CMV-puro
R
 vectors were generated and the levels 
of expression of either the GFP or the HSVtk transgenes driven by CMV or Grp78 promoters 
were quantified over time. To monitor GFP expression, stably transduced 9L and U87 cells 
with RGD4C AAVP/Grp78-GFP-puro
R
 and RGD4C AAVP/CMV-GFP-puro
R
 were grown in 
the presence of puromycin until the individual cell clones were noticeable. Initially GFP 
expression was monitored by counting the GFP positive and negative individual selected 
clones under a fluorescent microscope over two weeks time. Subsequently, due to growth of 
clones, this process was further followed by flow cytometry analysis of the pooled clones. 
For HSVtk expression, initially cells were stably transduced with RGD4C AAVP/Grp78-
HSVtk-puro
R
 and RGD4C AAVP/HSVtk-GFP-puro
R
 and Western blot analysis was 
performed on cell lysates at one month intervals. Interestingly, by utilizing a different 
experimental approach, I confirmed over time silencing of the CMV promoter in the context 
of AAVP in both 9L and U87 cells, while a sustained or even increased activity of the Grp78 
promoter was observed. Our findings regarding silencing of the CMV promoter in both 9L 
and U87 cells in culture are in agreement with previous studies demonstrating gradual 
silencing of the CMV promoter over a few months in vitro (Choi et al., 2005, Knust et al., 
1989, Palmer et al., 1991, Verma and Somia, 1997). 
In stably transduced 9L cells, FACS analysis of GFP expression as well as Western blot 
studies of HSVtk protein level driven by the Grp78 promoter demonstrated higher activity of 
this promoter than that of the CMV, but an opposite pattern was observed in the U87 cell line. 
While, CMV- controlled GFP or HSVtk transgene expression in stably transduced U87 cells 
was higher than that under the control of Grp78, transgene expression eventually reached 
levels beneath those in RGD4C AAVP/Grp78 in the course of time. Collectively, these data 
justify research into alternate promoters, such as Grp78, when long-term transgene 
expression is of primary importance.  
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In addition to investigating CMV promoter silencing overtime, we further aimed to confirm 
the superior effectiveness of RGD4C AAVP/Grp78-HSVtk over RGD4C AAVP/CMV-HSVtk 
in suicide gene therapy of cancer in vitro, after GCV treatment. Interestingly, the obtained 
data are consistent with previous results described in chapter 3, section 3.3.3 showing 
superior therapeutic effect of AAVP/Grp78-HSVtk over AAVP/CMV-HSVtk in non-selected 
transduced cells.  
As shown in chapter 3 and in agreement with previous reports, Grp78 is up-regulated in 
highly proliferating 9L cells compared to the less aggressive U87 cells. Thus, within 9L cells, 
the Grp78 promoter may ultimately upregulate HSVtk expression in the context of AAVP. 
Consequently, a higher level of HSVtk expression in RGD4C AAVP/Grp78-HSVtk 
transduced 9L cells relative to RGD4C AAVP/CMV-HSVtk allows more rapid 
phosphorylation, and thus activation, of the GCV prodrug to the toxic GCV triphosphate.  
In U87 cells, GFP and HSVtk expression regulated by CMV surpasses that regulated by 
Grp78 suggesting that overall activity of the Grp78 promoter is lower in this cell line. 
Interestingly, although a lower activity of Grp78 relative to CMV in this cell line was 
observed, more cell death was caused by AAVP/Grp78-HSVtk than AAVP/CMV-HSVtk. This 
finding raised the question of whether the toxic form of GCV is capable of inducing ER stress 
and consequently activates the UPR pathway. This objective will be further addressed in the 
next chapter.  
Previous studies have shown that silencing and down regulation of the CMV promoter leads 
to reduced transgene expression (Brooks et al., 2004, Chen and Townes, 2000). Consistently, 
our data suggest that CMV silencing in both 9L and U87 cells has led to a progressive 
decrease in HSVtk expression and therefore cell killing becomes a far less effective 
endeavour.  
This is not the first study to suggest that the CMV promoter is silenced. While the promoter is 
popular due to its constitutive activity in most mammalian tissues (Cheng et al., 1993), a 
number of silencing mechanisms including DNA methylation and histone deacetylation have 
been implicated in its down regulation (Grassi et al., 2003, Prosch et al., 1996, Chen and 
Townes, 2000). In this chapter, I further aimed to characterise the CMV promoter silencing 
and evaluate its activity in the presence of 5-Aza inhibitor of DNA methylation, and HDAC 
inhibitors TSA, SAHA, VPA and nicotinamide.   
Interestingly following in vitro treatment with 5-Aza, a DNA methyltransferase inhibitor, the 
CMV promoter was induced and its activity restored in stably transduced 9L cells as both 
percentage of GFP positive cells and MFI were increased overtime. However, in contrast to 
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the effect of 5-Aza on CMV promoter reactivation, treatment of RGD4C AAVP/CMV-GFP 
stably transduced 9L cells with either of HDACs inhibitor drugs resulted in no relevant 
differences in the CMV reactivation trend. Interestingly different sets of results were observed 
in U87 cells. 
It has been demonstrated that the mechanism of CMV promoter inactivation can be mediated 
by methylation dependent or independent pathways and are cell-type specific (Radhakrishnan 
et al., 2008). Thus, this report might explain the fact that different mechanisms of CMV 
silencing are involved in U87 and 9L cells. 
In a previous study (Grassi et al., 2003), a correlation between CMV activity and 5-Aza 
concentration was reported at days 2 and 5 post treatment in U87 cells. Within the same 
study, two days of treatment of U87 cells stably transfected with GFP under the control of the 
CMV promoter with 1 µM 5-Aza resulted in approximately 1.5- fold increase in MFI. 
Interestingly, in our study after treating cells with the same concentrations of 5-Aza for 3 
days, 1.4- fold increases in MFI are detected. Although this part of our study was consistent 
with previous work, I could not detect any effect on the percentage of GFP positive cells. 
Unfortunately, it is important to note, the previous study had not shown the percentage of 
GFP positive cells following 5-Aza treatment.  
Regarding the effect of TSA in CMV promoter activity in U87 cells, our data are in 
agreement with previous reports which have demonstrated an effect of TSA on the CMV 
promoter activity (Grassi et al., 2003).  
As mentioned before, other research has shown extensive methylation of both 5’CpG and 
non-CpG sites in the CMV promoter region and moreover complete silencing of CMV 
promoter due to methylation was observed (Das and Singal, 2004, Prosch et al., 1996). 
Interestingly, another study showed that over a period of 60 days, the expression of AAV 
transduced CMV-lacZ genes was silenced in 80% of HeLa cell clones (Chen et al., 1997). 
Surprisingly, the same as our observation in U87 cells stably transduced with RGD4C 
AAVP/CMV-GFP, treatment with TSA but not 5-Aza resulted in dramatic reactivation of 
transgene expression (Chen et al., 1997).  
As discussed, only TSA and SAHA which both are Zn
2+ 
binding HDAC Inhibitors mediate 
inhibition of HDACs class of I and II (Table 4.1), could increase both the percentage of GFP 
positive cells and MFI driven by the CMV promoter in U87 cells. Neither VPA, an inhibitor 
of class I HDACs nor nicotinamide, a class III HDAC inhibitor, could affect the CMV 
promoter activity. Based on these observations we can postulate the possible involvement of 
HDAC family class II in CMV promoter silencing in U87 cells.  
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In contrast to U87 cells, reactivation of the CMV promoter in 9L cells was achieved by 5-Aza 
treatment while treatment with HDAC inhibitors resulted in no change of the CMV activity 
demonstrating that in this cell line, hypoacetylation of histones is not a mechanism involved 
in CMV silencing.  
Another interesting observation was a dose-dependent induction of the Grp78 promoter by 
TSA and SAHA in both 9L and U87 cells. However, the mechanism of this function remains 
unclear and necessitates further investigation. Nevertheless, overexpression of the Grp78 
promoter in response to the HDAC inhibitor TSA in a variety of cancer cells from colon, 
breast to brain tumours have been previously reported (Baumeister et al., 2009). Also in 
addition to in vitro study, induction of Grp78 by HDAC inhibitors has been detected in 
xenograft models. Moreover this induction was also detectable in biopsies from breast cancer 
patients receiving TSA treatment (Baumeister et al., 2009). Since Grp78 has been 
characterised as a major effector of drug resistance, the induction of Grp78 upon HDAC 
inhibitor treatment might address resistance of solid tumours against HDAC inhibitors in 
clinical trials. Indeed, as Grp78 promotes tumour growth and at the same time inhibits 
apoptosis induced by stress (Dong et al., 2008). Grp78 gene knock down using siRNA results 
in a significant increase in cell death upon TSA treatment (Baumeister et al., 2009). 
HDAC deregulation has been associated with several cancers. Also usage of HDAC 
inhibitors proved to mediate cell growth inhibition and induce terminal differentiation. 
Moreover administration of HDAC inhibitors has been shown to mediate inhibition of tumour 
formation in mice models, thus HDAC inhibitors are considered as potential candidates for 
cancer treatment. SAHA has recently been approved by the FDA as a new class of anti-
cancer drugs with great therapeutic potential against cutaneous T cell lymphoma (CTCL) 
(Grant et al., 2007). SAHA has also been used in phase I and II clinical trials for 
hematological malignancies and solid tumours (Modesitt et al., 2008, Garcia-Manero et al., 
2008, Galanis et al., 2009). Although HDAC inhibitors are clinically effective against 
hematologic cancers, they are solely considered poor anti-cancer agents against solid tumours 
(Modesitt et al., 2008, Luu et al., 2008).  
Based on our data, the Grp78 promoter can increase the therapeutic benefits of HDACs 
inhibitors as these drugs are able to induce overexpression of therapeutic transgenes under the 
control of the Grp78 promoter within solid tumours. In addition to sustained long-term Grp78 
activity, these data validate another beneficial usage of this promoter in cancer gene therapy. 
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Chapter 5 
 
 
 
 
HSVtk/GCV suicide gene therapy induces Grp78 promoter activity 
 
 
 
 
 
5.1 Introduction 
 
In eukaryotic cells, ER is the main organelle in charge of protein synthesis and modification. 
Grp78, which belongs to the HSP70 family, is a highly abundant ER chaperone. The primary 
function of this protein is to bind to hydrophobic regions of nascent ER polypeptides and 
assist their proper folding. Along with its role in protein folding, Grp78 is also known as an 
important component to promote degradation of proteins if their misfolding is irreversible.  
Regulation of Grp78 expression is controlled by a conserved signalling cascade termed UPR 
(unfolded protein response) pathway. In non-stressesd cells, Grp78 is bound to three 
endoplasmic reticulum (ER) transmembrane proteins from the ER lumen side and maintain 
them in inactive forms. These three proteins which represent three arms of the UPR are: 
protein kinase- like ER kinase (PERK), inositol requiring enzyme 1 (IRE1) and activating 
transcription factor 6 (ATF6) (Hetz et al., 2011, Zhang and Zhang, 2010).  
However, in a condition referred to as ER stress caused by accumulation of unfolded or 
misfolded proteins load within the ER, Grp78 dissociates from the PERK, IRE1 and ATF6, 
and further binds to unfolded proteins to facilitate their proper folding and thus re-establish 
ER homeostasis. Dissociation of Grp78 from the ATF6, IRE1 and PERK proteins will also 
mediate initiation of the UPR signalling cascade. UPR mainly assists cell desensitization to 
ER stress by reducing overall translation (Zhang and Zhang, 2010). Moreover this pathway 
will subsequently induce the up-regulation of ER chaperone protein expression such as Grp78 
which has been shown to prevent apoptosis in stress-induced cell death.  
128 
 
However under conditions in which UPR cannot re-establish the ER homeostasis, the UPR is 
capable of inducing programmed cell death (Pfaffenbach and Lee, 2011). Upon dissociation 
of Grp78, the 90 kDa activating transcription factor 6 (ATF6-90 kDa) is released and 
transported to the Golgi where it is cleaved by site-1 and site-2 proteases (S1P and S2P) to 
generate and release the 50 kDa ATF6 (ATF6-p50) into the cytosol (Fig. 5.1) (Haze et al., 
1999, Zhang and Zhang, 2010). ATF6-p50 is the active nuclear form of ATF6. Previous 
studies showed that upon ER stress, S2P-mediates proteolytic cleavage of the transcription 
factor ATF6, which targets the ERSE region of the Grp78 promoter and thus strictly activates 
transcription of Grp78 (Ye et al., 2000, Lee et al., 2002). 
As explained in chapter 1, transcriptional activation of the Grp78 promoter is mediated and 
controlled by highly conserved elements located in the Grp78 promoter which is referred to 
as ER stress response element (ERSE). In the mammalian Grp78 promoter, ERSE contribute 
to ER stress–induced transcriptional activation (Roy and Lee, 1999). Apart from ATF6-p50, 
other transcription factors including TFII-I, YY1 and NF-Y bind to ERSE and regulate the 
Grp78 promoter activity. 
Further, when it is no longer bound to Grp78, inositol-requiring enzyme 1(IRE1) dimerizes 
and this will activate its endoribonuclease activity, thus resulting in splicing of the mRNA 
encoding X-box binding protein 1 (XBP1) (Calfon et al., 2002, Samali et al., 2010). Spliced 
XBP1 protein is a highly active transcription factor, and like ATF6- p50, it can bind to ERSE 
sequences and induce the transcription of ER chaperone genes (Fig. 5.2) (Yoshida et al., 
2001). XBP1 is present in cells in both, spliced and unspliced form, with the unspliced form 
acting as a dominant negative (Wang et al., 2010). Spliced XBP1 has greater stability than its 
unspliced counterpart (Samali et al., 2010). The IRE1-XBP1 arm of the UPR regulates genes 
responsible for differentiation, inflammation, lipogenesis, and apoptotic pathways (Wang et 
al., 2010). Increased expression of spliced XBP1 is correlated with tumour survival, whereas 
XBP1 knockout and XBP1 unspliced-expressing cells demonstrated an increased occurrence 
of apoptosis (Wang et al., 2010). These data suggest an anti-apoptotic role for Grp78 via the 
downstream effector spliced XBP1 in tumour cells. 
Upon dissociation of Grp78 from pancreatic ER kinase (PERK), the third arm of UPR, this 
transmembrane protein will homooligomerize and subsequently phosphorylate Ser51 of α 
subunit of the eukaryotic initiation factor 2α (eIF2α). Phosphorylated-eIF2α can selectively 
trigger translation of the transcription factor ATF4 which mediates activation of the Grp78 
promoter independent of the ERSE (Fig. 5.3). In mammalian cells, CRE/ATF sequence 
localized upstream of the ERSE within the Grp78 promoter has been described as an ATF4 
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binding site (Luo et al., 2003). Phosphorylated-eIF2α can also attenuate mRNA translation 
and thus prevent a new load of polypeptides from entering the ER lumen (Fig. 5.3) (Back et 
al., 2009).  
Each of these three arms plays a cytoprotective role in the UPR pathway, ultimately 
upregulating pro-survival genes such as Grp78 via transcriptional activation in the nucleus. 
In chapter 3 and chapter 4, I showed that in both 9L and U87 cells, the Grp78 promoter 
driving the HSVtk transgene in the context of AAVP leads to dramatic cell death compared to 
that of the targeted RGD4C AAVP/CMV-HSVtk after GCV treatment. In contrast, Western 
blot analysis of HSVtk expression, (before GCV treatment) under the control of either 
promoter, as well as GFP analysis by flow cytometry in U87 cells showed higher activity of 
the CMV relative to the Grp78 promoter. 
In summary although, lower activity of the Grp78 promoter relative to the CMV promoter 
was observed in the U87 cell line, more cell death was achieved by the RGD4C 
AAVP/Grp78-HSVtk vector after GCV treatment. Thus, an important question arises whether 
the Grp78 promoter exhibits higher activity over the CMV promoter upon HSVtk/GCV 
treatment. I previously explained that HSVtk can mediate phosphorylation of the GCV 
prodrug and subsequently leading to the formation of toxic GCV triphosphate which is able 
to incorporate into DNA and result in cell death. Thus toxic GCV triphosphate might play a 
role as an inducer of Grp78.  
To date no study has addressed this phenomenon; thus, for the first time I aimed to 
investigate the effect of the HSVtk plus GCV cytotoxic gene therapy on the activity of Grp78 
promoter at both the endogenous and AAVP/Grp78 vector level. Moreover, I further aimed 
to study the possible mechanism involved in Grp78 overexpression upon HSVtk/GCV 
therapy. Since expression of Grp78 is tightly controlled by the UPR pathway, my goal was to 
gain insight into UPR activation upon HSVtk/GCV treatment. 
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Figure 5.1. The ATF6 arm of the UPR. In normal conditions, ATF6 is maintained in an 
inactive state through an association with Grp78. However in the presence of ER stress I) the 
unfolded protein load will increase and II) Grp78 will dissociate from ATF6, then binds the 
unfolded proteins, thus III) ATF6 will be activated and translocate into the Golgi apparatus. 
IV) In the Golgi, ATF6 is cleaved and a 50kDa ATF6 fragment (ATF6-p50) is released into 
the cytosol. ATF6-p50 migrates to the nucleus and binds ERSEs to activate transcription of 
ER chaperon genes. 
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Figure 5.2. The IRE1 arm of the UPR. In non-stressed cells, IRE1 is inactive through an 
association with Grp78. I) upon an increase in unfolded protein load due to ER stress II) 
Grp78 dissociates from PERK to bind unfolded proteins, III) leading to spontaneous 
dimerization and phosphorylation of IRE and also activation of its RNase. IV) The 
endogenous endoribonuclease activity of IRE1 splices XBP1 mRNA. The spliced mRNA is 
translated into the functional XBP1 protein, which migrates to the nucleus and binds the 
ERSE regions of chaperone proteins such as Grp78. 
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Figure 5.3. The PERK arm of the UPR. In normal conditions, Grp78 is bound to PERK and 
maintains it in an inactive state. Upon ER stress and thus I) an increase in unfolded protein 
load, II) Grp78 dissociates from PERK and binds the unfolded proteins, III) permitting 
homooligomerization and phosphorylation of PERK. IV) PERK facilitates the 
phosphorylation of eIF2α, which then V) attenuates translation and VI) stimulates the 
translation of ATF4. The ATF4 migrates to the nucleus where it transcriptionally activates 
the ER chaperone genes.  
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5.2 Results 
 
5.2.1 Induction of Grp78 promoter activity upon HSVtk/GCV treatment in 9L cells  
 
To gain further insight into the understanding of the beneficial effects by the double-targeted 
RGD4C/Grp78-HSVtk vector, I investigated the effect of HSVtk plus GCV cytotoxic gene 
therapy on the activity of the Grp78 promoter, both at the endogenous Grp78 and RGD4C 
AAVP/Grp78 vector level. 9L cells stably transduced with RGD4C AAVP/Grp78-HSVtk-
puro
R
 or RGD4C AAVP/CMV-HSVtk-puro
R
 were incubated with 20µmol/L of GCV from 
1hr to12hr. Untreated cells were used as a negative control. Total cell lysates were prepared 
from 9L stably transduced cells under normal conditions or GCV treatment, and equal 
amounts of protein were separated by SDS-PAGE and then subjected to Western blot 
analysis. As shown in figure 5.4, HSVtk in combination with GCV treatment can mediate 
endogenous Grp78 induction in 9L cells transduced with RGD4C/Grp78-HSVtk-puro
R
 or 
RGD4C/CMV-HSVtk-puro
R
; a gradual increase of endogenous Grp78 level with GCV 
treatment was observed over-time. Grp78 level normalized to the loading control GAPDH 
has demonstrated ~3- fold increase in endogenous Grp78 levels after 12 hours of incubation 
with GCV. 
 
More interestingly, in cells in which the HSVtk transgene was driven by the Grp78 promoter, 
HSVtk level was increased upon GCV treatment, with ~2.5- fold increase detected at 12 
hours post GCV treatment (Fig. 5.4a). In contrast no effect of GCV on HSVtk expression 
driven by the CMV promoter was observed in cells stably transduced with RGD4C/CMV-
HSVtk-puro
R
 (Fig. 5.4b). These data show that HSVtk/GCV suicide therapy can induce both 
promoters of endogenous Grp78 and of the double-targeted RGD4C AAVP/Grp78 vector. 
Thus, induction of the representative UPR marker Grp78 indicates that GCV in combination 
with HSVtk might be a novel inducer of ER stress. 
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Figure 5.4. Combination of HSVtk expression and GCV treatment induces Grp78 
promoter activity. 9L cells stably transduced with a) RGD4C/Grp78-HSVtk-puro
R
 or b) 
RGD4C/CMV-HSVtk-puro
R
 were grown in the presence of GCV for the indicated times. 
Then, equal amount of cell lysate were subjected to Western blot and analyzed with 
antibodies against Grp78, HSVtk and GAPDH as control. Endogenous Grp78 and HSVtk 
levels were measured and normalized to GAPDH. Fold increase of endogenous Grp78 and 
HSVtk over the time zero- control was calculated for each sample (n=3). *p < 0.05, **p < 
0.01, ***p < 0.001 and ns: non-significant. 
 
 
5.2.2 Induction of the UPR pathway upon HSVtk/GCV treatment 
 
5.2.2.1 Activation of the PERK arm of UPR 
 
Regulation of Grp78 is controlled by an evolutionary conserved signalling cascade termed the 
UPR pathway. Here, to address whether induction of Grp78 level in the presence of GCV-
triphosphate was driven by activation of the UPR, I first examined the PERK pathway. The 
detection of PERK is quite difficult due to lack of good commercial antibodies. Thus, in 
order to detect PERK induction upon HSVtk/GCV treatment I attempted to detect its 
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downstream protein target eIF2α. Activated PERK, upon dissociation of Grp78, will 
subsequently phosphorylate eIF2α which blocks general protein synthesis by suppressing 
mRNA translation. However, Phosphorylated eIF2α will selectively promote translation of 
the transcription factor ATF4 which will subsequently translocate into the nucleus and induce 
Grp78 transcription. To detect the phosphorylated eIF2α after GCV treatment, 9L cells stably 
transduced with RGD4C/Grp78-HSVtk-puro
R
 were incubated with GCV from 1 to 12 hours. 
Cell lysates were analyzed by Western blot with an antibody against phospho- eIF2α, which 
can detect phosphorylated eIF2α only when phosphorylation occurs at the Ser51position, 
mediated by activated PERK. Interestingly, the phosphorylated eIF2α, a downstream target of 
PERK, was first detected after 9 hours and maintained at least through 12 hours of GCV 
treatment (Fig. 5.5). Detection of phosphorylated eIF2α after GCV treatment demonstrates 
the induction of the PERK pathway upon GCV/HSVtk treatment of 9L cells. 
 
 
 
 
 
Figure 5.5. HSVtk/GCV treatment induces phosphorylation of elF2α. 9L cells stably 
transduced with RGD4C/Grp78-HSVtk-puro
R
 were grown in the presence of GCV for the 
indicated times. Next, equal amount of cell lysates were analysed by Western blot using 
antibodies against phosphor-elF2α and GAPDH as control. The above Western blots are 
representative of three independent experiments. 
 
 
5.2.2.2 Activation of the ATF6 arm of UPR 
 
Upon Grp78 dissociation, ATF6 will be converted from a 90 kDa protein (ATF6- p90) to a 
50 kDa protein (ATF6-p50) which can translocate to the nucleus and subsequently activate 
transcription of target genes such as Grp78. To evaluate ATF6 activation after GCV 
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treatment, 9L cells stably transduced with RGD4C/Grp78-HSVtk-puro
R
 were incubated with 
GCV from 1 to 12 hours. Due to technical difficulties, we were unable to detect the 50-kDa 
ATF6 by Western blot analysis; however, results indicated an increase in ATF6-p90 level 
after treatment with GCV in the 9L cells stably transduced with RGD4C/Grp78-HSVtk-puro
R 
(Fig. 5.5). The induction became evident after 6 hours of GCV treatment and persisted as 
well as intensified, at least, through the 12 hours of treatment (Fig. 5.5). Although we were 
unable to detect the 50-kDa ATF6, a previous study reported that an increase in 90-kDa 
ATF6 level after GCV treatment demonstrates ER stress and UPR activation (Teske et al., 
2011). 
 
 
 
 
Figure 5.6. HSVtk/GCV treatment induces ATF6-p90 expression. 9L cells stably 
transduced with RGD4C/Grp78-HSVtk-puro
R
 were grown in the presence of GCV for the 
indicated times. Then equal amount of cell lysates were analysed by Western blot using 
antibodies against ATF6 and GAPDH as control. The above Western blot is representative of 
three independent experiments. 
 
 
5.2.2.3 Activation of the IRE1 arm of UPR 
 
The induction of the ATF6 and PERK arms of the UPR pathway has been confirmed in 9L 
cells after HSVtk/GCV treatment. Next, I aimed to characterise the effect of GCV 
triphosphate on IRE1, the third arm of UPR. As detection of IRE1 is not possible due to lack 
of efficient commercial antibody, I tried to analyse its downstream protein target XBP1. 
Activated IRE1 upon ER stress can splice a 26-nucleotide intron from XBP1 mRNA which 
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leads to a shift in the open reading frame. Spliced mRNA is an effective transcription factor 
which can mediate activation of Grp78 promoter activity. To detect the spliced XBP1 
mRNA, 9L cells stably transduced with RGD4C/Grp78-HSVtk-puro
R
 were incubated with 
GCV from 1 to 12 hours and semiquantitative RT-PCR was performed by using a set of 
primers which were able to detect both the spliced and unspliced form of XBP1 mRNA 
(Samali et al., 2010). 
Semi-quantitavive RT-PCR results showed that the level of mRNA of XBP1 was 
constitutively spliced in 9L cells, similar to both positive control TG treated and negative 
control untreated cells, and GCV treatment did not induce any further increase in spliced 
XBP1 mRNA level (Fig. 5.7a). Similar to 9L cells, constitutive expression of spliced XBP1 
mRNA has been reported in C-26 colon adenocarcinoma cells and some human melanoma 
cell lines (Nowis et al., 2007, Jiang et al., 2009) . Moreover, the important role of the 
IRE1/XBP1 arm of UPR in tumour growth and also tumour survival has been described 
(Romero-Ramirez et al., 2004, Lin et al., 2007, Feldman et al., 2005). 
In contrast to 9L cells, in U87 cells stably transduced with RGD4C/Grp78-HSVtk-puro
R
, the 
spliced XBP1 mRNA was only detectable in TG treated cells but not in GCV treated or 
untreated cells. Taken together, I can state that HSVtk/GCV treatment does not have any 
effect on the IRE1 arm of the UPR pathway; however, I could reveal the constant expression 
of spliced XBP1in 9L cells but not in U87, which can address the more stress resistant 
character and high proliferation rate of 9L cells over U87 cells. 
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Figure 5.7. Constitutive expression and splicing of XBP1 in 9L cells. Total RNA from a) 
9L cells stably transduced with RGD4C AAVP/Grp78-HSVtk-puro
R
 and b) U87 cells stably 
transduced with RGD4C AAVP/Grp78-HSVtk-puro
R
 grown in the presence of GCV for the 
indicated times or TG was isolated and analysed by semiquantitative RT-PCR. PCR products 
were separated by 1.5% agarose gel for GAPDH or 3% agarose gel for XBP1. Size of PCR 
products: unspliced XBP1= 289 bp and spliced XBP1= 263 bp. Shown are results of two 
independent experiments. 
 
 
 
 
 
139 
 
5.3 Discussion 
 
Current available drugs for cancer treatment such as chemotherapeutic agents are not tumour 
specific as they cannot discriminate in their mode of action. Thus, suicide genes such as 
HSVtk have gained an increasing interest in cancer treatment as this approach proved to have 
no significant systemic toxicity (Shen and Nemunaitis, 2006). Suicide gene therapy also 
known as prodrug therapy requires the presence of prodrugs for their action. In particular, 
HSVtk suicide gene therapy is induced by administration of the GCV prodrug. The protein 
product of the HSVtk suicide gene which has almost 1000 times more affinity for the prodrug 
GCV than the host cell tk (Elion et al., 1977) can phosphorylate GCV and thus convert it into 
toxic metabolites resulting in significant cell death. In addition, the bystander effect of toxic 
GCV makes this system more efficient for cancer treatment. Indeed in the original 
AAVP/CMV vector, the HSVtk suicide gene was used for cancer treatment and proved 
efficient to mediate cell death in solid tumours in vivo after GCV administration (Hajitou et 
al., 2006b).  
In this project, to assess systemic gene therapy efficacy of the double-targeted RGD4C 
AAVP/Grp78 vector, I inserted the HSVtk gene under the control of Grp78 promoter. To our 
surprise, despite the fact that the Grp78 was a weaker promoter than CMV in U87 cells, the 
efficacy of the therapeutic HSVtk gene driven by Grp78 promoter in the context of AAVP 
vector proved more efficient than the original vector and resulted in higher rate cell death in 
both U87 and 9L in vitro. Our data are also consistent with previous work reporting the 
stronger tumour cell killing efficacy of HSVtk under the Grp78 promoter in vivo in 
comparison to viral promoter LTR, although a higher activity of LTR over Grp78 promoter in 
vitro has been reported (Azatian et al., 2009). The authors stated that in vivo the tumour 
microenvironment can strongly induce Grp78 promoter activity. 
 However, since in this project our first goal was to characterise the therapeutic efficacy of 
our novel double-targeted vector in vitro prior in vivo study, I observed that higher expression 
of HSVtk under the control of Grp78 in glioblastoma cells is not limited by the tumour 
microenvironment in vivo and indeed it can be achieved in vitro by using cancer cells. This 
fact raised the question of whether toxic GCV triphosphate can mediate ER stress and thus 
induce Grp78 promoter activity. To further characterize and address the effect of HSVtk/GCV 
in Grp78 induction, 9L cells stably transduced by RGD4C AAVP/Grp78-HSVtk-puro
R
, were 
incubated with GCV and our results revealed the induction of the Grp78 promoter activity for 
both endogenous Grp78 level and HSVtk level driven by the Grp78 promoter. 
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Numerous recent studies have shown that treatment with several drugs such as 
chemotherapeutic drugs and HDACs inhibitor can stimulate Grp78 expression (Lin et al., 
2011, Jiang et al., 2009, Baumeister et al., 2009, Pyrko et al., 2007, Mandic et al., 2003). Yet, 
this is the first report to show that HSVtk/GCV suicide gene therapy induces Grp78 at both 
the endogenous and vector level, leading to increased HSVtk expression and subsequently to 
enhanced tumour cell killing. Our discovery that GCV in combination with HSVtk is an 
inducer of Grp78 suggests that it might mediate ER stress.  
As Grp78 expression is tightly controlled by the UPR pathway, our next goal was to verify 
the effect of GCV/HSVtk treatment on this conserved pathway. PERK, ATF6 and IRE1, the  
threes arms of UPR, get activated upon ER stress and each initiates the downstream 
signalling pathway itself which results in activation of a set of transcription factors that will 
subsequently induce the Grp78 expression. Technically, the detection of phosphorylated 
PERK and IRE1 are quite difficult and is not advisable due to the low quality of 
commercially available antibodies (Samali et al., 2010); hence, I tried to assess their 
activation upon HSVtk/GCV treatment by analysing their downstream protein targets such as 
phosphorylated eIF2α and spliced XBP1 mRNA, respectively. 
Indeed, incubation of stably transduced 9L cells by RGD4C AAVP/Grp78-HSVtk-puro
R
 with 
the GCV prodrug resulted in phosphorylation of eIF2α which was detectable after 9hours of 
GCV treatment and maintained through 12 hours. This result confirmed the activation of the 
PERK pathway upon GCV treatment. In addition, an increase in ATF6-p90 level was 
observed through GCV treatment. As some other studies suggested, detection of ATF6-p50, 
an active transcription factor, is quite difficult as this cleaved fraction is maintained at very 
low level within cells and, moreover, there is currently a lack of good commercial antibodies 
for accurate detection.  
Indeed Teske et al. have shown that activated PERK/phosphorylated-eIF2α can mediate the 
activation of ATF6 transcription and also control its translation in response to ER stress 
(Teske et al., 2011). Through this process there will be sufficient amounts of newly 
synthesized ATF6 available for continued processing into the ATF6- p50 or ATF6 active 
form in the presence of ER stress. In this scenario an increase in ATF6-p90 level detected 
upon GCV treatment is an indication of ER stress induction.  
In contrast to PERK and ATF6 activation upon HSVtk/GCV treatment, no specific induction 
was observed for the IRE1 arm of UPR. IRE1 induction was characterised by detection of its 
downstream target, spliced mRNA XBP1. To our surprise, semiquantitative RT-PCR analysis 
revealed the constant presence of the spliced XBP1 mRNA in 9L tumour cells, which acts as 
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a transcription factor for the Grp78 promoter. In contrast I could not detect spliced XBP1 
mRNA in U87 tumour cells neither in untreated cells nor in the presence of GCV. Indeed, the 
presence of spliced XBP1 in 9L cells can address its higher Grp78 level relative to U87 cells, 
as discussed in chapter 3.  
 
The main roles of XBP1 in tumour growth and tumour survival have been established 
(Romero-Ramirez et al., 2004, Lin et al., 2007, Feldman et al., 2005). Moreover, a recent 
study has argued the fact that through induction of Grp78, XBP1 may prevent apoptosis in 
cells surviving drug treatment. They also demonstrated prolonged survival of the quiescent 
fraction upon Grp78 induction (Schewe and Aguirre-Ghiso, 2009). 
As shown in chapter 3, 9L cells grown in medium containing 10% FBS, depict higher 
proliferation rate relative to U87 cell over time. Here, to further investigate the effect of 
spliced XBP1 on quiescent cells, 9L and U87 cells were incubated with 0.5% FBS-containing 
medium. As shown in figure 5.8, consistently with previous studies, 9L cells could survive 
and proliferate once they have entered a prolonged quiescent state (G0-G1 arrest) while 
quiescent U87 cells could not survive over-time. Based on previous studies and our data 
obtained in this chapter I can address the correlation between the constant presence of spliced 
XBP1 and proliferation of quiescent 9L cells. 
 
 
 
 
Figure 5.8. Proliferation of quiescent 9L cells over time. Proliferation rate of 9L and U87 
glioblastoma quantified by counting the cells over time. For growth curves, 1x10
4 
cells of 9L 
and U87 cell lines were plated in 24-wells plates and grown in DMEM medium suplemented 
with 0.5% FBS. Triplicates were collected on days 2, 3, 4, 5 and 6 using trypsin- EDTA, and 
counted using the trypan blue. This experiment was performed twice. Error bars represent 
standard error of the mean (s.e.m). ***p < 0.001.  
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In summary for the first time I show induction of the Grp78 expression upon HSVtk/GCV 
treatment. Moreover, I confirmed this induction by showing ER stress mediated by toxic 
GCV as I could successfully detect UPR activation through induction of the PERK and ATF6 
pathways known to control and induce Grp78 expression. 
In this manner, cells transduced by RGD4C AAVP/Grp78-HSVtk unintentionally facilitate 
their own death upon GCV administration. Consequently, our studies also provide proof of 
concept supporting the usage of our novel double-targeted vector for cancer treatment. I also 
strongly believe that this system might mediate treatment against therapy-resistant tumours; a 
quest that has long been a challenge in oncology. 
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Chapter 6 
 
 
 
In vivo efficacy of double-targeted vector RGD4C AAVP/ Grp78 in 
tumour-bearing mice 
 
 
 
 
 
6.1 Introduction 
 
To date, the usage of the Grp78 promoter in cancer gene therapy has been tested in the 
context of retroviral vectors. Therapeutic efficacy of a retroviral vector carrying the HSVtk 
suicide gene under the control of the Grp78 promoter followed by administration of GCV 
proved efficient to eradicate murine tumours and human xenografts in mice with no 
recurrence of tumour growth (Dong et al., 2004, Chen et al., 2000). Moreover, by using the 
same vector another group demonstrated gastroesophageal junction and gastric 
adenocarcinoma cell death in vitro and tumour regression in vivo (Azatian et al., 2009). 
However, in all the previous studies, tumour cells were first transduced with a vector carrying 
a Grp78 transgene expression cassette, and then implanted in mice. Thus no vector 
administration was applied directly in mice. 
This is the first study designed to utilise the Grp78 promoter in a ligand targeted AAVP 
vector for systemic cancer gene therapy. After demonstrating that transgene expression in 
tumour cells in vitro is clearly improved in the context of the double-targeted RGD4C 
AAVP/Grp78 vector and most importantly after full characterisation of the therapeutic 
efficacy of this novel vector carrying HSVtk gene, our next goal was to evaluate the 
specificity and efficacy of gene delivery into tumours in vivo after systemic administration of 
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the RGD4C AAVP/Grp78 vector and compare it alongside the original RGD4C AAVP/CMV 
vector. In addition, to the specificity of the double-targeted vector in vivo, I aimed to evaluate 
the long-term activity of the Grp78 promoter, in living tumour-bearing mice following single 
intravenous administration (IV) of vector. 
As an initial preclinical model, we used immunodeficient nude mice bearing subcutaneous 
tumours derived from either 9L rat glioblastoma or U87 human glioblastoma cells. In this 
chapter for non-invasive monitoring of Luc expression in living tumour-bearing mice 
following intravenous administration (IV) of Luc-expressing vectors, we used a standard 
experimental setup for in vivo imaging of the firefly Luc reporter transgene. By using 
repetitive bioluminescence imaging (BLI), we have visualized and quantitated Luc expression 
after a single systemic administration of RGD4C AAVP/Grp78-Luc or RGD4C AAVP/CMV-
Luc, or control insertless vectors in 9L or U87-derived tumours and other tissues in nude 
mice.  
In addition to the above studies, we will evaluate the therapeutic efficacy of the double-
targeted vector in vivo using both 9L glioblastoma cells as an aggressive tumour model and 
U87 cells as a fast-moderate tumour model. 
 
 
6.2 Results 
 
6.2.1 Bioluminescence imaging reveals activation of the Grp78 promoter in growing 
tumours overtime 
 
In chapter 4, I demonstrated long-term activity of the Grp78 promoter activity in stably 
transduced 9L and U87 cells. Interestingly, in contrast to the Grp78 promoter, silencing of 
CMV promoter in the 9L and U87 cells transduced with RGD4C AAVP/CMV-puro
R
 was 
observed over time. These results were obtained by monitoring either the GFP reporter gene 
or HSVtk suicide gene expression under the control of either promoter in the context of the 
AAVP vector. After demonstrating both promoter activities overtime in tumour cells in vitro, 
we further aimed to examine the possibility of improved transgene expression in RGD4C 
AAVP/Grp78-puro
R
 stably transduced cells overtime in an in vivo context.  
Thus, 9L cells were first stably transduced with RGD4C AAVP/Grp78-puro
R
 or RGD4C 
AAVP/CMV-puro
R
 vectors expressing the Luc reporter transgene. At day 25 post-vector 
transduction, stably selected 9L cells were subcutaneously implanted into immunodeficient 
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nude mice. At day 14 post-cell implantation, the BLI of whole living tumour-bearing mice 
was initiated and continued at the indicated days to measure the luciferase signal driven by 
the Grp78 promoter within stably transduced 9L tumour-bearing mice and was compared to 
the CMV promoter (Fig. 6.1a). Note that in figure 6.1, the same scale bars have have been 
applied for all the images and thus comparisons are valid. Within the initial tumour growth 
phase, the luciferase signal was comparable between the two groups of tumours. However, 
long-term, the luciferase signal increased significantly in tumours derived from 9L cells 
stably transduced by RGD4C AAVP/Grp78- Luc in which at day 36 post imaging, luciferase 
activity in the Grp78 tumour was on average 6 times greater than in RGD4C AAVP/CMV-
Luc derived 9L tumours (Fig. 6.1b). The direct effect of the tumour microenvironment on 
Grp78 induction has been reported by several studies and indeed our results demonstrate the 
effect of in vivo growing 9L tumours on the Grp78 promoter induction in the context of 
AAVP. In contrast, luciferase expression driven by the CMV promoter in stably transduced 
9L tumours was only detectable in one edge of the tumour. The CMV activity was completely 
silenced in other parts of the tumour as no specific luciferase signal could be observed (Fig. 
6.1a). As the implanted tumour cells were previously stably transduced and selected with 
RGD4C AAVP/CMV-Luc-puro
R
, the increase in luciferase expression upon tumour growth 
was expected, while in contrast luciferase expression driven by the CMV promoter remained 
at the same level overtime (Fig. 6.1b).  
Interestingly the above long-term in vivo imaging results directly correlate with our in vitro 
study demonstrating the CMV promoter silencing over time.  
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Figure 6.1. Evaluation of Grp78 and CMV promoter activity in vivo over time. a) In vivo 
bioluminescent imaging (BLI) of immunodeficient nude mice (n=5) bearing 9L glioblastoma 
cells stably transduced with either RGD4C AAVP/Grp78-Luc-puro
R 
or RGD4C 
AAVP/CMV-Luc-puro
R
 vector over indicated days of bioluminescence imaging. b) 
Luciferase expression driven by either Grp78 or CMV promoter was measured at the 
indicated times. **p < 0.01 and ***p < 0.001. 
 
 
 
6.2.2 Systemic tumour targeting of gene delivery in vivo by the double-targeted vector 
RGD4C AAVP/Grp78 
 
6.2.2.1 RGD4C AAVP/Grp78 targeting 9L glioblstoma xenografts 
 
To evaluate AAVP vector-mediated transgene expression after systemic delivery in tumour-
bearing mice, we first established 9L glioblastoma tumours by injecting 10
6
 9L cells into the 
right flank of immunodeficient nude mice. Then, a single dose (5 x 10
5 
TU) of targeted 
RGD4C AAVP/CMV or double-targeted RGD4C AAVP/Grp78 as well as control insertless 
vectors carrying the Luc reporter gene was administered intravenously (IV) to nude mice 
bearing subcutaneous 9L glioblastomas (~100 mm
3
).  
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The BLI technique was used to monitor the Luc reporter transgene expression in living 
tumour-bearing mice after RGD4C AAVP administration. The BLI of Luc expression is a 
very sensitive method for reporter gene imaging in mice and has almost no nonspecific 
background activity in the images (Gross and Piwnica-Worms, 2005, Gelovani Tjuvajev and 
Blasberg, 2003, Hajitou et al., 2006b). Serial in vivo BLI measurement with D-luciferin 
substrate (on days 0, 3, 5, 7, 14 and 18) was performed. We have visualized and quantitated 
Luc expression within the 9L-derived tumour and other organs and tissues of nude mice, at 
the indicated days post systemic administration of RGD4C AAVP/Grp78-Luc or RGD4C 
AAVP/CMV-Luc, or control insertless vectors (Fig. 6.2).  
Consistent with previous reports (Hajitou et al., 2007), luciferase expression within 9L 
tumours was detectable at very low levels at day 3 after RGD4C AAVP/CMV-Luc 
administration (Fig. 6.2a and 6.2b). While low luciferase expression at day 3 was followed by 
a linear increase that reached a maximum of transgene expression at day 5, this short time 
increase in CMV activity within 9L tumours was followed by a marked decrease at day 7 
post-vector administration. In sharp contrast to mice administered with the RGD4C 
AAVP/CMV-Luc vector, a significantly higher luciferase expression level within tumour cells 
was achieved at day 3 post IV administration of the RGD4C AAVP/Grp78-Luc vector, 
followed by a gradual and much longer stabilization of luciferase expression levels towards 
day 8 (Fig. 6.2a and 6.2b). 
Although both promoters proved to have similar activity within the 9L tumour, the Grp78 
promoter operated earlier and lasted longer compared to the CMV promoter (Fig. 6.2b). 
Finally, no tumour-associated bioluminescent signals were observed in mice receiving 
control vectors (Fig. 6.2a). 
Moreover, consistent with a previous study no bioluminescence was observed in normal 
organs of mice such as lung, liver, spleen, or kidneys from all experimental groups.  
However, luciferase expression was detected in animal’s paws and also at the site of IV 
injection of the RGD4C AAVP/CMV-Luc vector, while mice administered with double-
targeted RGD4C AAVP/Grp78-Luc vector did not show such an effect (Fig. 6.2a).  
Although αvβ3 and αvβ5 integrins are barely detectable in quiescent vessels, their up-
regulation during wound -induced angiogenesis has been previously reported (Max et al., 
1997, Christofidou-Solomidou et al., 1997, Sheppard, 1996, Hodivala-Dilke et al., 2003). 
Thus, the non-specific expression of the RGD4C AAVP/CMV-Luc vector in mice tails and 
paws might be mediated by targeting the αv integrins overexpressed on injured endothelial 
cell surfaces and further constitutive expression of Luc under the control of CMV promoter. 
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Interestingly, Luc expression driven by the Grp78 promoter was only detectable within the 
tumour as evidenced by the absence of specific BLI signals in mice paws and tail (Fig. 6.2a). 
In agreement with previous reports, these data indicate quiescent activity of the Grp78 
promoter in non-malignant cells in vivo, proving its significant role in controlling transgene 
expression within the solid tumour and tumour endothelial cells only.  
 
6.2.2.2 RGD4C AAVP/Grp78 targeting of U87 glioblastoma xenografts 
 
Having shown that systemic delivery of the RGD4C AAVP/Grp78 vector could successfully 
mediate transgene expression solely in tumours in mice bearing 9L glioma, we further aimed 
to evaluate the AAVP vector-mediated transgene expression in another tumour model. Thus, 
as a second preclinical model we used immunodeficient nude mice bearing subcutaneous 
tumours derived from U87 glioblastoma cells.  
 
To visualise Luc transgene expression in mice after vector administration, serial in vivo BLI 
was performed on days 0, 3, 5, 7 and 10 post AAVP injection. To our surprise and in contrast 
to 9L xenografts, no U87 tumour-associated bioluminescent signal was observed after 
systemic administration of the targeted RGD4C AAVP/CMV or double-targeted RGD4C 
AAVP/Grp78 vector over time (Fig. 6.3a). Also, no luciferase signal was detected in mice 
receiving control insertless vectors.  
 
Interestingly, although no luciferase signal was detected within the tumour areas (Fig. 6.3a 
and 6.3b), RGD4C AAVP/CMV-Luc vector mediated luciferase activity was detectable in 
paws and tail of injected mice (Fig. 6.3a). Moreover, non-specific transduction of RGD4C 
AAVP/CMV-Luc vector was observed in different parts of mice bearing U87 tumours, mainly 
localized close to the site of injection (Fig. 6.3a). Quantified luciferase expression within the 
whole animal body demonstrated non-specific transgene expression after systemic 
administration of RGD4C AAVP/CMV-Luc vector while in sharp contrast, IV administration 
of the RGD4C AAVP/Grp78-Luc vector resulted in no vector-mediated expression in mice 
bearing U87 glioblastoma (Fig. 6.3c). 
The lack of detection of luciferase in U87 tumours by BLI is consistent with our in vitro data 
showing better and stronger transgene expression of the RGD4C AAVP/Grp78 vector in 9L 
cells compared to U87 cells. 
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However, despite the fact that no tumour-associated bioluminescent signals were observed 
and detected in mice bearing U87 tumours, RGD4C AAVP/Grp78 proved safer and more 
reliable than the original RGD4C AAVP/CMV vector. 
 
Figure 6.2. Systemic administration of the RGD4C AAVP/Grp78 mediates early and 
durable expression of the Luc reporter transgene in 9L tumours. a) In vivo 
bioluminescent imaging (BLI) of Luc expression. Immunodeficient nude mice bearing size-
matched 9L subcutaneous xenografts (~100 mm
3
) received a single intravenous (IV) dose of 
the double-targeted RGD4C AAVP/Grp78-Luc or targeted RGD4C AAVP /CMV-Luc as well 
as control insertless vectors (5x 10
10
 TU/mouse). Luc transgene expression was monitored at 
the indicated days post-vector administration. A standard calibration scale is provided. b) 
Serial real-time quantification of Luc expression in tumour-bearing mice. Luc expression 
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from RGD4C AAVP/Grp78-Luc and RGD4C AAVP/CMV-Luc was normalised to that of 
control insertless AAVP/Grp78-Luc and AAVP/CMV-Luc, respectively.   
 
 
Figure 6.3. Undetectable luciferase activity in U87 tumours upon systemic 
administration of the RGD4C AAVP/Grp78-Luc. a) In vivo bioluminescent imaging (BLI) 
of Luc expression. Immunodeficient nude mice bearing size-matched U87 subcutaneous 
xenografts, received a single intravenous (IV) dose of the double-targeted RGD4C 
AAVP/Grp78-Luc or targeted RGD4C AAVP /CMV-Luc as well as control insertless vectors 
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(5x 10
10
 TU/mouse). Luc transgene expression was monitored at the indicated days post-
vector administration. A standard calibration scale is provided. Serial real-time quantification 
of Luc expression in b) tumour area c) whole mouse body. Luc expression from RGD4C 
AAVP /Grp78-Luc and RGD4C AAVP /CMV-Luc was normalised to that of control 
insertless AAVP/Grp78-Luc and AAVP/CMV-Luc, respectively. ***p < 0.001.  
 
 
 
6.3 Generation of SV40- pGL4.20 plasmid 
 
To assess therapeutic efficacy of the RGD4C AAVP/Grp78-HSVtk vector in vivo, in addition 
to tumour size we sought to measure the tumour viability before and after HSVtk/GCV 
treatment. Thus, stably luciferase-labelled 9L and U87 cells were implanted into the flank of 
nude mice. To generate cells stably expressing the Luc reporter gene (2.8.6), the pGL4.20 
(2.2) was used. The pGL4.20 vector encodes the Luciferase reporter gene Luc2 (Photinus 
pyralis); however, as this plasmid does not contain any promoter to mediate Luc expression 
prior to cell transfection using this plasmid, we had to insert a constitutive promoter upstream 
the Luc gene. For this purpose, the SV40 promoter was removed from pPUR plasmid (2.2) by 
PvuII and HindIII double digestion and subsequently ligated to pGL4.20 digested with 
EcoRV and HindIII, located in multiple cloning sites, to control Luc transgene expression 
(PvuII can ligate to EcoRV) (Fig. 6.4). 
In order to find the positive clones and release the SV40 fragment, HindIII and NheI double 
digestion was performed (Fig. 6.4). 
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Figure 6.4. Schematic chart describing construction of the pGL4.20- SV40 plasmid. the 
SV40 promoter flanked by PvuII and HindIII was released from pPUR plasmid and ligated to 
the pGL4.20 plasmid digested with EcoRV and HindIII to control Luciferase gene 
expression. (Amp: ampicillin resistance gene, Puro: puromycin-resistance gene, Luc2: 
Luciferase reporter gene). 
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6.4 Therapeutic efficacy of the double-targeted vector carrying HSVtk suicide gene in vivo 
in small size glioblastoma  
 
6.4.1 Systemic administration of the double-targeted RGD4C AAVP/Grp78- HSVtk 
mediated 9L tumour growth suppression in mice after GCV treatment 
 
We next aimed to use the RGD4C AAVP/Grp78 vector encoding the HSVtk as a therapeutic 
gene to determine therapeutic efficacy of this vector in vivo in combination with GCV 
treatment. To this end, Luc-expressing 9L rat glioblastoma cells which were previously stably 
transfected with pGL4.20- SV40 plasmid were subcutaneously implanted into the flank of 
nude mice. Cohorts of mice bearing size-matched Luc-expressing 9L tumours (~100 mm
3
) 
received a single IV dose (5 x 10
5 
TU) of either RGD4C AAVP/Grp78-HSVtk or RGD4C 
AAVP/CMV-HSVtk. Also as a control, insertless AAVP/Grp78-HSVtk and AAVP/CMV-
HSVtk vectors were systemically administered. At day 3 post-vector delivery, daily GCV 
treatment started for all groups of mice.  
The Effects of HSVtk/GCV therapy were evaluated on tumour size by using calliper 
measurement (Fig. 6.5a) as well as on tumour viability by monitoring Luc expression of 
tumours (Fig. 6.5b). 
As shown in figure 6.5, similar tumour growth suppressive effects were initially observed 
after GCV treatment in both tumour-bearing mice receiving RGD4CAAVP/Grp78-HSVtk or 
RGD4CAAVP/CMV-HSVtk as compared to control mice treated with control insertless 
vectors. As both vectors demonstrated the same therapeutic efficacy in the small size 9L 
tumours, we then aimed to stop GCV treatment in recurrent tumours from day 10 until day 13 
post-vector injection; hence, we could assess the therapeutic efficacy of vectors in larger 
tumours. Interestingly, repeated daily treatment with GCV after day 13 post-vector injection 
resulted in complete growth suppression of the large growing back tumours (~400 mm
3
) in 
mice that received double-targeted RGD4C AAVP/Grp78-HSVtk compared to mice 
administered with control insertless vector (Fig. 6.5a). In contrast, as shown in figure 6.5a, 
daily administration of GCV showed no effect on the large recurrent tumours which received 
the original RGD4C AAVP/CMV-HSVtk vector.  
Moreover, in addition to tumour size, BLI of the Luc reporter gene expression in tumours 
showed better suppressive effects with the RGD4C AAVP/Grp78-HSVtk vector against the 
large growing back tumours than the original vector RGD4C AAVP/CMV-HSVtk (Fig. 6.5b). 
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Figure 6.5. Therapeutic 
efficacy of the RGD4C 
AAVP/Grp78-HSVtk vector 
in small size 9L xenografts 
after GCV treatment. a) 
Cohorts of nude mice with 
established 9L tumours (~100 
mm
3
) received a single 
intravenous administration of 
either double-targeted RGD4C 
AAVP/Grp78-HSVtk or 
RGD4C AAVP/CMV-HSVtk, 
or control insertless vectors (5 
x 10
10
 TU). GCV (75 
mg/kg/day) was injected from 
day 3 posttreatment until day 
10, and then re-administered 
from day 13 until the end of 
the experiments. Shown are 
the mean tumour volumes ± 
standard errors of the mean 
(s.e.m). *p < 0.05 and **p < 
0.01. b) Changes in tumour 
viability after GCV therapy were assessed with BLI of luciferase expression in 9L tumour 
cells stably expressing the Luc transgene. Error bars represent standard error of the mean 
(s.e.m). (n=5).  
 
 
6.4.2 U87 human glioblastoma growth suppression in mice after systemic administration of 
RGD4C AAVP/Grp78- HSVtk 
 
To rule out the possibility that the observed antitumour effects obtained in 9L tumour 
xenografts were tumour specific, we further aimed to analyse efficacy of the RGD4C 
AAVP/Grp78-HSVtk vector on the human U87-derived xenografts. To determine therapeutic 
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effects, we started intraperitoneal injections of GCV at day 3 post IV injection of the vector 
and this treatment continued for 23 days. Tumour size was measured by calliper. In vivo BLI 
of Luc- expressing U87 cells was also applied to validate tumour cell viability during therapy 
assessment.  
As shown in figure 6.6, results demonstrated rapid growth of tumours in mice receiving either 
insertless AAVP/CMV-HSVtk or insertless AAVP/Grp78-HSVtk with no therapeutic effect 
observed in these groups (Fig. 6.6a). 
Interestingly, similar to 9L tumours, comparable antitumour effects were initially detected 
following GCV treatment of mice administered with RGD4C AAVP/Grp78-HSVtk or 
RGD4C AAVP/CMV-HSVtk as compared to control mice injected with insertless vectors 
(Fig. 6.6). Next, we sought to confirm whether the Grp78 promoter retained its activity in 
recurrent tumours. Thus, GCV treatment was stopped between days 17 to 22 post-vector 
injection. Yet again, when tumours grew back (around 300 mm
3
 in size), repeated GCV 
treatment resulted in clear regression of the large volumes of the growing back tumours from 
mice that received the double-targeted RGD4C AAVP/Grp78-HSVtk vector while tumour 
growth continued in mice administered with targeted RGD4C AAVP/CMV-HSVtk vector 
(Fig. 6.6).  
As shown in figure 6.6a and 6.6b, tumour viability was reduced at day 26 post-vector 
injection in mice that received RGD4C AAVP/Grp78-HSVtk vector as evidenced by loss of 
Luc activity of the Luc-expressing U87 tumours. Moreover, consistent with tumour viability, 
tumour size decreased in mice administered with RGD4C AAVP/Grp78-HSVtk (Fig. 6.6c). In 
contrast, administration of RGD4C AAVP/CMV-HSVtk vector initially resulted in reduced 
tumour growth after 5 days of GCV treatment. However, such an effect was not observed in 
the long-term (day 26 post-vector injections) as clear tumour growth as well as increase in 
tumour luciferase signals were observed (Fig. 6.6). These results in addition to previous data 
obtained from 9L xenografts demonstrate that no significant effect with the original vector 
RGD4C AAVP/CMV-HSVtk on recurrent tumours were obtained while in contrast the 
double-targeted vector RGD4C AAVP/Grp78-HSVtk in combination with GCV treatment 
resulted in significant tumour regression. 
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Figure 6.6. Therapeutic efficacy of RGD4C AAVP/Grp78-HSVtk vector in the human 
U87. Nude mice bearing subcutaneous U87 xenografts derived from Luc-expressing U87 
cells were intravenously administered with a single dose (5x 10
10
 TU/mouse) of RGD4C 
AAVP/Grp78-HSVtk or RGD4C AAVP/CMV-HSVtk as well as insertless control Grp78-
HSVtk or CMV-HSVtk vectors. GCV treatment (75 mg/kg/day) started when tumours reached 
~ 100 mm
3
 and was given daily until day 24 post-vector transduction, then re-administered 
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again at day 29 and continued until the end of experiment. a) Representative images of in 
vivo BLI showing tumour size and tumour luciferase activity in tumour-bearing mice at the 
indicated time points post-vector administration. b) Changes in tumour viability before and 
after GCV treatment as measured by BLI of tumour luciferase activity. c) Tumour growth 
curves after GCV treatment. Error bars represent standard errors of the mean (s.e.m). ***p < 
0.001 and ns: non-significant. 
 
 
 
6.5 Systemic administration of double-targeted RGD4C AAVP/Grp78-HSVtk and GCV 
treatment induces regression of aggressive and large tumours 
 
Our results using the double-targeted RGD4C AAVP/Grp78-HSVtk vector proved more 
efficient than original vector to suppress large tumours after vector administration. This 
remarkable result was achieved in both human U87 and rat 9L glioblastoma models in vivo.  
However in previous therapy assessments using both U87 and 9L models in mice, prodrug 
GCV treatment was started randomly at day 3 post-vector administration. To avoid this 
uncontrolled GCV administration, we aimed to set up a new experiment to be able to detect 
Grp78 activity within tumours prior to GCV treatment. 
To monitor Grp78 activity during the growth of 9L tumours in mice prior to GCV treatment, 
9L cells were first stably transduced with the RGD4C AAVP/ Grp78-Luc-puro
R
 vector and 
selected in the presence of puromycin to express the Luc transgene under the control of the 
Grp78 promoter. Next nude mice were subcutaneously injected with 1x10
6 
Grp78-Luc 
expressing 9L cells. When tumour volume reached around 250-300 mm
3
, a single dose of 
either double-targeted or targeted as well as control insertless vectors driving the HSVtk 
therapeutic gene were intravenously administered to tumour-bearing mice. At day 3 post-
vector injection, tumours grew rapidly to reach large size (~400-450 mm
3
) and luciferase 
activity of 9L tumour cells driven by the Grp78 promoter was evaluated using the IVIS 
imaging system. BLI of Luc expression revealed high activity of the Grp78 promoter within 
the 9L tumours (Fig. 6.7a). Therefore, GCV treatment was immediately initiated and 
continued for 4 days at which time the experiment was terminated.  
As shown in figures 6.7a and 6.7b, following 4 days of GCV treatment, the double-targeted 
RGD4C AAVP/Grp78-HSVtk vector resulted in marked regression of the large volume 
tumours, while no effect on tumour suppression was observed in tumour-bearing mice 
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administered with RGD4C AAVP/CMV-HSVtk vector. Moreover, no effect on tumour 
growth was observed in mice treated with control insertless vectors (Fig. 6.7a and 6.7b)  
Consistently, the RGD4C AAVP/Grp78-HSVtk vector administration resulted in less viable 
tumours after 4 days of GCV treatment (Fig. 6.7c). In contrast, mice administered with 
RGD4C AAVP/CMV-HSVtk vector showed less tumour cell viability after GCV treatment, 
although there was no effect on tumour size (Fig. 6.7c). No therapeutic effect was observed in 
mice bearing tumour administered with control insertless vector as tumour cell viability 
increased at the same rate as tumour growth. 
To check for post-treatment effects, tumour tissues were snap frozen after 4 days of GCV 
treatment, sectioned and stained with Hematoxylin and Eosin (H&E). The stained tumour 
sections revealed extensive tumour destruction by the single systemic administration of the 
double-targeted RGD4C AAVP/Grp78-HSVtk vector plus GCV treatment. Most of the 
tumour destruction was observed in the central area of tumours. In contrast to the double-
targeted RGD4C AAVP/Grp78-HSVtk vector, slight tumour disruption resulted from the 
original targeted RGD4C AAVP/CMV-HSVtk vector (Fig. 6.7d). No effect resulted from 
control insertless vectors.  
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Figure 6.7. Regression of large-size 9L tumours in mice by a single intravenous dose of 
RGD4C AAVP/Grp78-HSVtk plus GCV. a) Representative tumour-bearing mice from all 
the experimental groups before and after GCV therapy. Immunodeficient nude mice were 
subcutaneously implanted with 9L cells stably expressing the Luc transgene reporter under 
the Grp78 promoter to establish tumours. Next, mice bearing size-matched (~400-450 mm
3
) 
9L xenografts received an intravenous dose of either RGD4C AAVP/Grp78-HSVtk or 
RGD4C AAVP/CMV-HSVtk, or control insertless vectors (5 x 10
10
 TU). GCV was 
administered to mice at day 3 post-vector delivery and continued for 4 days. Luc transgene 
expression was monitored before and after GCV treatment. b) Individual tumour volumes are 
shown. c) Tumour viability before and after GCV treatment as measured by BLI of tumour 
luciferase activity before (open circles) and after (filled circles) GCV treatment. d) 
Hematoxylin and eosin (H&E) staining of representative tumour sections from all the 
experimental groups (scale bar = 100µm).  
 
 
6.6 Discussion 
As discussed before, the original vector RGD4C AAVP/CMV has been previously 
administered for cancer gene therapy and proved efficient to express therapeutic genes within 
the tumour models such as Kaposi’s sarcoma, bladder carcinomas, prostate carcinomas and 
soft tissue sarcoma and more interestingly resulted in marked suppression of tumour growth 
in mice and dogs (Hajitou et al., 2006b, Hajitou et al., 2008), (Tandle et al., 2009, Paoloni et 
al., 2009). 
Indeed while the use of a viral CMV promoter is the preferred choice to drive transgene 
expression, its usage in some tissues proved to be problematic due to strong silencing of 
transgenes. In mouse tissues, the CMV promoter exhibits different expression pattern, while it 
is active in testis, neurons and some other known tissues (Fritschy et al., 1996, Schmidt et al., 
1990, van den Pol and Ghosh, 1998), the in vivo silencing of this promoter has been reported 
by several studies (Choi et al., 2005, Meier, 2001, Grassi et al., 2003, Mehta et al., 2009, 
Brooks et al., 2004). 
 
In fact, we showed in chapter 4, that 9L and U87 cells stably transduced by RGD4C 
AAVP/CMV demonstrated a dramatic decrease in transgene expression over time while in 
contrast both cells stably transduced by RGD4C AAVP/Grp78 demonstrated either stable or 
increasing transgene expression in the long-term. This superiority of Grp78 over the viral 
CMV promoter was achieved by monitoring the GFP reporter gene, and Western blot analysis 
of HSVtk.  
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In this chapter as a proof of principle our first aim was to elucidate both promoter activity in 
the context of AAVP in vivo over time. Interestingly, consistent with our previous in vitro 
studies, serial in vivo BLI of Luc in mice implanted with 9L cells stably transduced with 
targeted RGD4C AAVP/CMV-Luc-puro
R
 vector demonstrated loss of the CMV viral 
promoter activity over-time. In contrast to the CMV promoter, Grp78 promoter activity 
within the stably transduced 9L tumours with RGD4C AAVP/Grp78-Luc-puro
R
 increase over 
time as the tumour size increased.  
After validating the silencing of the CMV promoter in the context of AAVP in glioblastoma 
in vivo and proving the strong activity of Grp78 promoter within the large tumours over time, 
our next aim was to determine the efficacy and safety of the RGD4C AAVP/Grp78 vector 
after systemic IV administration.   
Interestingly in mice bearing 9L tumours, transgene expression by RGD4C AAVP/Grp78 -
Luc not only started at about 2 days earlier than the original vector, but also lasted longer than 
that. The drop of Luc expression was observed in both RGD4C AAVP/CMV-Luc and, at a 
later time point, with RGD4C AAVP/Grp78-Luc, which might be due to dilution effects of 
the proliferating transduced cells within a larger population of proliferating non-transduced 
cells (Hajitou et al., 2008).  
In contrast to 9L tumour xenografts, no luciferase signal was detected within the U87 
tumours after systemic administration of either vector. Although Grp78 is reported to be 
highly expressed in glioma (Lee et al., 2008), its expression shows a positive association with 
tumour growth rate, with rapidly growing tumours expressing more Grp78 than those that 
proliferate more slowly (Pfaffenbach and Lee, 2011). 
 
Indeed, the higher endogenous Grp78 levels in the 9L cells, which are a more aggressive cell 
line and has a greater proliferation rate than U87 has been previously demonstrated. 
Moreover, spliced XBP1 predominates in 9L, suggesting chronic ER stress and activation of 
the UPR. In the U87 cell line, however, spliced XBP1 levels were undetectable. These data 
imply that U87 cells undergo less ER stress relative to 9L cells and this fact might explain the 
lack of detection of luciferase within the U87-derived tumours.  
 
In addition to stability and to higher transgene expression by the double-targeted vector 
within 9L xenografts or even no detectable transgene expression within U87 xenografts, this 
vector proved safer than the original vector as luciferase expression was solely detectable 
within the tumour tissue while in mice administered with targeted RGD4C AAVP/CMV-Luc 
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vector apart from the tumour tissue, luciferase expression was observed in mice paws and at 
the site of vector injection. This effect was observed in both 9L and U87 tumour-bearing 
mice following IV administration of the RGD4C AAVP/CMV-Luc vector. 
Indeed, while αvβ3 and αvβ5 integrins are barely detectable in quiescent vessels, their 
upregulation during wound -induced angiogenesis has been previously reported (Max et al., 
1997, Sheppard, 1996, Hodivala-Dilke et al., 2003, Christofidou-Solomidou et al., 1997). In 
addition to injury, inflammation can also play an important role in altering the local 
concentration of integrins (Sheppard, 1996). Thus RGD4C AAVP vectors can mediate 
transduction of injured endothelial cells and subsequently the constitutive CMV promoter can 
mediate transgene expression within these cells, while the inducible Grp78 promoter can 
tightly control the expression of the transgene within the tumour tissues as this promoter is 
quiescent in non-tumour cells.  
After confirming the efficacy and safety of the double-targeted vector to deliver transgene 
expression in tumours after systemic vector administration, we subsequently aimed to 
evaluate therapeutic effects of the double-targeted vector carrying HSVtk in preclinical 
models of glioblastoma. Interestingly, a single IV administration of the RGD4C 
AAVP/Grp78-HSVtk or RGD4C AAVP/CMV-HSVtk vector in mice bearing small size 9L or 
U87 tumours (~100 mm
3
) and daily prodrug GCV treatment resulted in similar tumour 
suppression at early time points. Although Grp78 promoter activity was shown to start earlier 
than that of the CMV promoter in 9L tumours (Fig. 6.2), it was expected to obtain a faster and 
better antitumour activity by the double-targeted vector; however, the comparable antitumour 
effects of both vectors at early time points after GCV treatment might be due to the bystander 
effect of the HSVtk/GCV as the CMV promoter could increase its activity to reach Grp78 
level. 
Next at a later time point, when the tumour was growing back, once again the RGD4C 
AAVP/Grp78-HSVtk vector resulted in marked tumour suppression; while, the RGD4C 
AAVP/CMV-HSVtk had no such effect. 
This data is consistent with our previous results of silencing of the CMV promoter which may 
explain why the original vector had no effect on tumour suppression at a late time point.  
Moreover, previous studies have shown that, unlike most of the popular constitutive 
promoters utilised in gene therapy vectors such as LTR or CMV promoters, which are active 
in small size tumour and lose their potency when the tumours grow large, inducible Grp78 
promoter activity elevates as tumour size increases (Dong et al., 2004, Chen et al., 2000). The 
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above data establish the potential of the Grp78 promoter in the context of AAVP for systemic 
treatment of aggressive tumours. 
Next, we aimed to monitor the Grp78 inducible promoter activity using a non-invasive 
imaging procedure prior to GCV treatment with the prospect to control GCV treatment and to 
predict response to therapy; thus, stably transduced 9L cells with RGD4C AAVP/Grp78-Luc-
puro
R
 were implanted in nude mice. Single IV administration of RGD4C AAVP/Grp78-
HSVtk in mice bearing large size tumours (~400-450 mm
3
) and 4 days of GCV treatment, 
initiated after Grp78 promoter activity within the tumours, resulted in significant tumour 
regression. Also luciferase quantification of tumours administered with the RGD4C 
AAVP/CMV-HSVtk vector showed some reduction in tumour viability after GCV treatment; 
however, this amount of tumour cell killing was not sufficient to suppress tumour growth.   
 
In summary, here for the first time we reported a unique and superior antitumour effect of the 
double-targeted vector over the original vector after systemic vector administration into mice 
bearing therapy resistant as well as large glioblastoma tumours. These effects from the 
double-targeted vector might be explained by: (i) the tumour environment in large aggressive 
tumours, such as insufficient blood supply, an acidic pH, glucose deprivation and anoxia 
which will induce the Grp78 promoter activity, and (ii) our previous findings that 
HSVtk/GCV treatment stimulates the UPR stress pathway leading to increased Grp78 
activity. 
In addition to the advantage of the Grp78 promoter to drive and control the expression of the 
therapeutic gene HSVtk, we found that the dual targeting design mediates selective and long-
term transgene expression within the tumour tissues while leaving normal tissues virtually 
safe.  
In conclusion, the above in vivo studies demonstrate the effectiveness of the double-targeted 
RGD4C AAVP/Grp78 vector for systemic targeted gene therapy directed against large 
malignant and therapy resistant tumours. More importantly, our studies show the potential for 
this novel double-targeted vector in human cancer gene therapy. 
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Chapter 7 
 
 
 
Chemotherapeutic drugs induce Grp78 promoter activity in the 
context of the double-targeted AAVP vector 
 
 
 
7.1 Introduction 
 
Conventional cytotoxic therapies, such as radiation and chemotherapy, are currently the 
methods of choice for cancer treatment. However, both therapies have had little success, 
significantly against solid and metastatic cancers and are often highly toxic with a wide 
variety of severe side effects. For glioblastoma tumour treatment, chemotherapy has been 
extensively used for recurrent glioma after surgery and radiotherapy. Unfortunately 
glioblastoma is greatly resistant to the effects of chemotherapy and thus, its treatment remains 
a major challenge. This effect is not limited to glioblastoma which is the most frequent and 
aggressive brain tumour, but many other cancers have shown chemoresistance. Although 
chemotherapeutic drugs must effectively work on fast growing tumours as these agents 
mediate cell death by impairing cell division, fast growing malignant gliomas confer 
resistance to apoptosis after chemotherapy treatment.  
Several studies using human cancer cells have demonstrated a correlation between Grp78 
overexpression and chemoresistance (Wey et al., 2012, Lee et al., 2011, Al-Rawashdeh et al., 
2010, Lee, 2007). In fact anti-cancer drugs that target and eradicate the tumour vasculature 
are intended to starve the tumour of oxygen and nutrients. However, these drugs 
consequently induce the UPR, and thus Grp78 expression, which aids the tumour cells to 
become resistant to these drug (Lee, 2007). Upon consideration of this knowledge, it is clear 
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that Grp78 induction is one of the mechanisms by which cells counteract the cytoxicity of 
chemotherapeutic drugs. 
Previous studies have shown that malignant glioma tumour vasculature develop 
chemoresistance through upregulation of Grp78 (Virrey et al., 2008). More interestingly, the 
authors have shown that upregulation of Grp78 in normal endothelial cells is also capable of 
rendering them chemotherapy-resistant (Virrey et al., 2008). Knockdown of Grp78 or 
blockage of the ATPase domain of Grp78 with (-)-epigallocatechin gallate was able to 
increase chemosensitivity of these endothelial cells (Virrey et al., 2008). The Grp78 level has 
also been used as a marker to predict breast cancer patient response to chemotherapy, with 
Grp78-positive cancers having a decreased sensitivity to the drugs and an increased risk of 
recurrence (Lee et al., 2006). 
Amongst many clinically used chemotherapeutic drugs, the effects of cisplatin and 
temozolomide on UPR activation and thus Grp78 induction have been demonstrated by 
numerous studies (Jiang et al., 2009, Lin et al., 2011, Virrey et al., 2008, Pyrko et al., 2007).  
 
7.1.1 Cisplatin 
 
Cisplatin is a widely used chemotherapeutic drug to treat various types of cancers such as 
testicular, ovarian, bladder, cervical, head and neck, and small lung cancer cells (Cepeda et 
al., 2007, Boulikas and Vougiouka, 2004).  
This agent is known to induce apoptosis by causing DNA damage. As an electrophile in 
aqueous solution, it reacts with nucleophilic DNA, RNA, and protein sites to form adducts. 
By binding to genomic DNA, cisplatin can inhibit DNA replication and/or transcription 
which subsequently lead to cancer cell death (Gonzalez et al., 2001, Cepeda et al., 2007).  
Despite the success of cisplatin in treatment of some cancer cells, others such as melanoma 
cells are resistant to cisplatin. Interestingly, similar to glioblastoma cells, constitutive 
expression of spliced XBP1 and high level of Grp78 have been reported in melanoma cells, 
indicating constant UPR activation (Jiang et al., 2009). 
In addition to the fact that the level of endogenous Grp78 is constantly elevated within 
melanoma cells, incubation of these cells with cisplatin has been shown to induce the 
expression of this chaperon protein. Indeed incubation of melanoma cells with cisplatin 
resulted in 2.6- fold increase in Grp78 protein expression (Mandic et al., 2003). In addition to 
the above reports, a dramatic increase in the Grp78 expression following cisplatin treatment 
has been shown in other tumour cells such as hepatocellular carcinoma (Chen et al., 2011). 
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Cisplatin has been shown to mediate ER stress in many cell types and induce the activation of 
the Grp78 promoter through the generation of reactive oxygen species (Miyajima et al., 1999, 
Benhar et al., 2001, Adler et al., 1999). 
The activation of UPR and thus expression of Grp78 have been reported to be involved in 
resistance of tumour cells to cisplatin. In glioblastoma cells, Grp78 overexpression has been 
reported to protect tumour cells from cisplatin- induced apoptosis; however, silencing of 
Grp78 could significantly increase cell sensitivity to cisplatin treatment (Lee et al., 2008). 
Also, it has been reported that Grp78 can promote tumour cell resistance to cisplatin by 
inhibiting the caspases 4 and 7 (Jiang et al., 2009). Moreover, Grp78 was shown to be 
required for downstream phosphorylation of the serine/threonine protein kinase Akt, which is 
required for cisplatin resistance in lung cancer cells (Lin et al., 2011).  
 
7.1.2 Temozolomide 
 
Temozolomide is a DNA-methylating chemotherapeutic drug, which by deposition of methyl 
groups on DNA guanine bases can induce formation of nicks in the DNA and activate the 
mismatch repair mechanisms. Recognition of recurring mismatches by cells, leads to 
programmed cell death (Nagasubramanian and Dolan, 2003, Wesolowski et al., 2010).  
Due to its small size (194 Da), temozolomide can easily penetrate and pass the blood brain 
barrier. Thus temozolomide monotherapy or in combination with other chemotherapeutic 
drugs such as cisplatin have been widely used for glioblastoma muliforms treatment (Villano 
et al., 2009, Friedman et al., 2000, Zustovich et al., 2009).  
Previous research has shown that treatment of glioblastoma tumour cells with temozolomide 
induces Grp78 expression (Pyrko et al., 2007). Moreover they have shown that knockdown of 
Grp78 can sensitize cells to temozolomide. These data suggest that, much like cisplatin, 
temozolomide induces ER stress and thus its cytotoxic activity is antagonized in tumour cells 
by Grp78-regulated chemoresistance mechanisms. 
As both Cisplatin and temozolomide chemotherapy agents have been previously shown to 
induce Grp78 promoter activity and also used for glioblastoma tumour treatment, we aimed 
to administer cisplatin and temozolomide as two chemotherapy drug candidates, to 
glioblastoma cells in vitro and assess their effects on Grp78 activity both at endogenous and 
RGD4C AAVP/Grp78 vector level. 
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It is noteworthy to mention that the work presented in this Chapter was undertaken with the 
assistance of Miss Nastasia Nianiaris, MSc student in Molecular Medecine at Imperial 
College.  
 
7.2 Results 
 
7.2.1 Chemotherapeutic drug Cisplatin treatment of glioblastoma cells induces Grp78 and 
boosts transgene expression mediated by RGD4C AAVP/Grp78 
 
Numerous recent studies demonstrate an increase in Grp78 level in tumour cells following 
cisplatin treatment, implicating cisplatin as an ER stress inducer (Lin et al., 2011, Jiang et al., 
2009, Mandic et al., 2003). To further assess the effect of cisplatin on the Grp78 promoter in 
the context of the AAVP vector, 9L cells stably transduced with RGD4C AAVP/Grp78-
HSVtk as well as control 9L cells stably transduced by RGD4C AAVP/CMV-HSVtk were 
treated with increasing cisplatin concentrations (10-75µM) for 12 hours. Subsequently to 
analyse the expression level of the HSVtk gene controlled by either the CMV or Grp78 
promoters or of the endogenous Grp78, equal amounts of protein sample were subjected to 
Western blot analysis (Fig. 7.1a and 7.1b). Figures 7.1a, 7.1b and 7.1c show that a dose 
dependent increase in endogenous Grp78 expression resulted from both 9L populations. This 
result is in agreement with previous studies demonstrating Grp78 induction upon cisplatin 
treatment (Lee et al., 2008).  
Moreover quantification of the HSVtk band intensity and normalization to control GAPDH, 
revealed a dose dependent increase in HSVtk expression driven by the Grp78 promoter (Fig. 
7.1d), while in cells stably transduced with RGD4C AAVP/CMV-HSVtk-puro
R
, cisplatin 
treatment resulted in a slight increase in HSVtk expression. However, this increase generally 
remained below the 2- fold mark from the control (0µM cisplatin). HSVtk expression in 
RGD4C AAVP/Grp78-HSVtk-puro
R
 stably transduced cells appeared to exponentially 
increase with drug concentration, even surpassing a 4- fold increase in one instance. The 
average increase of HSVtk expression driven by the Grp78 promoter at 75μM was 
approximately 3- fold from the control. 
The above data indicate that cisplatin can induce both promoters of endogenous Grp78 and 
the RGD4C AAVP/Grp78 vector in 9L cells. 
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Figure 7.1. Chemotherapeutic drug cisplatin induces Grp78 promoter activity in 9L 
glioblastoma cells. Stably transduced 9L cells with a) RGD4C AAVP/CMV-HSVtk-puro
R
 or 
b) RGD4C AAVP/Grp78-HSVtk-puro
R
 were grown in the presence of increasing doses of 
cisplatin for 12 hours. Then equal amount of cell lysate were subjected to Western blot and 
analysed with antibodies against Grp78, HSVtk and GAPDH as control. c) Endogenous 
Grp78 and d) HSVtk levels were measured and normalized to GAPDH. Fold increase of both 
Grp78 and HSVtk over control untreated cells (0µM cisplatin) was calculated and graphed 
(n=3). 
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7.2.2 Temozolomide treatment of glioblastoma cells induces Grp78 and boosts transgene 
expression mediated by RGD4C AAVP/Grp78 
 
Temozolomide is an effective and widely used drug for glioblastoma treatment and its effect 
to induce the Grp78 promoter has been previously reported (Pyrko et al., 2007, Friedman et 
al., 2000, Stupp et al., 2005). Herein, we further aimed to assess the Grp78 promoter activity 
in the context of the double-targeted AAVP vector after temozolomide treatment in vitro. 
Thus Western blot analysis of 9L cells stably transduced with RGD4C AAVP/Grp78-HSVtk 
or RGD4C AAVP/CMV-HSVtk following treatment with various doses of temozolomide was 
performed to evaluate both endogenous Grp78 and transgene HSVtk expression.  
Figure 7.2 shows that, endogenous Grp78 expression increases in 9L cells stably transduced 
by RGD4C AAVP/Grp78-HSVtk following temozolomide treatment. However, the results 
demonstrated a slight increase in endogenous Grp78 in RGD4C AAVP/CMV-HSVtk stably 
transduced 9L cells following temozolomide treatment, which then returned to basal control 
levels between 200µM and 250µM temozolomide (Fig 7.2c).    
As expected, no effect of temozolomide was observed on HSVtk expression in cells stably 
transduced with RGD4C AAVP/CMV-HSVtk. In contrast, following temozolomide drug 
treatment, HSVtk expression driven by the Grp78 promoter increased exponentially in a dose 
dependent manner. The induction of HSVtk expression under the control of the Grp78 
prmoter became evident at 150µM of temozolomide and further intensified and reached 
maximum level at 250µM. 
Our results are in agreement with previous studies indicating the role of temozolomide in 
inducing ER stress (Pyrko et al., 2007), yet this is the first report showing that the 
chemotherapeutic drug temozolomide can mediate Grp78 promoter induction in the context 
of the RGD4C AAVP/Grp78 vector in 9L glioblastoma cells.  
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Figure 7.2. The chemotherapeutic drug temozolomide induces Grp78 promoter activity 
in 9L glioblastoma cells. Stably transduced 9L cells with a) RGD4C AAVP/CMV-HSVtk-
puro
R
 or b) RGD4C AAVP/Grp78-HSVtk-puro
R
 were grown in the presence of increasing 
doses of temozolomide for 12 hours. Then equal amount of cell lysate were analysed by 
Western blot with antibodies to Grp78, HSVtk and GAPDH. c) Endogenous Grp78 and d) 
HSVtk levels were measured and normalized to GAPDH. Fold increase of both Grp78 and 
HSVtk over control untreated cells (0µM cisplatin) was calculated and graphed (n=3). *p < 
0.05 and ns: non-significant. 
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7.3 Discussion 
 
Resistance of some cancers, in particular glioblastoma multiform, to chemotherapeutic drugs 
is a major obstacle to effective treatment (Giles, 1995). It has been previously shown that 
overexpression of Grp78 within tumour cells after treatment with chemotherapeutic agents 
can increase tumour resistance against chemotherapy. Induction of UPR activation and Grp78 
expression in a variety of human tumour cells and tumour vasculature upon treatment with 
chemotherapeutic drugs such as cisplatin and temozolomide, have been reported (Jiang et al., 
2009, Lin et al., 2011, Pyrko et al., 2007, Mandic et al., 2003). Herein, using glioblastoma 
cells, we attempted to further assess the effect of the above chemotherapy agents on Grp78 
promoter activity to drive the HSVtk therapeutic gene in the context of the double-targeted 
vector.  
Consistent with previous reports, endogenous Grp78 expression increased in vitro in 9L cells 
upon treatment with either cisplatin or temozolomide indicating that both drugs are UPR 
inducers. Next, we assessed the HSVtk expression by the Grp78 promoter after treating 9L 
cells with either drug. The results revealed dose-dependent induction of the Grp78 promoter 
following treatment with temozolomide and cisplatin; with temozolomide showing the 
highest effect on the Grp78 promoter activity. Note that statistical analysis of Western blots 
showed some variability in the fold increase of HSVtk expression driven by the Grp78 
promoter, which might be due to natural heterogeneity of the Grp78 promoter activity. 
In summary both cisplatin and temozolomide induce activation of Grp78 at both endogenous 
and vector level in 9L cells in vitro. 
In contrast to the Grp78 promoter, CMV activity was not induced upon temozolomide 
treatment as the transgene expression under the control of CMV stayed at the same level or 
even decreased through treatment. However following treatment with cisplatin a slight 
increase in HSVtk expression driven by the CMV promoter was detected. This result is in 
agreement with a previous study showing the induction of the CMV promoter activity both in 
vitro and in vivo after cisplatin treatment (Kamensek et al., 2011).  
Although Cisplatin and temozolomide have been shown to induce Grp78 in 9L cells, more 
studies are needed to find out whether this observation is applicable to other glioma cells as 
well. 
Moreover, further in vivo studies will be necessary to confirm the induction of the Grp78 
promoter in the context of the AAVP vector in vivo using glioblastoma xenografts following 
chemotherapy treatment.  
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In previous studies, systemic administration of the original vector RGD4C AAVP/CMV-
HSVtk in mice bearing tumours inhibited the tumour growth in mice after GCV treatment; 
however, the viable outer tumour rim was intact following completion of therapy (Hajitou, 
2010, Hajitou et al., 2008). Moreover, it is of primary interest to accelerate suicide gene 
therapy to reduce the time duration of human exposure to potentially harmful drugs, such as 
GCV. As chemotherapeutic drugs cisplatin and temozolomide can mediate the induction of 
Grp78 activity within the AAVP vector and thus a combination therapy regiment, using 
AAVP vector carrying the HSVtk and GCV treatment in addition to chemotherapy, has the 
potential to address both issues mentioned above. 
Based on our obtained data in this part of the study we can hypothesize that administration of 
low-doses of chemotherapy drugs in combination with the AAVP/Grp78-HSVtk vector might 
prove efficient to enhance tumour cell death following GCV treatment. The administration of 
low dose of chemotherapeutics will be both cost effective and will lower the side effects 
associated with the treatment (Giaccone, 2000). 
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Chapter 8 
 
 
Discussion and Conclusions 
 
 
For successful cancer gene therapy, the designed vector must be able to deliver and mediate 
sustained expression of the desired therapeutic gene within the tumour after systemic 
administration. In this thesis I showed that the double-targeted RGD4C AAVP/Grp78 vector 
is a promising gene therapy tool that implements ligand-directed and transcriptional targeting 
into a single particle for effective cancer treatment. 
The results of this project for the first time demonstrate the efficacy of systemic gene therapy 
with the Grp78 promoter and show that the double-targeted RGD4C AAVP/Grp78 vector is 
superior to the original targeted RGD4C AAVP/CMV vector in providing striking persistence 
of gene expression in tumour cells. Furthermore, a clear advantage of the HSVtk and GCV 
suicide gene therapy of cancer was observed by the double-targeted RGD4C AAVP/Grp78 
vector in which this effect was shown to persist long-term, while in contrast silencing of the 
CMV promoter in the context of AAVP was detected. 
The in vitro long-term transgene expression mediated by the double-targeted RGD4C 
AAVP/Grp78 vector was demonstrated using both FACS analysis of the GFP reporter 
transgene expression and Western blot analysis of HSVtk showing persistence of gene 
expression by Grp78 in glioblastoma cells. In contrast, silencing of the CMV promoter was 
observed. In addition to the in vitro studies, silencing of the CMV promoter was spotted in 
vivo by serial imaging of the Luc expression under the control of the CMV promoter. Yet this 
is not the first report demonstrating the silencing of the CMV promoter in vitro and in vivo by 
mammalian host cells (Grassi et al., 2003, Brooks et al., 2004, Prosch et al., 1996, Chen and 
Townes, 2000).  
In the first part of the thesis I showed that the overall activity of the Grp78 promoter is lower 
in moderate- slowly growing tumour cells such as MCF-7 and U87 compared to aggressive- 
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fast growing 9L glioblastoma cells. These data are in agreement with a previous study 
showing a positive correlation between cell proliferation rate and Grp78 activity (Pfaffenbach 
and Lee, 2011). Moreover, we showed that U87 cells are under less ER stress compared to 9L 
cells which are under constitutive ER stress, and that the proliferation rate of U87 is lower 
than that of 9L. Although in U87 cells, the primary activity of the Grp78 promoter in the 
context of AAVP was lower than the constitutive CMV promoter, more cell death induced by 
RGD4C AAVP/Grp78-HSVtk than RGD4C AAVP/CMV-HSVtk was observed following 
GCV treatment. This phenomenon can be explained by the fact that those U87 cells 
expressing the HSVtk suicide transgene might experience ER stress following GCV 
treatment. Indeed this is the first report to show that HSVtk/GCV suicide gene therapy 
activates Grp78 at both the endogenous and vector level, leading to increased HSVtk 
expression and subsequently to enhanced cell killing. Moreover, these data were confirmed 
by the induction of the UPR stress pathway upon overexpression of the HSVtk and GCV 
treatment which consequently led to Grp78 induction. In this manner, cells transduced by 
RGD4C AAVP/Grp78-HSVtk unintentionally facilitate their own death upon GCV treatment 
by activating one of their most effective stress-managing mechanisms that lead to the UPR 
stress pathway, then Grp78 activation. These data are also consistent with previous work 
reporting the stronger tumour cell killing efficacy of HSVtk under the control of the Grp78 
promoter in comparison to viral promoters (Azatian et al., 2009). 
In addition to in vitro studies presented in the first part of the thesis, the superiority of Grp78 
to the popular and commonly used CMV viral promoter in cancer gene therapy was observed 
in vivo, when both promoters were systemically targeted to tumours. 
In vivo systemic administration of the double-targeted RGD4C AAVP/Grp78-Luc mediated 
higher transgene expression with a more stable pattern than the original RGD4C AAVP/CMV 
vector. Moreover the Grp78 promoter appeared to be selective and active within the tumour 
tissues in animal models as no transgene expression or related toxicity was detected 
following systemic administration of the double-targeted RGD4C AAVP/Grp78-Luc vector, 
while in addition to tumours, the original vector containing the constitutive CMV promoter 
resulted in transgene expression in animal paws and tail vein at the site of vector injection.  
Interestingly comparable antitumour effects were obtained at early time points on small size 
tumours, which could be explained by the increased expression levels of transgene expression 
reached by CMV within few days and the bystander effect of the HSVtk/GCV. On the 
contrary, the effect of the double-targeted RGD4C AAVP/Grp78-HSVtk was clearly 
demonstrated on large 9L tumours. In contrast to small size tumours, the double-targeted 
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RGD4C AAVP/Grp78-HSVtk vector proved more efficient than the original targeted RGD4C 
AAVP/CMV-HSVtk vector in reducing large size 9L tumours following GCV treatment. 
Given that specific activation of the endogenous Grp78 promoter has been reported in 
aggressive and poorly perfused malignant tissues, including tumour-associated vasculature 
and tumour cells themselves (Virrey et al., 2008), the results obtained from the large size 
tumours are consistent with the literature.  
 
Taken together, there are three explanations for the unique antitumour effect of the double-
targeted RGD4C AAVP/Grp78 on therapy-resistant and recurring tumours. First, being a 
stress-inducible gene, Grp78 encodes a potent anti-apoptotic protein that plays a critical role 
in tumour survival and resistance to therapy. Second, Grp78 is specifically over-active in 
aggressive cancers. Third, I found that HSVtk/GCV treatment stimulated the UPR stress 
pathway leading to increased Grp78 activity.  
In the last part of the thesis I have clearly shown the effect of the temozolomide and cisplatin 
chemotherapeutic drugs on Grp78 induction in the context of the AAVP vector. Thus a 
combination therapy using both a double-targeted AAVP vector carrying suicide gene such as 
HSVtk and chemotherapy might accelerate treatment of cancer in particular the aggressive, 
chemotherapy-resistant tumours such as glioblastomas. 
 In conclusion I showed that the RGD4C AAVP/Grp78 can potentially eradicate large 
malignant and therapy-resistant tumours, after systemic administration, a route applicable for 
both localised and metastatic tumours. Moreover, dual targeting ensures increased tumour 
targeting while leaving normal tissues virtually safe. Toxicity to healthy tissues is an ever-
present problem with systemic cancer therapies, like chemotherapy.  
Our studies prove in principle the efficacy of combining homing ligands and a mammalian 
tumour specific promoter in the context of bacteriophage in order to generate a novel 
chimeric vector for targeted systemic gene delivery to cancer. Based on this study, it seems 
that the translation of the double-targeted RGD4C AAVP/Grp78 particle may lead to realistic 
gene therapy with the Grp78 promoter in cancer patients. Moreover, and given that any of 
our ligands could also target angiogenic vasculature in addition to tumour cells, these 
advances are likely to extend the potential of disease-specific gene therapy targeting to other 
applications and human angiogenesis-related diseases. Indeed, tissue-double-targeted 
particles can also be developed for targeted systemic gene delivery to normal tissues and 
other human diseases. The in vivo phage display technology is thus a powerful tool to be used 
to isolate and identify phage clones able to target, diffuse and achieve internalization in the 
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target cells after systemic administration. The selected phage clone displaying a specific 
ligand can then be directly combined with a tissue specific promoter to generate a double-
targeted phage particle for systemic gene delivery. 
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Other Achievements 
 
Publications: 
Paper: Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter 
induces tumor regression. Molecular Cancer Therapy 2012. (A copy of the paper can be 
found at the end of the thesis). 
 
Poster: ‘Targeted Systemic Gene Therapy Against Glioblastoma with a Dual Tumour 
Targeted Bacteriophage’ Presented at the British Neuro-Oncology Society (BNOS) 
International Meeting 2012, Manchester, UK. 
 
Awards: Winer of the award for Best Science at British Neuro-Oncology Society (BNOS) 
International Meeting 2012, Manchester, UK.   
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